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Background/Aims: Lymphoma is one of the most prevalent malignancies among young 
persons. The survival rate is high, though comes with a risk of late effects including 
secondary cancer, cardiovascular disease (CVD) and chronic fatigue (CF). Some lymphoma 
patients require especially intensive treatment, high dose chemotherapy with autologous 
stem-cell transplantation (auto-SCT), to achieve curation or prolonged survival. This thesis 
aimed to investigate sexual function and lifestyle factors among auto-SCT survivors and to 
compare the results to controls. Methods: A national cross-sectional survey was conducted, 
inviting 399 survivors who were >18 years at auto-SCT, treated during 1987-2008 and 
without ongoing cancer treatment. Participants responded anonymously on a mailed multi-
item questionnaire. Independent t-test and X2-test were performed for comparison of mean 
and prevalence, respectively, between groups. Age-adjusted and multivariable logistic and 
linear regression models were used to assess associations between explanatory variables and 
categorical and linear outcome variables, respectively. Effect size was estimated to assess 
clinical significance of differences. Controls were randomly drawn from three normative 
cohorts, using frequency matching. Results: In total, the response rate was 78%, 60% was 
men and median follow-up time was 8.5 years. In paper I, male survivors had lower sexual 
functioning and satisfaction than controls. In multivariable models, lower sexual functioning 
was related to increasing age, less physical activity and CF. Reduced erectile function was 
related to CVD. In paper II, female survivors more frequently reported personal-issues as 
cause of sexual inactivity than controls. Sexual activity was related to younger age, being in a 
relationship and hormone replacement therapy among the postmenopausal women. Sexually 
active survivors had more sexual discomfort (vaginal dryness and coital pain) and were more 
often too tired to have sex compared with controls. Reduced sexual functioning was related 
to younger age, total body irradiation, mental distress and CF. In paper III, 55% was 
sedentary and overweight while 18% smoked. Compared to controls, more survivors were 
adhering to lifestyle recommendations. Among survivors, an unhealthier lifestyle was related 
to male gender, less chemotherapy prior to auto-SCT, a higher burden of somatic disease and 
CF. Conclusions: Sexual function was lower among survivors than controls and there was a 




SAMMENDRAG   
Mange lymfompasienter er unge på diagnosetidspunktet og kurasjonsraten er høy.  
Høydosebehandling med autolog stamcellestøtte (HMAS) tilbys enkelte subgrupper og de 
uten tilstrekkelig effekt av 1.linjes behandling. I etterkant av HMAS har overleverne økt 
risiko for seneffekter som ny kreftsykdom, kardiovaskulær sykdom og kronisk fatigue. 
Målsetningene med dette arbeidet var å kartlegge seksualfunksjon og livsstils faktorer blant 
overlevere etter HMAS for lymfom. 
 Studien er del av en nasjonal tverrsnittsundersøkelse. Inklusjonskriterier: >18 år ved 
tidspunkt for HMAS for lymfom, behandlet fra 1987 til 2008 og ingen pågående 
kreftbehandling. Totalt 399 overlevere ble invitert, og 78% besvarte et omfattende 
spørreskjema. Totalt blant responderne var 60% menn, median alder 55 år og median tid 
siden HMAS var 8.5 år. Alders- og kjønnsmatchede kontroller ble randomisert trukket fra 3 
ulike norm materialer. Ved bruk av t-test, effektstørrelser og logistisk regresjonsmodeller 
fant vi at mannlige overlevere hadde dårligere seksualfunksjon enn kontrollene, i justerte 
modeller var dette knyttet til økende alder, mindre fysisk aktivitet og kronisk fatigue. 
Kardiovaskulær sykdom var relatert til redusert ereksjonsevne. Blant kvinnelige overlevere, 
fant vi ved bruk av x2-kvadrat at overleverne hyppigere rapporterte «personlige-forhold» som 
årsak til seksuell inaktivitet enn kontroller. Seksuell aktivitet var relatert til yngre alder, å 
være i et forhold samt at de som brukte hormon substitusjonsbehandling oftere var seksuelt 
aktiv enn de postmenopausale uten slik behandling (aldersjustert logistisk regresjonsmodell). 
De seksuelt aktive overleverne hadde oftere ubehag ved samleie (tørr vagina og smerter) og 
de var for trøtt til å ha sex, sammenlignet med kontrollene (uavhengig t-test og 
effektstørrelser). Redusert seksualfunksjon var relatert til yngre alder, helkroppsbestråling, 
angst, depresjon og kronisk fatigue (aldersjusterte lineære regresjonsmodeller). I artikkel III 
overholdt ikke 55% anbefalinger om fysisk aktivitet, 55% var overvektig og 18% røkte. Dog, 
sammenlignet med kontroller imøtekom flere overlevere disse livsstilsrådene (logistisk 
regresjonsmodeller). Økende grad av usunn livsstil var relatert til å være mann, færre linjer 
kjemoterapi før HMAS, flere somatiske sykdommer og kronisk fatigue (multivariat ordinal 
logistisk regresjonsmodell).  
 Redusert seksualfunksjon ser ut til å være en seneffekt etter HMAS og det er grunn til 
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1    Chapter:  INTRODUCTION 
The population of cancer survivors is rapidly growing and survivorship care is an emerging 
field within oncology. In line with improved survival of cancer, the knowledge of treatment 
consequences in the long-term (>5 years) has evolved. This knowledge has become a part of 
the judgment of patients’ therapeutic benefit [1], and raised the awareness of survivors need 
for information, follow-up, support and intervention in order to mitigate risk of late effects 
and improve mastering of life beyond cancer.  
Many lymphoma patients treated with high dose chemotherapy with autologous stem-
cell transplantation (auto-SCT) are young or middle-aged adults [2], with presumably 
expectations of a normal sexual function, however sexual function among survivors after 
auto-SCT in the long term is largely unstudied. Lifestyle behavior may influence on risk of 
late effects, yet knowledge of auto-SCT survivors health-promoting behavior is lacking. 





1.1 Lymphoma  
1.1.1 Epidemiology 
The incidence of lymphoma, especially non-Hodgkin lymphoma (NHL) has increased over 
the last five decades. In 2018, 144 adults were diagnosed with HL in Norway, and 1053 were 
diagnosed with NHL [3]. Lymphoma affects people of all ages; the incidence of HL is 
highest among young adults age 20-35 years and older people >60 years with median age at 
diagnosis of 44 years. The incidence of NHL increase with older age and median age at 
diagnosis is 69 years (Figure 1a and b) [3].  
 
 
Figure 1 a and b. Age specific incidence rates per 100 000 person-years and five-year age group, 2013-2017 
for Hodgkin lymphoma and non-Hodgkin lymphoma, respectively. Based on data from Cancer in Norway 2018, 
Cancer Registry of Norway [3]. 
 
During these last decades, the 5-year survival rates have increased due to 
improvements in diagnosis and treatment. In 1983-87, the 5-year relative survival for patients 
diagnosed with HL was about 67%, increasing to 86% in 2018 (Figure 2a and b), 
corresponding numbers for NHL was 45%, increasing to 76% in 2018 (Figure 2c and d) [3]. 
Consequently, the prevalence of lymphoma survivors increased with 60% from about 8000 in 
2007 to almost 13000 persons in 2017, (2868 HL and 9989 NHL). Sixty-five percent of these 
persons were alive >5 years after diagnosis, thus defined as long-term survivors (total 8418, 






   
      
Figure 2 a-d. Trends in incidence and mortality rates and 5-year relative survival proportions of Hodgkin (a and 
b) and Non-Hodgkin lymphoma (c and d). Reprinted with permisson from Cancer Registry of Norway. Cancer 
in Norway 2018 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of 
Norway, 2019 [3].  
 
1.1.2 Etiology and classification 
The lymphoma classification used in this thesis is according to the World Health 
Organization (WHO) report on classification of hematopoietic and lymphoid tumors [5]. A 
revised 4th edition has been published in 2017 [6]. Correct classification depends on clinical 
and morphological features, immunophenotype (expression of proteins named cluster of 
differentiation (CD)) and genetic alterations. These features are provided using 
histopathology, immune-histochemistry, flowcytometry, fluorescence in-situ hybridization 
(FISH) and cytogenetic analyses.  
There are two major types of lymphoma, HL and NHL, which both arises from a 
malignant transformation of lymphocytes. HL is subdivided into classical HL (cHL) and 
a) b) 
c) d) 
Hodgkin lymphoma: Hodgkin lymphoma: 




nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL); the latter makes up only 
5% of all HL. The Hodgkin and Reed-Sternberg cells and lymphocyte predominant cells 
represents cHL and NLPHL, respectively, and both originate from a germinal center B-cell.  
NHL is a larger and much more heterogenic group of lymphomas; constitutes more 
than 60 subentities and 85% of all lymphomas [5]. The major distinctions are between very 
aggressive/aggressive (lymphoblastic lymphoma, Burkitt lymphoma, diffuse large B-cell 
lymphoma, mantle cell lymphoma, T-cell lymphoma and transformed lymphoma) and 
indolent NHL (follicular lymphoma, marginal zone lymphoma, small cell lymphocytic 
lymphoma). The WHO classifications divide lymphoma into B-, T-/NK cell neoplasia of 
either precursor or mature cell type and Hodgkin lymphoma.  For the purpose of this thesis, 
the lymphomas were categorized into three groups; HL, indolent NHL (mainly follicular 
lymphomas) and aggressive NHL (lymphoblastic lymphoma, Burkitt lymphoma, diffuse 
large B-cell lymphoma, mantle cell lymphoma, T-cell lymphoma and transformed 
lymphoma). 
 
1.1.3 Clinical features, staging, prognostic factors 
Lymphomas most often affect lymphatic glands and patients present with a “lump”. The 
presentation may however show great diversity as the lymphoma can affect all parts of the 
human body. Advanced disease (stage ≥IIB)  is less common in HL (49%) than NHL patients 
(65%), as is extranodal involvement [3, 7]. Clinically significant lymphoma progression may 
occur during few weeks to years, depending on the growth rate of the lymphoma. 
Of note, a correct classification of the lymphoma, staging and determination of 
prognostic factors are essential as treatment recommendations are based on these factors [8].  
 
Staging of lymphoma is referred in table 1. The B-symptoms of lymphoma disease are: 
Persistent or residual body temperature >38O C last month, weight loss >10% during last six 








Table 1. Staging of lymphoma. 
Ann Arbor staging of nodal lymphoma [9]: 
Stage I One lymph node region 
Stage II 
Two lymph node regions (suffix 1 or 2 if the disease is includable in one radiation field or 
not) 
Stage III Two non-neighboring lymph node regions on the same side of diaphragm 
Stage IV 
Lymph node regions on both side of diaphragm or involvement of extranodal tissue or bone 
marrow. 
Suffixes added in case of: 
A/B B-symptoms present or not 
X Bulky disease defined by tumor mass ≥7 cm but varies according to entity 
E Extranodal disease   
Musshof’s staging of extranodal lymphoma [10]: 
PeI Extranodal organ/tissue 
PeII 1 Extranodal organ/tissue with regional lymph node involvement 
PeII2 
Extranodal organ/tissue with involvement beyond regional lymph nodes, but on the same side 
of diaphragm 
Suffix added in case of: 
E Growth per continuitatem on another extranodal organ/tissue, used from ≥ stage PeII 
 
Prognostic indices are available for diffuse large B-cell lymphoma [11], follicular 
lymphoma [12], mantle cell lymphoma [13] and risk factors associated with HL have been 
identified [14, 15]. It is beyond the scope of this thesis to describe these in detail. A common 
feature is that the risk factors generally mirror clinical or para-clinical disease burden of the 
patient, in addition to age. E.g. risk factors for diffuse large B-cell lymphoma (The revised 
International Prognostic Index score) includes age >60 years, ≥ stage III-IV disease, 
performance status ≥2, lactate dehydrogenases > reference level and extranodal involvement 
[11]. 
 
1.1.4 Treatment strategies for lymphoma during 1970-2008  
Survivors in the study cohort were diagnosed during 1973-2008, and treatment was 
performed according to national and international guidelines. Lymphomas are generally 
sensitive to both chemo- and radiotherapy and combined modality treatment are often used. 




agents (cyclophosphamide, ifosfamide, mechlorethamine, chlorambucil, melphalan, busulfan, 
BCNU®/carmustine and procarbazine), anthracyclines (doxorubicin, epirubicin), vinca 
alkaloids (vinblastine, vincristine), anti-metabolites (methotrexate, cytarabine) in addition to 
bleomycin, etoposide and carmustine. Combinations of these agents were used in multi-agent 
chemotherapy regimens. 
Immunotherapy was introduced in the late 1990s and was a game changer for 
treatment of B-cell NHL. The first agent was rituximab, a monoclonal antibody directed to 
the B-cell specific cell surface protein CD20 [16]. The adding of rituximab to CHOP1  based 
chemotherapy increased 6-year event-free survival from 56% to 74% among young patients 
with good prognosis diffuse large B-cell lymphoma [16, 17]. 
 
Primary treatment of Hodgkin lymphoma  
Early stage HL (stage I-IIA): 1970-80: The first curative treatment for HL was extended field 
radiation (mantle field irradiation, inverted Y/ L, dog-leg) to 40 Gy in 2 Gy fractions [18]. 
Later, chemotherapy was introduced prior to radiotherapy for patients with risk factors 
(1980-88, four courses MVPP2 [19]/ChlVPP3; 1988-97, two-four courses EBVP4) and from 
1998 all patients with early stage HL received combined modality treatment (no risk factors, 
two courses ABVD5 [20]; risk factors, four courses ABVD) [21, 22]. The radiotherapy 
changed during these years with dose and fractioning: 1982-97, 1.8 Gy x 23; 1997-2007, 1.75 
Gy x17-20 and from 1997 the fields were reduced from extended to involved fields (Figure 
4) [18, 23]. 
 
                                                        
1 CHOP: doxorubicin, cyclophosphamide, vincristine and prednisone. 
2 MVPP: mechlorethamine, vincristine, procarbazine, and prednisone. 
3 ChlVPP: chlorambucil, vincristine, procarbazine, and prednisone. MVPP-like regimen. 
4 EBVP: epirubicin, bleomycin, vinblastine and prednisone. ABVD-like regimen. 





Figure 4. Illustrations of extended (left) and involved field (middle) radiation therapy, and involved node 
(right) radiation therapy. Reprinted with permisson from Specht et al. Int Journ Clin Oncol, 2015 [23]. 
 
Advanced disease HL (stage IIB-IV): MVPP was the first chemotherapy regimen with a 
curative potential for patients with advanced stage HL [19]. Eight courses of this regimen (or 
the MVPP-like, ChlVPP) was used in Norway from 1970-85 for these patients. During 1985-
1991, 8 courses of ChlVPP or a combination with alternating ABVD [20] for a total of 8 
courses were used. In 1992, 6-8 courses of AVBD replaced CvLPP as standard 
chemotherapy for HL due to increased efficacy and considerably less gonado- and bone 
marrow toxicity, including secondary myeloid malignancies. The ABVD regimen has been 
the backbone of HL treatment ever since [22, 24]. During 1999-2007, a more intense regimen 
BEACOPP6 (2 courses of escalated BEACOPP + 6 courses BEACOPP) was used on a 
subgroup of patients with at least four out of seven risk factors [25].  
The chemotherapy was consolidated with radiotherapy, during 1970-80 all stage III 
patients received total nodal irradiation (mantle field + inverted Y). Stage IV patients 
received radiotherapy to areas of initial bulky mass or residual mass post-chemotherapy and 
the fractioning regime was 2 Gy x 20. From 1980, indications for consolidative radiotherapy 
to stage III patients were restricted according to indications for stage IV patients. During 
1985-1991, the dosage and fractioning was either 2 Gy x 20 or 1.8 Gy x 23, and from 1997-





                                                        




Primary treatment of aggressive non-Hodgkin lymphoma 
Limited stage disease (I-II): During 1980-90 these patients were treated with radiotherapy 
only, 2 Gy x 20. From 1990, combined modality treatment with CHOP prior to radiation was 
used.  
Advanced stage disease (III-IV): These patients have been treated with CHOP regimen (6-8 
courses) for almost five decades [26]. Consolidation with radiotherapy to involved field was 
used in case of initial bulky disease, skeletal or testicular involvement or a residual mass 
post-chemotherapy, 2 Gy x 18-20 [8].  
Slight adjustments have been made to subgroups of patients with diffuse large B-cell 
lymphoma such as: intensification from three to two week intervals for those with age-
adjusted IPI-score ≥2; addition of etoposide for younger patients, in particular those with 
mediastinal large B-cell lymphomas; addition of high dose methotrexate and cytarabine 
(intravenous or intrathecal or both) for patients with risk of central nervous system disease 
[8]. 
Systemic peripheral T-cell lymphomas had a poor prognosis with conventional 
chemotherapy, thus patients were included in a clinical trial (2000-2008) investigating the 
efficacy of auto-SCT in first remission [27]. 
 
Primary treatment of very aggressive non-Hodgkin lymphoma 
Lymphoblastic lymphoma and Burkitt lymphoma patients have a dismal prognosis with 
CHOP based chemotherapy. Introduction of ALL-like treatment, Hammersmith regimen 
(1992) and GM ALL (1995) for lymphoblastic and Burkitt lymphoma, respectively, 
improved survival. From 1999, patients with lymphoblastic lymphoma received auto-SCT as 
consolidation in first remission instead of maintenance chemotherapy and additionally 
mediastinal radiation in cases of a mediastinal mass [28]. 
 
Primary treatment of indolent Non-Hodgkin lymphoma 
Limited stage disease (I-IIA): Radiotherapy to involved area including the draining lymph 
node region 2 Gy x 15 was used with curative intent [8]. 
Advanced stage disease (IIB-IV): Patients in need of systemic treatment, received per oral 




later rituximab-monotherapy was introduced as a non-chemo containing regimen [29]. In 
cases of an aggressive clinical presentation and advanced disease, rituximab-chemotherapy 
(usually CHOP) was the preferred therapy to achieve a rapid response [8]. 
 
1.1.5 High dose chemotherapy with autologous stem-cell transplantation 
 Auto-SCT was initially introduced in Norway as part of clinical trials, and the selection of 
patients was strictly specified both when it came to indication and suitability of the patient 
[30, 31]. During 1987-1995, median age at auto-SCT was 11 years lower than in 1996-2008 
[31]. Based on results from clinical trials, auto-SCT was implemented as standard treatment 
for relapsed/refractory diffuse large B-cell lymphoma and Burkitt lymphoma, followed by 
relapsed/refractory Hodgkin lymphoma and other lymphoma entities (Figure 5), hence the 
number of treated patients increased until 2004 [30]. Later on, reports on improved overall 
survival for mantle cell and follicular lymphoma patients, pawed the way for auto-SCT as an 
indication not only for curative intent but also as a recommendation for extending disease 
free and overall survival [32-34].  
 
Figure 5. Illustration of clinical studies giving rise to established indications for high-dose therapy with 
autologous stem cell support for lymphomas in Norway. Yellow, single-centre phase 2 study; green, multicenter 
phase 2 study; red, randomized phase 3 study; blue, established indication/treatment. Reprinted with permission 
from Smeland et al. 2013 Tidsskr Nor Legeforen [30]. References in figure presented in footnote7. 
                                                        
7 12) Schmitz 2002, 13) Smeland 2004, 14) Sweetenham 2001, 15) Linch 2010, 16) Blystad 1999, 17) 





The process leading up to the auto-SCT is illustrated in figure 6. The eligible and fit 
patient in remission after induction (immuno-)chemotherapy is admitted to the hospital on 
day -7 and receives the myeloablative treatment (1987-1996, total body irradiation and high 
dose cyclophosphamide; 1996 – today, high dose chemotherapy, usually BEAM8). The acute 
side effects of the high dose chemotherapy present at the time of aplasia with febrile 
neutropenia and symptoms of gastro-intestinal toxicity during which the patient is under 
careful observation. After regeneration of stem cells and normalization of peripheral blood 
cell levels, the patient slowly recovers and is discharged from the hospital. 
 
 
Figure 6. Illustration of the process leading up to auto-SCT. 
 
Auto-SCT lymphoma survivors are a heterogeneous group according to lymphoma 
entities and treatment prior to auto-SCT. First line treatment depends on year of diagnosis, 
lymphoma subgroup, classification, prognostic factors in addition to age and fitness of the 
patient. Additionally, the treatment necessary to achieve a second remission (induction 
treatment) may differ. Hence, the patient cohort providing data for this thesis have received 
various treatments, even though they all received auto-SCT for lymphoma.  
 
                                                        




1.2 Late effects  
Complications after cancer treatment are referred to as long-term or late effects and are 
adverse effects occurring during cancer treatment and lasting >1 year, or presenting >1 year 
after end of treatment (Figure 1) [35]. Examples are treatment induced premature ovarian 
insufficiency (POI) presenting as amenorrhea shortly after chemotherapy treatment and 
persisting throughout life, and secondary malignancy, which usually occurs many years after 
treatment. In this thesis, I will use the term late effects including both long-term and late 
effects.  
 
Figure 1. Adverse effects according to time of cancer treatment. 
 
Childhood cancer and Hodgkin lymphoma (HL) in young adults represents cancer 
trajectories in which long-term consequences of treatment (late effects), first became 
apparent [36]. These cancer survivors have a long life expectancy, and the risk of many late 
effects in lymphoma survivors is documented [37]. Auto-SCT is an especially intensive 
lymphoma treatment with a high risk of late effects [38-40]. 
When the work on this thesis begun, knowledge on the following late effects in this 
study cohort were published; secondary cancer, cardio-pulmonary toxicity and negative 
consequences for working ability [2, 41-46]. Later, a report on chronic fatigue (CF), bone 
mineral density and knowledge of late effects after auto-SCT has been published [47-49]. In 
the following, I will give a description of the late effects most relevant for my thesis.  
 
1.2.1 Life threatening late effects: second cancer and cardiovascular disease 
Excess mortality among lymphoma survivors compared with the general population has been 




lymphoma is the main cause of death, later surpassed by secondary cancer and cardiovascular 
disease (CVD) as reported in survivors of early stage HL [36, 50] and auto-SCT survivors 
[38]. In a former study on the cohort of survivors included in this thesis, life expectancy 
approximated that of the general population for those who were alive 10 years after auto-
SCT, (conditioning on 10-years survival), however this may not occur with longer follow up 
time due to late-onset secondary cancer and CVD [2]. 
Second cancer is a well-known late effect after lymphoma treatment with 
hematological secondary malignancies occurring 2-10 years after treatment while solid 
malignancies usually occur decades after treatment [52, 53]. In a large cohort of HL 
survivors, they found a 4.6-fold increased risk of second cancers compared with the general 
population persisting >35 years after treatment (median follow-up time 19 years) [54]. The 
relative risk of secondary cancer was lower after chemotherapy-only for HL than after 
combined modality treatment, relative risk 2.0 and 3.9, respectively [53]. Breast- (among 
females), lung-, gastrointestinal cancer and NHL were the malignancies who contributed 
most to overall absolute excess risk [54].  
In lymphoma patients risk factors for a second primary cancer are younger age (after 
combined modality treatment), alkylating chemotherapy, radiation and shared risk factors 
[52-55]. It has previously been shown that among the study cohort of this thesis, the risk of 
secondary cancer was increased 2-fold compared to the general population, with a median 
follow-up time of five years [56]. In line with an earlier report, with a 2.6-fold increased risk 
of secondary cancer after seven years. In the study by Tarella et al, older age, radiotherapy 
post-transplant and rituximab were independent risk factors of secondary solid tumors [57]. 
Of note, the incidence of secondary cancers in both these cohorts is expected to increase with 
longer follow up time. 
CVD include disorders affecting the heart and blood vessels and include; 
hypertension, thromboembolism, disease of peripheral and coronary arteries in addition to 
disease of heart valves and the myocardium. Risk factors for stroke and coronary heart 
disease are tobacco use, physical inactivity, obesity, alcohol misuse, diabetes type I/II, 
hypertension and hyperlipidemia [58, 59]. In lymphoma survivors, late effects on coronary 
structures (arteries, valves, myo- and pericardia) are documented, and related to both radio- 




dependent pattern and has been related to oxidative stress, cardiomyocyte death and 
remodeling from these injures [61, 62]. Mediastinal irradiation induces cardiac damage 
largely due to fibrosis and endothelial damage and is related to dose, fractioning and heart-
volume irradiated [62, 63]. 
The risk of CVD was increased 3-5 fold in HL survivors compared with the general 
population [64], confirmed in a 20 years up-date of these data [65]. The risk of CVD seems 
to persist even 20-35 years after treatment [65-67]. CVD-related mortality was increased 7- 
and 5-fold among HL and NHL treated patients, respectively, compared with the general 
population (median follow-up time 13.8 years) [68]. After auto-SCT for hematological 
malignancies, the risk of heart failure was increased 4.5-fold compared to the general 
population, with a cumulative incidence increasing from 5 to 15 years after auto-SCT. Risk 
factors for heart failure were older age at transplantation, female gender, anthracycline dose 
and comorbidity (hypertension and diabetes), pre-transplantation radiotherapy was not 
significantly related possibly due to lack of power [69]. In a study on the same cohort as used 
in this thesis, increased risk of left ventricular systolic dysfunction was related to 
anthracycline dose >300 mg/m2 and mediastinal irradiation >30Gy, with greatest risk among 
survivors with both these risk factors [42]. 
 
1.2.2 Gonadal endocrinopathy after lymphoma treatment 
The gonads are responsible for adequate levels of sex hormones and maturation of germ 
cells. The focus in this thesis will be on sex hormones, and the production of these may be 
affected by both radio- and chemotherapy. Risk of chemotherapy induced gonadal 
endocrinopathy are related to high doses, especially of alkylating agents, in addition to age at 
diagnosis for both gender [70-72]. Alkylating agents (cyclophosphamide, ifosfamide, 
mechlorethamine, chlorambucil, melphalan, busulfan, BCNU®/carmustine and procarbazine) 
are present in MOPP, ChlVPP, BEACOPP, CHOP and BEAM but not included in the ABVD 
regimen.  
Males: The testicular Leydig cells responsible for testosterone production are 
relatively robust to radio- and chemotherapy in contrast to the sperm producing Sertoli cells  
[73]. In testicular cancer patients, hypogonadism occurred in 30% after irradiation of testis 




reported after lymphoma treatment [71, 75]. In male HL, testosterone levels have been 
reported to be reduced after conventional chemotherapy, but not below reference values, not 
even after six courses of BEACOPP [71]. Kiserud at al. reported that chemotherapy of 
≥medium-risk of gonadotoxicity in HL survivors and high-risk in NHL survivors, were 
related to an increased risk of lower testosterone levels compared with men treated with low-
risk chemotherapy [72]. Auto-SCT treatment was included in the high-risk gonadotoxic 
chemotherapy group and 20/41 of these men had endocrine hypogonadism related to older 
age at diagnosis and at survey [72].    
 Females: The toxic effect of chemotherapy on ovarian function is not fully 
understood, however possibly related to: 1) Induced apoptosis of maturing primordial 
follicles causing loss of menstrual bleeding shortly after chemotherapy. 2) Ovarian cortical 
fibrosis and vascular damage injuring the primordial follicles and a compensatory increased 
recruitment of primordial follicles into maturing follicles, called the follicular “burn-out 
hypothesis”. This “burn-out” causes depletion of the primordial follicle reserve and POI [70].  
In female HL survivors treated with conventional chemotherapy, irregular menstrual 
cycles were reported in 10-55% at a median follow-up of 46 months, the prevalence was 
highly dependent of age at diagnosis and accumulated doses of alkylating agents [71]. 
Another study reported POI in 56% and 23% of HL survivors treated with or without 
alkylating chemotherapy, respectively, confirming the negative impact of conventional 
chemotherapy on ovarian function [76]. Risk of radiation induced ovarian failure are strongly 
related to age at treatment and radiation dose. Hence, ovarian failure may occur after 6 Gy in 
40-50-year-old women, and after 20 Gy in women <40 years [77]. After auto-SCT treatment, 
POI has been reported in 64-100% of women [78, 79] and related to both total body 
irradiation and high doses of alkylating chemotherapy [70]. 
 
1.2.3 Chronic fatigue  
Fatigue after cancer treatment is defined as “a distressing, persistent, subjective sense of 
physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer 
treatment that is not proportional to recent activity and that significantly interferes with 
usual functioning” [80]. Duration of fatigue ≥6 months defines chronic fatigue (CF) [81]. CF 




factors and may have debilitating consequences for daily-life and functioning in cancer 
survivors [82]. However, the underlying mechanisms of CF are largely unknown. Pro-
inflammatory markers, has been associated with prevalence of CF in the current study 
population [47], still researchers are calling out for more research on the biological origin of 
CF [1]. 
The first reports on energy-loss in HL survivors were published in 1986. About a 
third of the survivors reported problems median 9 years after treatment [83]. In later reports 
on CF in cancer survivors, including studies among lymphoma survivors, a prevalence of 25-
35% has been found [84]. In a recent study, severe CF was present in 37% of NHL survivors 
(additionally 27% had moderate CF) with a median follow up of 11 years [1]. Treatment 
intensity, including auto-SCT, does not seem to influence on the prevalence of CF [1, 85]. 
However, a relationship between fatigue at end of therapy and later has been reported in HL 
survivors [86]. Recently, the level of CF in long-term HL and NHL survivors was reported to 
increase with follow-up time [87].  
In lymphoma survivors, CF has been associated with increasing age, anxiety, 
depression, obesity, impaired pulmonary diffusing capacity and general health disorders [1, 
87-90]. CF might influence multiple aspects of life after lymphoma treatment, including 
working ability, economic status [91] and health-related QoL [89]. To what extent CF is 
related to healthy behavior remains to be investigated in lymphoma survivors after auto-SCT. 
Among lymphoma survivors, CF is associated with lower sexual function [92, 93], whether 
this association is relevant among auto-SCT survivors is largely not studied [94]. 
 
1.2.4 Anxiety and depression 
A longitudinal study reported anxiety and depression rates between 17-24% among HL 
(n=180) and NHL survivors (n=309) which was higher than the general population [95], and 
in line with previous reports [96, 97]. Among SCT survivors of hematological malignancies 
(29% lymphomas) 15% reported moderate to severe depression, compared to 9% in the 
general population [98]. Depression was less prevalent among auto-SCT survivors compared 
with allogeneic-SCT (allo-SCT). These findings were in contrast to an earlier report, where 
no difference in anxiety or depression was found between allo- and auto-SCT treated 




1.3 Sexual function 
WHO defines sexual health as “a state of physical, emotional, mental and social well-being 
in relation to sexuality”, and sexuality is “the result of a dynamic interaction between 
physiological, psychological and social dimensions which in a positive manner enriches and 
enhances personality, communication and love” [100] (full text in footnote9).  
The sexual health of an individual is influenced by multiple factors of which sexual 
function is an important part [101]. The sexual response cycle is a model of sexual function 
(see below in paragraph 1.3.1). Factors influencing on sexual function might be explained 
using a biopsychosocial model, where multiple factors influence on, relate to and probably 
overlap the other (figure 7) [102, 103].  
Sexual function was important for health-related QoL among HL survivors [92, 104] 
and after SCT for hematological malignancies [105].  
 
   




                                                        
9 Sexual health is a state of physical, emotional, mental and social well-being in relation to sexuality; it is not 
merely the absence of disease, dysfunction or infirmity. Sexual health requires a positive and respectful 
approach to sexuality and sexual relationships, as well as the possibility of having pleasurable and safe sexual 
experiences, free of coercion, discrimination and violence. For sexual health to be attained and maintained, the 




1.3.1 The sexual response cycle  
The sexual response cycle describes the physiological processes that occur during sexual 
activity and was first described by Masters and Johnsen in 1966 [106]. Their original model 
had four phases and is called linear as the entry to sexual activity was excitement (arousal) 
leading to a plateau (advanced arousal) followed by orgasm and finally resolution.  
 
a)  b)  
Figure 8a og b. Models of the sexual response cycle, a) Linear model. Reprinted with permission from 
McGrawHill Education [106, 107] b) Circular model. Reprinted with permission from Basson, Women’s Health 
2010 [108]. 
 
Later Kaplan added desire to this model, a phase preceding arousal [109]. Further 
modifications have been proposed, yet the basic elements of this model are still relevant 
[110]. In 2000, Basson proposed a circular model for female sexual response taking into 
account other entries to sexual activity in addition to innate desire [111]. She described 
emotional or relational benefits as motivation to be receptive of sexual stimuli causing 
responsive desire, arousal and engagement in sexual activity. The linear models have been 
endorsed by the vast majority of males and about half of females, however the circular model 
has shown increased relevance among women with sexual dysfunctions [112, 113]. The 
biopsychosocial model and sexual response cycles identify areas which might be related to 




1.3.2 Sexual dysfunction in the general population and in lymphoma survivors  
There is a significant difference between sexual dysfunction and a sexual problem, as sexual 
dysfunction not necessarily imply a problem for the individual. A sexual problem is present 
only if the individual defines it as such [100].  
General population: Sexual dysfunction are common in the general population (age 16-80 
years), and more prevalent among women (43-51%) than men (30-42%) [114-116]. Of note, 
only 10% of both genders reported distress related to the sexual dysfunction [115]. Women 
report on lack of sexual interest, difficulties reaching orgasm, vaginal dryness and lack of 
sexual enjoyment, while the most prevalent problems among men were lack of interest and 
erectile problems [115]. The most important risk factors for a lower sexual functioning were 
increasing age, depression, self-reported poor health status, lower frequency of sexual 
activity and sexual factors in relationships, additionally among women; postmenopausal 
status probably due to loss of estrogen stimulation of the vaginal mucosa causing 
vulvovaginal atrophy and dryness in addition to reduced sexual responsiveness (arousal, sexual 
pleasure and orgasm) and among men; vascular disease [115-117]. 
In a cohort of younger cancer patients, aged 15-39 years at diagnosis and 52% with a 
lymphoma diagnosis, 43% experienced a negative influence on sexual life by their cancer 
diagnosis at two years follow-up [93]. In lymphoma survivors after conventional 
chemotherapy, 24-36% reported that the lymphoma experience had negatively influenced 
their sexual life (mean follow-up time of 20 years) [118]. In NHL lymphoma survivors with 
follow-up time of 2-5 years, 24-29% usually or always had sexual dysfunctions, while 31-
46% of the survivors reported sexual dysfunctions to occur sometimes, no comparison to the 
general population was reported [104]. In a study on HL survivors, median 18 years follow-
up time, the prevalence of sexual problems was high (54% decreased sexual interest and 41% 
decreased sexual activity). However, this did not differ from sibling controls [119] and 
illustrates the importance of a control group in studies on sexual function. In a longitudinal 
study of HL patients, sexual dysfunction at time of diagnosis improved with time in younger 
persons with early stage disease, while those >50 years with advanced stage disease 
experienced longer lasting sexual difficulties [92]. In that study, Behringer and colleagues 
found a strong association between sexual functioning at time of diagnosis and later during 




Among SCT survivors, sexual function was one of the most frequently reported 
transplant-related concerns; reported by 28-31%, 1-3 years after treatment [98]. In a 
longitudinal study on sexual function in auto- or allo-SCT treated men and women with 
hematological malignancies with 3 years follow-up, the survivors had lower sexual 
functioning than normative controls, and female survivor had inferior sexual functioning 
compared with males [120]. The difference in sexual functioning between gender was in line 
with a report on SCT-survivors of hematological cancer from 1999 [94]. Still, data on sexual 
function in long-term lymphoma survivors after auto-SCT are sparse. In a cross-sectional 
study on 50 lymphoma survivors after auto-SCT with a median follow-up of 30 months, 33%  
had reduced sexual desire and 40% reduced sexual function, while 12/31 men had erectile 
dysfunction (ED) [121]. 
Previously reported risk factors for sexual dysfunctions in lymphoma survivors were 
older age, female gender, shorter time since diagnosis, advanced stage disease, altered body 
image, mental distress, CF, lower physical health, and lower social functioning [92, 93, 104, 
118, 122] in addition to low testosterone level among males [122]. Among SCT-survivors, 
risk factors for sexual dysfunctions were older age, female gender, lower education and 
income, fatigue, decreased emotional functioning, global QoL and graft vs. host disease [94, 
120] and among males and female leukemia survivors; total body irradiation [120, 123]. 
However, knowledge on sexual function and associated risk factors among long-term auto-
SCT lymphoma survivors is limited and one of the reasons for including this in my thesis. 
 
1.4 Lifestyle behavior 
It is expected that noncommunicable diseases10 will continue to be the main cause of years of 
life lost in high-income communities also in the future [58, 124]. The major 
noncommunicable diseases contributing to morbidity and mortality are; CVD, cancer, 
chronic respiratory disease and diabetes [125]. CVD and secondary cancer are conditions 
more frequent among auto-SCT lymphoma survivors compared with the general population 
                                                        
10 “Noncommunicable diseases, also known as chronic diseases, tend to be of long duration and are the result 
of a combination of genetic, physiological, environmental and behaviors factors. The main types of 




as described earlier. However, reducing the burden of noncommunicable diseases is possible 
with a shift towards a healthier lifestyle; non-smoking, weight control, physical activity and 
avoiding alcohol misuse [126]. Additionally, a healthy lifestyle may improve health-related 
QoL in survivors of non-hematological malignancies [127] and lymphoma survivors [128].  
 
1.4.1 Physical activity 
It is widely accepted that physical activity has positive implications for CVD and type 2 
diabetes and mental health in the general population [58, 59, 129]. In addition, studies have 
reported on positive effects of physical activity on the risk of primary cancer [130], cancer 
recurrence [131] and survival [132, 133]. Health institutions unanimously recommend 
physical activity in order to improve health outcomes in the general population [58, 134] and 
these recommendations also apply to cancer patients and survivors [135, 136]. The potential 
health benefits may be due to the physical activity per se, or indirectly due to a healthy 
energy balance and weight control. In a small study on lymphoma patients (n=29), 61% met 
recommendations for physical activity at time of diagnosis [137]. In previous studies on 
lymphoma survivors, physical activity has been related to better QoL [138] and an 
intervention study documented positive effect of physical exercise on psychological and 
physical fitness [139]. 
Despite recommendations on physical activity, studies indicate that cancer survivors 
are less physically active than cancer free controls [140]. Previous reports from Canadian and 
North-American cohorts found that 27%-33% of cancer survivors were physically active 
[127, 141], while 45% of Norwegian cancer survivors has been reported to be physically 
active [142]. Based on clinical experience, most lymphoma patients experience a significant 
reduction of physical functioning after auto-SCT treatment. 
 
1.4.2 Overweight 
Body mass index (BMI) is by definition not a human behavior, however often the result of 
the balance between diet and energy consumption through physical activity. In the following 
I will refer to BMI as a lifestyle factor. The prevalence of overweight is rapidly increasing in 
high-income countries and is a risk factor for noncommunicable diseases like CVD and type 




association between overweight and risk of several malignancies, including HL [143, 144]. 
Additionally, reduced survival has been reported in overweight persons with ovarian, 
endometrial, pancreatic, colorectal and prostate cancer and recurrence of breast cancer might 
be more frequent in overweight females than those with a normal weight [145]. As a 
consequence of the global epidemic of overweight and associations to negative health 
outcomes, obesity is ranked as the fifth cause of death worldwide [125]. In order to improve 
public health, health authorities recommend a BMI<25 for the adult population (table 2)  [58, 
126]. 
Weight gain after treatment has been reported in lymphoma patients both with and 
without B-symptoms at diagnosis [146], however data on prevalence of overweight in auto-
SCT lymphoma survivors, is sparse. 
 
Table 2 The classification of body mass index into different levels. 
Body mass index classes 
Class Body mass index (kg/m2) 
Underweight ≤18.5 
Normal weight 18.6 – 24.9 
Overweight 25.0 – 29.9 
Obesity ≥ 30.0 
 
1.4.3 Smoking 
Smoking tobacco is currently one of the main risk factors for noncommunicable disease-
related morbidity and mortality worldwide [58]. Smoking causes an increased risk of CVD 
and several malignancies of which lung cancer is the most frequent [147]. Preventable 
mortality due to lifestyle-changes is mainly related to CVD, chronic obstructive pulmonary 
disease and lung cancer [148]. Smoking cessation has been recommended for more than five 
decades [149], and the smoking prevalence has declined in Norway during this time. 
However, 19% of the population was smoking in 2017 (11% daily and 8% occasionally), 
with no difference between genders [150].  
In addition to the increased risk of CVD among lymphoma survivors, an increased 
risk of lung cancer among HL survivors treated with radiotherapy has been observed [54], 
and smoking had an additive effect on the risk [55]. Hence, smoking cessation is of great 





Diet is an important factor for maintenance of a healthy energy balance. On the other hand, 
certain nutrients have been associated with risk of cancer. The health authorities 
recommendations for a healthy diet incorporates these findings [58]. In spite of 
acknowledging the importance of a healthy dietary intake, this will not be the main focus in 
this thesis due to a high level of methodological uncertainty. 
 
1.4.5 Alcohol 
Alcohol misuse is associated with a more risky health behavior and relates to increased risk 
of both CVD and cancer as well as psychological illness [58]. Accordingly, it is of great 
importance to limit alcohol consumption after auto-SCT. In survivors of hematological 
malignancies treated with SCT, risky alcohol consumption was less frequent among 
survivors compared to sibling controls [151]. This issue will be briefly examined within this 
thesis. 
 
1.4.6 Risk factors of an unhealthy lifestyle 
The biopsychosocial model is also applicable to lifestyle behavior, as it is influenced by 
multiple factors which relate to and probably overlap the other [103]. Figure 9 illustrates the 
main influences on lifestyle behavior and the conceptual framework this thesis is based on.  
 
  




Facing the need of auto-SCT treatment might motivate for lifestyle change in order to 
avoid future illness, hence be a “teachable moment” [152, 153]. However, information on 
lifestyle behavior among auto-SCT lymphoma survivors is sparse [151, 154], and will be 




2    Chapter: AIMS OF THESIS  
 
Aim 1: Investigate sexual activity and sexual functioning in male and female long-term 
lymphoma survivors treated with auto-SCT, and to compare the results to those of gender 
and age-matched normative controls (paper I and II). 
 
Aim 2: Investigate the associations between relevant characteristics of the survivors and 
sexual activity and sexual functioning, with a special emphasis on the relationship between 
CVD in the male sample and menstrual status and hormone therapy in the female sample and 
sexual outcomes (paper I and II). 
 
Aim 3: Acquire information regarding lifestyle behavior in long-term lymphoma survivors 
treated with auto-SCT, and to compare the results to those of gender and age-matched 
normative controls (paper III). 
 
Aim 4: Investigate associations between adherence to recommendations for a healthy 




3    Chapter: MATERIAL AND METHODS 
3.1 Study design, setting and participants 
A cross-sectional study on auto-SCT lymphoma survivors in Norway was conducted during 
2012-2014 by the four university hospitals responsible for such treatment. The main purpose 
was to investigate long-term adverse effects in this group of heavily treated cancer survivors. 
This thesis is part of this comprehensive national study. The lymphoma patients treated with 
auto-SCT were identified through the Oslo Lymphoma Registry and records from 
multidisiplinary meetings at the Norwegian Radiumhospital and through separate treatment 
records at the other university hospitals. Eligibility criteria were; age ≥18 years at auto-SCT; 
auto-SCT treatment during 1987-2008 for lymphoma; alive per 31.12.2012. Exclusion 
criteria were ongoing cancer treatment and no or unknown domestic address. Eligible 
participants received postal invitation including a questionnaire with a reminder 6 weeks 
later, and 78% (n=312) of them returned the questionnaire (Figure 10). Overall 274 (69%) of 
the eligible auto-SCT lymphoma survivors participated in an outpatient clinical examination. 
During preparations for the chronologically second article, paper I, two men with 
active cancer treatment were identified, and excluded from further analyses (remaining study 
sample, n=310). Regarding the published article, paper III, the exclusion of these two 
participants was considered unlikely to alter the conclusions. Reasons for the lack of 
identification of these non-eligible survivors at an earlier time point has been evaluated and 
will be improved upon in future projects. Additional exclusion criteria for paper I and II 
were; total brain irradiation; treatment with allo-SCT; and incomplete assessment of sexual 
outcomes in respective questionnaires. Figure 10 details the eligibility process and 
participants providing data for paper I-III.  
Information on diagnosis and treatment were retrieved retrospectively from medical 
and radiation records at the respective hospitals and the Oslo Lymphoma Registry 
(Norwegian Radium Hospital). The respondents completed a multi-item questionnaire (men 
125-items, women 133-items), including socio-demographic, psychological and somatic 
factors in addition to information on sexual functioning and lifestyle behavior (physical 




Overall 274 (69%) of the eligible auto-SCT lymphoma survivors participated in an outpatient 
clinical examination. 
The attrition analysis did not identify any difference between respondents and non-
respondents regarding gender, lymphoma- or treatment-related factors. The mean age at 
survey was higher in respondents (55 years) than in non-respondents (52 years).  
 
 
Figure 10. Flowchart of lymphoma survivors after high dose chemotherapy with autologous stem-cell 
transplantation, detailing eligible and non-eligible survivors and among eligible survivors detailing samples 






In order to compare the findings in lymphoma auto-SCT survivors to controls, age- and 
gender matched controls were drawn from three different samples. 
Paper I: Normative data came from a sample of Norwegian males (age 20-79 years) were 
3494 men had received a postal invitation. A valid Brief Sexual Function Inventory (BSFI) 
questionnaire was obtained from 31% (n=1092) of these men. Response rate according to age 
was; 20-29 years, 19%; 30-39 years, 27%, 40-49 years, 32%, 50-59 years-old, 37%; 60-69 
years, 30% and >70 years, 29% [155].  
Paper II: Normative data came from a sample of Norwegian females (age 20-69 years). 
Overall, 2800 women received a postal invitation including the Sexual Activity 
Questionnaire (SAQ). A valid SAQ questionnaire was obtained from 42% (n=1165) of these 
women. Response rate according to age was; 20-34 years, 32%; 35-44 years, 47%; 45-55 
years, 50%; 56-69 years 41% [156]. 
Paper III: The Tromsø study is a population-based cohort, considered representative of the 
Norwegian population. The sixth wave of this survey (Tromsø 6, n=12,984) was conducted 
in 2007 – 2008 and included persons 30-87 years of age, the response rate was 63% and 68% 
for men and women, respectively. All participants had measurements of height and weight. 
Items regarding physical activity and smoking were identical to items in our questionnaire, 
while items on food habits were similar [157].  
3.3 Main outcomes   
3.3.1 Male sexual functioning  
The main outcome in paper I was sexual function in male auto-SCT lymphoma survivors, 
assessed by the BSFI (Appendix B). The BSFI is a validated short instrument assessing 
current sexual experiences among men. It was developed in men (median age 41 and 60 
years), attending either a urology clinic due to sexual problems or the general practitioner 
due to any cause. The BSFI has been used and validated in general population cohorts [158, 
159], and normative data from a sample of Norwegian men was available [156].  
The instrument (total 11 items) assess three functional subscales; drive (two items), 




erectile and ejaculatory function (one item on drive, erection and ejaculation, respectively), 
and overall sexual satisfaction (one item)[158]. Responses were rated 0-4, with zero 
presenting the poorest function, biggest problem and least satisfaction, and four the best 
function, no problem and greatest satisfaction. Subscale scores were calculated by adding 
values for corresponding items divided by number of items (possible range 0-4), and a total 
BSFI score (adding all values except sexual satisfaction, possible range 0-40). The total BSFI 
score was considered an assessment of overall sexual functioning. The response alternatives 
on item 7 was slightly different between survivors and controls, hence score 2 and 3 were 
merged for controls. In order to compare sexual problems between survivors and controls, a 
subscale caseness was defined. This operationalization was not part of the original BSFI, but 
has been described as a method to compare sexual problems between different cohorts [160]. 
Total sum score for each subscale was calculated, and the cut-off values for caseness 
(problem) were; drive 3, erection 7, ejaculation 5, DEE (a combined sum score for drive, 
erection and ejaculation) 10; satisfaction 1. A problem with overall sexuality was defined 
as either satisfaction or DEE caseness.  
Three men had missing values on one of the three items concerning erection. We 
performed a single imputation by adding the mean value of the two known item responses to 
the third unknown. Cronbach’s alpha coefficient for the BSFI within the study cohort was 
0.94. 
 
3.3.2 Female sexual functioning 
The main outcome in paper II was female sexual functioning assessed by the SAQ (Appendix 
C). This instrument was developed for breast cancer patients in order to assess sexual activity 
and sexual functioning among women with and without hormonal therapy [161]. The SAQ 
has been validated and used in several cancer populations, and shows good psychometric 
properties, response rates and acceptability among cancer patients [162, 163].  
 The SAQ consist of three parts; 1) information on marriage or intimate relation and 
sexual activity or not; 2) reasons for sexual inactivity, and 3) sexual functioning last month, 
addressing four subscales (domains): pleasure (six items on desire, enjoyment and 
satisfaction), discomfort (one item on vaginal dryness and dyspareunia each), habit (one item 




current study, two items (one on orgasm and one on arousal) were included and added to the 
pleasure subscale according to a previous study [163].  
Reasons for sexual inactivity were categorized into: no partner, partner issues and 
personal issues (items included in the two latter categories were: “too tired”, “physical 
problem” or “not interested in sex”). 
Responses to the four functional subscales; pleasure, discomfort, frequency of sexual 
behavior, and sexual tiredness were rated 0-3, (not at all/not as much/never- very much/≥5 
times/much more/ always). Low value representing low degree of pleasure, discomfort, 
frequency of sexual behavior and sexual tiredness. The sexual function subscales were made 
by summing up scores from respective items. Possible ranges were: pleasure (range 0-18 (0-
24 when items on arousal and orgasm were added)); discomfort (range 0-6), habit and 
tiredness (range 0-3 for both). Of note, values indicating sexual dysfunction were low values 
for pleasure and frequency of sexual behavior and high values for discomfort and sexual 
tiredness. 
Participants who were sexually inactive last month did not respond to items on sexual 
functioning, while those sexually active did not respond to items on reasons for sexual 
inactivity. Cronbach’s alpha coefficients for sexual functioning among the sexually active 
survivors was 0.83. 
 
3.3.3 Adherence to healthy lifestyle recommendations 
The main outcome of paper III was adherence to recommendations for a healthy lifestyle. 
The items on physical activity, smoking, alcohol consumption and diet were adopted from 
the Nord-Trøndelag Health Study [164] (Appendix A). Definitions of the recommendations 
for a healthy lifestyle investigated in this thesis were [134]: 
1) Moderate physical activity for ≥150 min per week or strenuous physical activity for ≥75 
min per week 
2) Normal weight (body mass index <25) 
3) Non-smoking 
4) Alcohol consumption less than 10g/day and 20g/day for women and men, respectively 





Assessment and operationalization of the outcome variables 
Physical activity: Respondents reported frequency (never, <once a week, once a week, 2-
3/week, about every day), intensity (no sweating or heavy breathing, sweat and heavy 
breathing, get exhausted) and duration (<15 min, 15-29 min, 30 min-1 hour, >1hour) with 
one item each. Physically active time per week was computed by multiplying frequency and 
duration. The maximum of the computed time-interval was registered. Physically active was 
defined as a proper intensity of physical activity for the required duration of time, as 
described above. The variable was dichotomized into adherence or no adherence (sedentary). 
Body mass index: see paragraph 3.3.2.  
Smoking: Respondents reported on whether they smoked currently, occasionally, prior or 
never had been smoking. The variable was dichotomized into adherence (prior or never) and 
no adherence (current or occasionally). 
Unhealthy alcohol consumption: Respondents reported on mean alcohol intake the last two 
weeks in number of glasses of beer, wine and spirit, respectively. One alcohol unit was 
estimated to be 12g alcohol. Adherence to recommendations was defined as >6 units or >12 
units/week for women and men, respectively, and the variable was dichotomized into 
adherence and no adherence. 
Diet: Respondents reported on intake of fruit and vegetables separately: “How often do you 
usually eat these foodstuffs?” (1/day, ≥2/day, 1-3/week, 4-6/week or 0-3/month). 
Consumption of juice or nectar was reported in a similar way, (one glass = one fruit). Five-a-
day was defined as ≥3 vegetables and ≥2 fruits. The variable was dichotomized into 
adherence and no adherence.  
Degree of adherence to lifestyle recommendations: An ordinal variable computed by sum 
score of the variables: physical activity, BMI <25, non-smoking and adherence to alcohol 
consumption recommendations was made. The possible range was 0-4 (lowest degree of 




Table 3. Explanatory and outcome variables according to paper I, II and III. Of note, a sedentary lifestyle was 
an explanatory variable in paper I and an outcome variable in paper III. 
 Paper I Paper II Paper III 
EXPLANATORY VARIABLES    
Age at auto-SCT x   
Age at survey x x x 
Time auto-SCT - survey in years x x  
Gender   x 
In a paired relationship x x x 
Education x x x 
Household income   x 
Lymphoma entity x x x 
Stage at diagnosis x x x 
NO of chemotherapy regimens prior to auto-SCT x x x 
Total body irradiation part of myeloablative regime x   
Radiotherapy   x 
Radiotherapy in sub-groups x x  
Relapse after auto-SCT   x 
Type D personality x x x 
Chronic fatigue x x x 
Anxiety x x  
Depression  x  
Mental burden    x 
Cardiovascular risk and comorbidity x   
Medication interfering with sexual function x   
Hormonal status and among women; replacement therapy x x  
Somatic burden   x 
Somatic illness, interference on activity of daily living   x 





Table 3 Continued. Explanatory and outcome variables according to paper I, II and III 
 Paper I Paper II Paper III 
OUTCOME VARIABLES    
Male sexual function x   
Male sexual problem caseness x   
Female sexual activity  x  
Female sexual function  x  
Sedentary lifestyle   x 
Overweight   x 
Smoking   x 
Alcohol consumption   x 
Degree of adherence to lifestyle recommendations   x 
 
 
3.4 Socio-demographics and lymphoma-related factors 
3.4.1 Socio-demographic information  
Data related to age were obtained from medical records, while the remaining data were self-
reported and used in all three papers (Appendix A).  
Age: Age at survey was analyzed according to four age-groups; 26-40 years, 41-55 years, 56-
65 years and >65 years in paper I. Age at diagnosis, age at auto-SCT and age at survey were 
analyzed as continuous variables in paper II and III.  
Household income: dichotomized with cut-off >600.000 nkr/year (≈ 63.900 €) or not.  
Education: dichotomized with cut-off >12 years of education or not.  
Being in a relationship: dichotomized into being married or cohabitant or not. 
 
3.4.2 Lymphoma-related factors 
These data were obtained from medical and radiation records and the Oslo Lymphoma 
Registry.  
Lymphoma diagnosis: Participants were sub-grouped according to HL (cHL and NLPHL), 
indolent NHL (follicular lymphoma and other indolent lymphomas) and aggressive NHL 
(lymphoblastic lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, mantle cell 




Lymphoma stage: Dichotomized with cut-off ≥ stage III (paper I-III). 
NO of chemotherapy regimens prior to auto-SCT: Sub grouped into one, two and ≥3 
chemotherapy regimens prior to SCT (paper I-III). 
Radiotherapy: Dichotomized between prior treatment with irradiation or not in paper III. In 
paper I and II the following sub-groups were defined: supradiaphragmal, subdiaphragmal, 
total body irradiation and other (irradiation not specified). 
TBI myeloablative regime: Dichotomized between a myeloablative regime containing total 
body irradiation or not (paper I-III). 
Relapse after auto-SCT: Dichotomized between lymphoma relapse after auto-SCT or not 
(paper III). 
 
3.5 Measurements  
In survivors attending the clinical examination the following measurements were performed 
at the respective hospitals: blood pressure (three consecutive measures with mean of the last 
two reported), height and weight, and collection of fasting blood samples by venipuncture 
(before 10.00 AM). Frozen samples were sent to The Department of Medical biochemistry, 
Oslo University hospital, The Norwegian Radium Hospital for assessment of low-density 
lipoprotein, hemoglobin A1c, glucose, testosterone, sex hormone-binding globulin (SHBG), 
estradiol, follicle stimulating hormone (FSH)) and luteinizing hormone (LH), (Roche E-
platform). The equation for estimation of free androgen index (FAI) was: testosterone*10/ 
SHBG.   
 
3.5.1 Psychological factors 
The Type D personality score (DS14) assesses two personality traits; negative affectivity 
(seven items) and social inhibition (seven items) [165]. Responses were given according to a 
Likert scale 0-4, possible range of responses 0-28 with cut-off ≥10 for negative affectivity 
and social inhibition. Presence of both these traits was consistent with a Type D personality. 
Cronbach’s alpha coefficients for negative affectivity/social inhibition were: 0.90/0.88 (paper 
I), 0.90/0.84 (paper II), 0.90/0.87 (paper III). 
Anxiety and depression were assessed by the Hospital Anxiety and Depression Scale with 




highly present). Possible range 0-21 for both anxiety and depression, with cut-off ≥8 for 
caseness of both these two conditions. Cronbach’s alpha coefficients for anxiety/depression 
were: 0.83/- (paper I), 0.89/0.85 (paper II), 0.86/0.82 (paper III). 
Symptoms of post-traumatic stress was assessed by the Impact of Event Scale with seven 
items on intrusion and eight items on avoidance [167]. Scoring of responses were: 0, not at 
all; 1, rarely; 2, once in a while; 3, sometimes; 4, quite often; 5, often. The responses were 
summarized into a total score with possible range 0-75. We considered a cut-off ≥35 to be 
consistent with a probability of post-traumatic stress syndrome. Cronbach’s alpha 
coefficients were: intrusion 0.92, avoidance 0.90 (paper III).  
Mental burden: We constructed a categorical variable on mental burden by adding caseness 
of anxiety and depression and post-traumatic stress symptoms with cut-off ≥2 for presence of 
mental burden (paper III).  
 
Chronic Fatigue is a condition with both psychological and somatic factors, however 
included in this paragraph. 
Chronic fatigue was assessed by the Fatigue Questionnaire with four items on mental fatigue 
and seven items on physical fatigue [81, 82]. Severity of symptoms the last four weeks are 
compared to similar symptoms the last time the respondent was well-being. Responses were 
rated 0-3, (as before-very much more). Summarizing respective item scores gave the 
following possible scores; mental fatigue 0-12, physical fatigue 0-21 and total fatigue 
summarizing all items 0-33. In this thesis, we used a dichotomized variable with CF 
considered present if ≥4 symptoms were graded ≥2 and the duration of symptoms was ≥6 
months. Cronbach’s alpha coefficients were: total fatigue 0.93 (paper I), total fatigue 0.92 
(paper II), total fatigue 0.92, physical fatigue 0.93, mental fatigue 0.80 (paper III). 
 
3.5.2 Somatic factors 
All participants reported on height, weight, prior or present somatic illness (secondary 
malignancy, heart-, lung-, kidney-, liver-, thyroidal- or hematological disease, stroke, high 
blood pressure, diabetes, gastric ulcer, arthritis, osteoarthritis, back pain or other diseases), 
medication and whether the somatic disease interfered on activity of daily living or not. 




additional information: measured blood pressure, height and weight; blood samples and a 
physicians’ report regarding transient ischemic attack, stroke, angina pectoris and myocardial 
infarction. Measured parameters were used when available and self-reported measures for the 
remaining participants. The following somatic factors were defined: 
Body mass index (BMI): calculated as weight (kg) divided by squared height (m2) and 
categorized into; normal weight BMI<25; overweight BMI ≥25; and obesity BMI ≥30. 
Hypertension: Systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or 
antihypertensive medication or self-report of high blood pressure (paper I). Self-report only 
(paper III).  
Hypercholesterolemia: Low-density lipoprotein ≥4.1 mmol/L (160 mg/dL) or cholesterol-
lowering medication (paper I). 
Diabetes: Hemoglobin A1c ≥6.5% or fasting glucose ≥7.0 mmol/L or anti-diabetic 
medication or self-report of diabetes (paper I). 
Cardiovascular comorbidity was based on risk factors for CVD (smoking, obesity, 
hypertension and hypercholesterolemia), diabetes mellitus and CVD (angina pectoris, 
myocardial infarction, transient ischemic attack or stroke). We divided this variable into four 
sub-groups: 1) neither cardiovascular risk factors, diabetes nor CVD, 2) 1 cardiovascular 
risk factor, but no diabetes or CVD, 3) prevalent diabetes and 4) prevalent CVD (paper I). 
Somatic burden: was based on self- report of the somatic diseases listed at the beginning of 
this paragraph and we constructed a summary score, with cut-off ≥4 for somatic burden 
(paper III). 
Interference of somatic disease on activity of daily living: Dichotomized between 
participants reporting somatic disease interfering on activity of daily living and not (paper 
III). 
 
3.5.3 Gonadal hormonal status and hormonal replacement therapy 
Male sample 
Age-specific reference values of free androgen index (FAI) and LH were used to define low, 
normal and elevated serum levels of male gonadal hormones and the FAI [168]. In order to 
distinguish between males with an adequate testosterone production and those with low 




variable with three subgroups: 1) Normal FAI + normal LH, 2) normal FAI + elevated LH 
and 3) low FAI + any level of LH. Additionally, the male sample was dichotomized 
according to ongoing testosterone replacement therapy or not, hence analyses excluding men 
on replacement therapy could be performed (paper I).  
 
Female sample 
A categorical variable for gonadal hormonal status with three subgroups was defined: 1) 
Premenopausal status with regular bleedings and cyclic ovarian function (any level of 
estradiol, FSH <20 IU/l and LH<15 IU/l), 2) postmenopausal status with persistent 
amenorrhea, estradiol <0.10 nmol/l, FSH >20 IU/l and LH >15 IU/l) [169], 3) hormone 
replacement therapy (HRT) (estrogen supplemental therapy n=25, oral contraceptives n=1) 
and we assumed these women to be postmenopausal. An individual consideration was 
performed in five cases with an inconsistency among reported menstrual bleeding and blood 
samples. Perimenopausal women (irregular bleeding or amenorrhea in addition to estradiol 
>0.10 - <0.30 nmol/l, FSH>20 IU/l and LH>15 IU/l, n=3) were categorized in the 
postmenopausal group. POI was defined by postmenopausal status or initiation of HRT 
before the age of 40 years, and dichotomized into POI or not (paper II).  
 
3.6 Statistics 
3.6.1 All papers 
Categorical variables were presented as number (percent), age and time as median (range) 
and the sexual function scores as mean (standard deviation (SD)). Independent sample t-test 
was used to compare means (normally distributed data) between survivors and controls and 
among sub-groups of survivors (equal variances not assumed, paper I).  
Age-adjusted binary logistic regression models were used to assess risk of dichotomic 
outcomes among survivors and controls (paper I, BSFI problem; paper II, sexual activity; 
paper III, physical activity, overweight and smoking) and to assess associations between 
explanatory variables and dichotomic outcome variables among the survivors (paper II, 
sexual activity; paper III, physical activity, overweight and smoking). Effect estimates were 
presented as odds ratios (OR) [95% Confidence Intervals (CI)]. Multivariable regression 




explanatory variables with a p-value ≤0.25 in age-adjusted regression models. Additionally, 
covariates relevant for each model were included in order to adjust for possible confounding. 
A two-sided p-value ≤ 0.05 was considered statistically significant. SPSS version 24 (paper 
III) and 25 (paper I and II) was used as statistical software (IBM Corporation, New York, 
USA).   
Controls were drawn by frequency matching with three (paper I) and five (Paper I and 
III) times as many controls as survivors randomly drawn within each ten-years age-interval 
[170]. Internal consistency reliability of the instruments in the study sample was measured by 
Cronbach’s coefficient alpha and 0.7-0.9 was considered acceptable [171].  
 
3.6.2 Paper I and II 
Analyses on sexual functioning (items and domains) among the total sample of male 
survivors and the sexually active sub-group of female survivors were performed and 
compared to respective controls. Additionally, differences between survivors’ and controls’ 
domain scores were analyzed according to age groups (males: 20-40 years, 41-55 years, 56-
65 years, >65 years and females: 20-44 years, 45-54 years and ≥55 years of age.) 
Age-adjusted linear regression models were used to assess associations between 
explanatory variables and continuous outcome variables (sexual functioning) among 
respective male and female cohorts of survivors (the sexually active sub-group). Effect 
estimates were presented as unstandardized regression coefficients [95% CI]. A second-
degree polynomial was added for age and observation time to assess non-linearity. 
Accordingly, in paper I, age at survey was included in the models as a categorical variable 
with four age-groups (20-40 years, 41-55 years, 56-65 years, >65 years). 
Standardized mean difference (SMD) was calculated as effect size and clinical 
significance was considered to be none (SMD 0-0.20), small (SMD 0.21-0.49), moderate 
(SMD 0.50-0.79) or large (SMD ≥0.80) [172, 173].  
Sensitivity analysis with non-parametric methods were performed and revealed few 





3.6.3 Paper I 
Agreement on obesity (BMI ≥30) based on measured and self-reported height and weight 
was considered to be good (kappa 0.86). In multivariable linear regression models, age at 
survey, relationship status, education and medication with possible interference on sexual 
function were added as covariates. In the estimation of SMD, SD of controls was used as 
denominator due to heteroskedasticity [173, 174].  
Equation (Glass delta):     
3.6.4 Paper II 
Pearson Chi-square test was used to compare proportion of sexually inactive survivors to the 
proportion among controls, and to compare differences in reasons for sexual inactivity 
between the same groups. In the estimation of SMD, the denominator was computed based 
on SD and sample size from both controls and survivors. Additionally, a correction factor for 
small sample size was added to the equation (not shown) [175, 176]. 
Equation (gHedges):    
3.6.5 Paper III 
The agreement on overweight (BMI ≥25) based on measured and self-reported height and 
weight was good (kappa 0.80). Ordinal logistic regression models were used to assess 
associations between explanatory variables and degree of unhealthy lifestyle in survivors. In 
multivariable analyses age, education and income were added as covariates. 
 
3.7 Ethics 
All procedures performed in this thesis involving the participants were in accordance with 
the ethical standards of Regional Ethics Committee South East (no #2011/1353) who 
approved the study. Informed consent was obtained from all individual participants included 




4    Chapter: SUMMARY OF MAIN RESULTS 
4.1 Paper I 
“Sexual function in long-term male lymphoma survivors after high-dose therapy with 
autologous stem-cell transplantation” 
This paper reports on a total of 159 male survivors median age 55 years at survey of whom 
75% were in a partnered relationship at a median of 8.2 years after auto-SCT. Low FAI and 
LH was found in15% and 5% used testosterone replacement therapy while 27%, 14% and 
12% reported CF, anxiety and CVD, respectively. A total of, 55% had a sedentary lifestyle. 
Forty-three percent of survivors had problems with sexual drive and 54% had erectile 
problems, corresponding proportions among controls were 24% and 31%. Odds ratio [95% 
confidence intervals] of sexual problems among survivors compared with controls are 
presented in figure 11 (figure 4 in the paper). 
 
 
Figure 11 (figure 4 in paper I). Odds Ratio (OR) and 95% confidence interval for BSFI caseness (problem).  
 
In multivariable models, the following statistically significant relations were found between 
characteristics of the male survivors and sexual outcomes: 
- Lower sexual drive: Age >55 years at survey, higher education, medication with 
possible adverse effect on sexual function, sedentary lifestyle. 
- Lower erectile functioning: Age >55 years at survey, CF, CVD, medication with 




- Lower ejaculatory functioning: Age >55 years at survey, medication with possible 
adverse effect on sexual function, sedentary lifestyle. 
- Perception of sexual functioning as problematic: Testosterone replacement therapy, 
sedentary lifestyle. 
- Lower overall sexual functioning: Age >55 years at survey, CF, medication with 
possible adverse effect on sexual function, testosterone replacement therapy, 
sedentary lifestyle. 
- Lower overall sexual satisfaction: CF. 
To conclude, this paper showed that the risk of sexual problems was significantly 
higher in male lymphoma auto-SCT survivors than controls. Older age, higher education, CF, 
CVD, medication interfering with sexual function and a sedentary lifestyle were associated 
with lower sexual outcomes. 
 
4.2 Paper II 
“Sexual function in long-term female lymphoma survivors after high-dose therapy with 
autologous stem-cell transplantation “ 
This paper report on a total of 110 female auto-SCT survivors median age 53 years and with 
a median follow-up time from auto-SCT of nine years. Thirty-seven percent of the survivors 
was sexually inactive, a prevalence which did not significantly differ from that of controls. 
However, female survivors were more likely to report personal issues as cause of sexual 
inactivity, than controls. In the sexually active survivors, vaginal dryness, pain during 
intercourse and sexual tiredness was reported by 30%, 22% and 35%, respectively while 
corresponding proportions among controls were 14%, 7% and 15% as shown in figure 12 







Figure 12 (figure 2b in paper II). Sexual Activity Questionnaire item response regarding sexual discomfort and 
sexual tiredness in sexually active survivors and controls. 
 
The sexual function domains; discomfort, habit and sexual tiredness were significantly worse 
in survivors compared with controls (p-values <0.001, 0.03 and <0.001, respectively). The 
differences in sexual discomfort and sexual tiredness were considered to be moderate as 
effect sizes were above 0.50. In age-adjusted models, the following statistically significant 
relations were found between characteristics of the female survivors and sexual outcomes: 
- Lower sexual pleasure: Total body irradiation, a distressed personality.  
- Too tired to have sex (sexual tiredness): Younger age, a distressed personality, 
anxiety, depression and CF. 
Sexual activity was related to younger age, being in a relationship and use of HRT, the 

















Figure 13. Proportion of sexually active and inactive female auto-SCT survivors according to hormonal group. 
Mean (SD)      p-value 
 
1.10 (1.07)      <0.001 
0.58 (0.83) 
 
0.80 (1.01)      <0.001 
0.30 (0.62) 
 
1.25 (0.90)      <0.001 
0.73 (0.80)  




In the total sample, 32 women had POI, 10 women before and 22 women after auto-SCT. 
As 42 women were premenopausal and <40 years at time of auto-SCT, the proportion of 
women developing POI post-SCT was 52%.   
To conclude, female survivors were more likely to report personal-issues as cause of 
sexual inactivity, while the sexually active experienced more sexual discomfort than controls. 
Among the survivors, younger age, having a partner and HRT-use was related to sexual 
activity. Total body irradiation and a distressed personality was associated with less sexual 
pleasure, whereas younger age, mental distress and CF was associated with sexual tiredness. 
 
4.3 Paper III 
“Lifestyle behavior among lymphoma survivors after high dose therapy with autologous 
hematopoietic stem-cell transplantation”  
This paper reports on the total cohort of 312 auto-SCT survivors, median age 55 years at 
survey and the majority, 60%, were males. Proportion of survivors and controls not adhering 
to lifestyle recommendations is illustrated in figure 14. The survivors had lower risk of not 
meeting recommendations compared with controls. The risk was reduced by 23%, 39% and 
45% for a sedentary lifestyle, overweight and smoking, respectively. An unhealthy alcohol 
consumption was reported by 5% of survivors and 3.7% of controls, however these numbers 












Figure 14 Proportion of non-adherence to lifestyle recommendations among survivors and controls.  
 
In multivariable models, the following statistically significant relations were found between 




- Sedentary lifestyle: Older age, low income, CF and a higher burden of somatic 
disease. 
- Overweight: Male gender, fewer chemotherapy regimens prior to auto-SCT. 
- Smoking: Younger age, not in a paired relationship, CF. 
In multivariable ordinal regression models an unhealthier lifestyle was related to male 
gender, more chemotherapeutic regimens prior to auto-SCT, CF and a higher burden of 
somatic diseases (figure 15). 
 
 
Figure 15. Odds ratio and 95% confidence interval for an unhealthier lifestyle according to explanatory 
variables. Adjusted for age, education and income. Reference group was the opposite subgroup and for 
chemotherapeutic regimens prior to auto-SCT, the reference was one regime. 
 
To conclude, despite adhering to more lifestyle recommendations than controls, the 
majority of survivors were sedentary and overweight and every fourth survivor <40 years at 
survey was smoking. Male survivors, those with CF and a higher burden of somatic diseases 
had a 1.8-2.6-fold increased risk for an unhealthier lifestyle than the opposite subgroup, 
while those with ≥3 chemotherapy lines prior to auto-SCT (vs. one regimen) had a 72% 




5    Chapter: GENERAL DISCUSSION 
5.1 Methodological considerations 
5.1.1 Validity 
Validity refers to “the degree to which an observation or measurement can be shown to be 
true and accurate” [177]. Validity of results depends on quality in all parts of the study 
process from establishment of the research questions to the final presentation of the data.  
Internal validity refers to how well the study measures what it claims to measure in 
the study population. This depends on the degree of systematic error and bias in the study 
[178]. This is determined by the quality and appropriateness of the study design, the selection 
process, the collection of information (instrument validity, systemic measurement errors, 
information bias, misclassifications), non-response bias, confounding as well as analytical 
methods, type I and II errors and the interpretation of results [177, 178].   
External validity refers to the generalizability of the results, or to which degree the 
results apply to populations or groups that did not participate in the study [178]. High internal 
validity is a prerequisite for external validity, moreover it depends on how much the study 
population differs from the group or population in question.  
 
5.1.2 Study design  
A cross-sectional study is an observational epidemiologic study investigating the prevalence 
of health outcomes and relationships between explanatory factors and outcomes of interest, 
in a specified population in a narrowly defined time period [178]. Based on an interest of 
prevalence and risk factors for late effects after cancer, the cross-sectional design was 
appropriate and allowed for recruitment of survivors with a long follow-up time. Hence, the 
survivors’ long-term sexual function after auto-SCT was established, even though new late 
adverse-effects may occur with a possible influence on sexual function. Comparisons to 
samples from the general population made it possible to assess differences in prevalence of 
outcomes between the survivors and controls without the cancer and auto-SCT experience, 
thus this thesis is based on a comparative cross-sectional study.  
This study design had limitations: the survey provided “snapshot” information about 




due to lack of baseline data it was not possible to explore the dynamics of the outcomes over 
time; and finally, no interpretations of causality could be made.  
 
5.1.3 Bias 
“Bias is a systematic deviation of results or inferences from truth” [178]. In this thesis, bias 
might result from error which applies unequally to the compared groups [177]. There are 
three main types of bias; selection, information and confounding bias which all might 
influence on the validity of the study. 
 
Selection bias  
Selection bias arises if there are systematic errors in the procedure of selecting participants to 
the study or analyses, which affects the estimation of prevalence of outcomes and 
associations between explanatory factors and outcomes. If selection bias occurs, the 
estimates will differ between the study sample and the population it was drawn from [170, 
178]. In this thesis, the sampling frame was well known, all eligible survivors nationwide 
were invited and the response rate was high. Additionally, the respondents only differed from 
non-respondents with regard to age at survey (55 vs 52 years respectively) and not regarding 
lymphoma-related factors. Hence, the sample is considered representative of Norwegian 
auto-SCT lymphoma survivors. The control groups were chosen based on comparability to 
the study samples regarding outcomes of interest and representativeness of the general 
population [155-157]. The latter is a weakness of the control group in paper I as the response 
rate was low, a trend reported in other population-based surveys on sexuality [179]. In paper 
III, the Tromsø-6 study was not the contemporaneous wave of the Tromsø-study, however it 
included age groups comparable to those of the study sample. 
Non-response bias may occur if characteristics differ between responders and non-
responders. In general population surveys, non-response is related to lower education, a less 
healthy lifestyle and more health issues [180]. However, among the study cohort, it is 
possible that those with more health issues had an increased motivation to participate owing 
to perceived self-interest [181]. Altogether; it is difficult to assess the direction of non-
response/response bias within this thesis. The responding survivors were older than the non-




inactivity and overweight while smoking was less prevalent in older age groups, which could 
cause an underestimation of smoking survivors.  
The motives for completion and response to questionnaires may differ between the 
study and control samples. The survivors might have an increased interest in the study 
questions due to high prevalence of problems at issue or they may have a strong wish to help 
future cancer patients and survivors. Whereas controls may respond due to loneliness, 
boredom, or perhaps non-respond due to lack of interest or because they were more easily 
intimidated by the sensitive aspect of the questionnaire [182]. There was an especially low 
response rate in the control group in paper I but they had a remarkably higher educational 
rate than survivors. It is possible that healthy men with greater sexual confidence are more 
likely to respond compared with healthy men with sexual problems. On the other side, sexual 
problems could be a motivating factor for response among survivors. Altogether, this would 
bias the comparison between survivors and controls towards a greater difference. A lower 
proportion of survivors were in a paired relation and a lower proportion had a higher level of 
education (males) compared with controls, factors which also could overestimate the 
difference in sexual function as not being in a relationship and less education (males) is 
related to more sexual dysfunctions [115, 116].  
 
 Information bias  
“Information bias arises in case of inaccurate measurement of independent, covariate and 
outcome variables” [178]. The inaccuracy may arise between participants of the study 
sample or between compared groups. 
The outcomes in this thesis were based on patient-reported outcome measures 
(PROMs) which have the inherent possibility of recall and social desirability bias factors that 
must be taken into consideration [183, 184]. Among the survivors, sexual expectations may 
differ according to age, and influence on reporting of sexual function [171]. The lymphoma 
survivors might be more likely to report on a symptom if they believe it to be caused by the 
cancer treatment [184]. Additionally, the survivors might have a greater wish of “good 
behavior” (social desirability) hence a tendency to report a healthier living than controls 
without a cancer experience. Such biases would influence on the differences between 




instrument and non-cancer related parts of the recall bias might be more similar, hence the 
comparison less affected by recall bias. Sexual activity and functioning can be assessed using 
other methods with less recall bias, or other PROMs, however compatibility with current 
study design and availability of normative controls were prioritized. 
Erroneous classification of participants’ characteristics is another possible source of 
information bias [178]. A systematic misclassification of outcomes may cause inaccurate 
prevalence estimates, while non-systematically occurring misclassifications of participants’ 
characteristics or outcomes may influence on estimates of associations between these 
variables [177].  
Self-reported measures are generally more prone to errors than measurements 
performed by objective personnel [177]. Hence the latter was used for assessment when 
available and in case of more than one source of data these were combined in order to reduce 
the chance of misclassification. I acknowledge that classification of explanatory variables 
and covariates based on different data sources could introduce bias.  
In paper II, based on mismatch between blood samples and self-report of menstrual 
bleeding in five women, one might suspect that women’s reporting of medication like intra-
uterine device was inadequate. Additionally, there was an ambiguity in the questioning of 
menstrual bleeding, as they did not report cause of non-bleeding, hence this could be either 
physiological or iatrogenic. In paper III, the agreement between self-reported and measured 
BMI was evaluated by estimation of kappa and a Bland-Altman plot [170] and the agreement 
was good, additionally no qualitatively differences was found in sensitivity analyses (data not 
shown).   
In paper III, shortness of breath was an indication of adherence to recommendations 
for physical activity. However, an alternative cause of dyspnea could be cardiorespiratory 
disease, hence survivors might fulfill criteria of intensity of physical activity not because of 
health-gain related to level of activity, but due to disease. This type of misclassification 
would cause an underestimation of physical inactivity in people with cardiorespiratory 
disease and an underestimation of the association between somatic comorbidity and a 
sedentary lifestyle. The operationalization of physical activity was liberal and might have 
underestimated the prevalence of sedentary living. This misclassification would be 




survey questionnaire was less capable than the Tromsø 6 questionnaire to differentiate 
between intake of 5-a-day and not. In both samples the computing of adherence to diet was 
strict, and might explain the very low number of survivors eating 5-a-day.  
In the interest of avoiding diurnal and inter-laboratory measurement differences, 
blood samples were collected before 10.00 AM, frozen, shipped and finally assessed at one 
laboratory (the Norwegian Radium Hospital). 
 
Confounding  
Confounding is the distortion of the direction and magnitude of the association between the 
explanatory and outcome variable, by a third variable (the confounder). The confounder is 
causally or non-causally related to the explanatory variable and causally related to the 
outcome of interest, however not as an intermediate between the explanatory and outcome 
variable [170]. Confounding bias may lessen validity, reliability and transferability of the 
results. In a cross-sectional study, confounding bias can be reduced by either stratification 
according to the confounder or by adding the confounders as covariates in the regression 
models, assuming the confounders have been identified and measured. 
Medication, age and education might interfere with sexual function and comorbidity; 
hence the multivariable models were adjusted for these variables in paper I [185]. Age and 
education are both related to comorbidity and lifestyle behavior and were added as covariates 
in the multivariable regression models in paper III [59]. Gender and income were also 
included as covariates in adjusted models in paper III, as lifestyle behavior differ between 
women and men and by different levels of income [59].  
The risk of residual confounding is still considerable as both psychological and 
somatic health, lifestyle behavior and sexual function are matters of great complexity and 
unidentified confounders are likely to be present. This has to be considered while interpreting 








5.1.4 Statistical considerations 
Collinearity  
Collinearity is the presence of a very strong linear relationship between two or more 
explanatory variables or covariates in a regression model [178]. The inclusion of such 
variables may cause unreliable or biased estimates of the relationship between these variables 
and the outcome, and one of the variables should be excluded. Of note, the removed 
explanatory variable or covariate might also be a confounder, and removal might cause 
confounding bias. 
In paper I, medication was included in the multivariable models to avoid 
confounding, however it is possible that this introduced collinearity to other variables like 
CVD and anxiety and influenced on their relationship to the outcomes. Multicollinearity was 
assessed by variance inflation factor (VIF) and was considered not to represent a problem as 
VIF were mostly below 3. 
 
Missing data  
Respondents with missing outcome data in paper I and II, 5.4% and 8.3%, respectively, were 
excluded from analyses. The latter proportion was higher than the acceptable 5% and might 
cause selection bias, which must be considered while interpreting the results in paper II. 
Missing data on main explanatory or covariate factors were <6%. With the exception 
described above, missing data was considered a minor problem in analyses of the work 
included in this thesis. 
 
Null hypothesis testing, type I and II errors  
The null hypothesis states that there is no effect and is the reverse of the research question. 
The statistical analysis examines the probability of the estimated effect truly being different 
from zero. The level of confidence is usually set to 5% (p-value ≤0.05), which relates to a 
max 5% probability of detecting a difference if the null hypothesis is true or a minimum of 
95% probability that a difference between two groups are in fact different and not present by 





Two errors can be made according to null hypothesis testing: Type I error, to 
conclude that there is a difference, when in fact there is not. Type II error, to conclude that 
there is no difference, when in fact there is. Statistical power relates to the probability of 
detecting an effect when an effect exists. An adequate level of statistical power is usually set 
to 80% and is influenced by effect size, sample size and level of significance. It is possible to 
calculate the required sample size for an 80% power to detect an effect (quantified) with a 
95% probability of a true difference. Overpowering by including many participants may lead 
to detection of statistical differences which have no clinical relevance. Underpowering by 
including too few participants may lead to a type II error. 
In paper II, the female sample was probably too small for statistically significant 
differences to be detected (type II error).  
 
Clinical relevance  
In order to investigate the magnitude of an effect, an effect size should be estimated. A small 
effect may be statistically detected if the sample size is big, however this effect may have no 
clinical relevance. Additionally, a sample size may be too small to detect a statistical 
difference, even though the difference exists and the magnitude is of clinical relevance. An 
effect size is less influenced by sample size and may provide information on the clinical 
relevance of an effect.  
In paper I-II, SMD was the reported effect size [173, 186]. The SMD indicates how 
many standard deviations the mean of the cases is from the mean of the general population; 
in this thesis survivors vs. controls: see paragraph 3.5.2 for interpretation of SMD. The SMD 
estimate becomes uncertain in small groups (<10-20), despite use of a correction factor 
[187], hence estimates of SMD in young male survivors were uncertain (paper I). 
 
Statistical assumptions 
In all papers, there was independence between observations in the compared groups, essential 
for the use of t-test and regression analyses. Linear models used in paper I-II assume a linear 




residuals and homoskedasticity [186]. The latter two assumptions were evaluated by residual 
analyses, which confirmed model assumptions.  
In paper I, non-linearity was present in the association between age at survey and the 
outcomes of interest, accordingly age at survey was treated as a categorical variable. The 
reported outcome scores in paper I-II could be considered skewed, with an argument for use 
of non-parametric methods. However, these methods are more likely to make a type II error 
than parametric methods [171] and the linear regression models are robust models against 
violation of the assumption of normality [171, 188]. Additionally, a normal distribution of 
the means was assumed in variables with a sample size >30, according to the central limit 
theorem [186]. Another strong incentive for the use of regression models, was the concern 
about confounding bias, and current choice of methods allowed for adjustment to reduce 
confounding of the results.  
In paper I-II, the lowest possible number of values for the outcome variables was 
four, however these were assumed to be approximations of an underlying continuous scale 
and moderate variations in scoring systems infrequently produce marked changes in 
conclusions [171]. Additionally, linear regression models have been reported to perform well 
with ordinal outcomes, which further supports the use of this model [171, 189].  
Sensitivity analyses with non-parametric methods was performed and showed that 
most of the main outcomes in paper I-II remained qualitatively unchanged and gave support 
to appropriateness of the selected methods (data not shown).  
 
5.1.5 Considerations regarding the validity of this project 
The internal validity was considered good with high representativeness, internal consistency 
and limited bias. Major confounders were adjusted for in statistical models.  
The generalizability to today’s patients is affected by changes in primary treatment 
and auto-SCT between the study cohort and the lymphoma patients of today. The change 
with strongest impact on risk of late effects is probably the abortion of total body irradiation 
as part of the conditioning regime for auto-SCT. In addition, reduced radiotherapy dose and 
improvements in radiotherapy with reduced field size and improved tumor/normal tissue 




dimensional based CT dose planning and respiratory-gating techniques and use of PET/CT to 
better select patients with residual viable tumor tissue. These factors decrease number of 
irradiated patients, and reduce the amount of tissue irradiated with high doses.  
Nevertheless, the health system in Norway assures equal treatment to all inhabitants 
regardless of ethnicity, religion, socioeconomic status or domestic address. The results are 
therefore transferable to other populations of auto-SCT lymphoma survivors treated within 
the same time period, with the same eligibility criteria for auto-SCT, in countries with a 
similar health system and probably also restricted to developed Western countries. 
Altogether, external validity seems satisfactory. 
 
5.2 Discussion of main results   
5.2.1 Sexual function in males treated with auto-SCT for lymphoma (Paper I) 
In this paper, 43% and 54% of male survivors had problems with sexual drive and erectile 
function, respectively. The risk of sexual problems was higher among survivors than 
controls. Reduced erectile function was related to CVD, while age above 55 years and a 
sedentary lifestyle were related to lower sexual functioning overall. Additionally, CF was 
related to both lower sexual functioning overall and lower sexual satisfaction. 
Sexual problems are common in the general population where 31-42% of men report 
some difficulties [114, 115], as well as among male lymphoma survivors not treated with 
auto-SCT with 22-50% reporting sexual dysfunctions [92, 104, 118]. A recent study on auto-
SCT treated lymphoma survivors, found sexual problems to be the most frequently reported 
late effect, reported by 62% (men and women) [190]. In this thesis, the mean level of sexual 
function was 0.5-0.9 SDs lower in the cohort of long-term male auto-SCT survivors 
compared with controls indicating a clinically significant reduction in sexual functioning.  
Increasing age was a risk factor for sexual dysfunction in the general male population 
and among cohorts of lymphoma survivors treated with and without auto-SCT, [92, 94, 115, 
122]. Corroborating results from the current study cohort. Additionally, considering 
differences between survivors compared to their peers, within different age groups, we found 
the difference in erectile function and sexual satisfaction to increase with increasing age 




sexual function as considerably more problematic compared to their peers, than survivors 
>55 years. This might be explained by either the younger survivors being more concerned by 
a smaller degree of sexual dysfunction, or the older survivors had greater acceptance for the 
sexual dysfunction, possibly due to a response shift [171]. Nonetheless, the difference in 
sexual satisfaction was lower in younger survivors compared with controls which might 
indicate a greater tolerance for sexual dysfunctions as long as it did not affect satisfaction.  
Previous studies have reported an association between worse physical health, and 
lower sexual function in the general population, especially among men, [115, 116, 191]. In 
line with reports on male NHL survivors, where worse physical health was related to 
decreased sexual activity [104, 122]. In this thesis, there was a trend for lower erectile 
function with increasing severity of CVD risk factors/morbidity and a statistically significant 
relationship between current CVD and ED. This finding was in line with ED being a 
predecessor of CVD events in the general population [192]. Male auto-SCT survivors have 
increased risk of CVD, possibly due to accelerated atherosclerosis [193] and endothelial 
dysfunction, factors known to increase the risk of ED [116, 194]. Identification of ED may 
disclose CVD risk or disease which could elicit risk reducing interventions [40, 68]. 
Additionally, CVD related interventions may also improve ED [195]. Lately, a theory of 
accelerated aging after cancer treatment has been proposed, which might be an explanation 
for premature onset of age-related sexual dysfunction [196, 197]; this will be further 
discussed later. The results in this paper might be hypothesis generating for future clinical 
studies exploring the importance of cardiovascular etiology vs. other causal factors for ED in 
male auto-SCT survivors.  
CF was strongly associated with poorer sexual function in a previous report on HL 
patients not treated with auto-SCT [92] and related to lower sexual pleasure and a decreased 
ability to have sex in SCT-survivors [94]. In the cohort of male auto-SCT survivors, CF was 
the only explanatory factor with a negative association to both sexual function and 
satisfaction and I will return to this relationship later in the discussion. 
Mental distress (anxiety, depression and poorer mental function) has been associated 
with reduced sexual function and satisfaction in male lymphoma survivors after conventional 
chemotherapy [104, 122] and in survivors after SCT for hematological malignancies [198]. 




lower sexual functioning overall. Antidepressant or anxiolytic medication were included in 
this variable which might indirectly be a measure of the relationship between mental distress 
and sexual function in this cohort.  
A sedentary lifestyle was related to lower sexual functioning overall in the study 
cohort, in line with results in a previous meta-analysis on lifestyle and erectile function [195]. 
Physical activity has been proposed to cause changes in systemic vascular inflammation and 
thereby influence ED [195]. In this cohort, physical activity might be an indirect measure of 
the importance of good health for maintenance of a sexually active life as described in the 
general population [191].  
In the study cohort, we found an association between low free-androgen index and 
lower sexual outcomes. In general, a certain level of testosterone is necessary for adequate 
sexual function. In addition, low testosterone level is related to increased risk of CVD [199]. 
Hence, low testosterone level might influence sexual function through more than one 
mechanism among auto-SCT survivors. It is however, unclear how testosterone replacement 
therapy influences CVD risk in younger cancer survivors [200]. Altogether; one has to 
include an evaluation of hypogonadal symptoms in addition to possible adverse effects on 
CVD when considering initiation of  testosterone replacement therapy in males with low 
testosterone levels [201].  
The proportion of male survivors reporting use of pro-erectile medication was only 
2%, which is surprisingly low considering that half of this cohort reported erectile problems. 
This may be due to underreporting, but may also illustrate a lack of attention on sexual 
problems among auto-SCT lymphoma survivors and health care personnel. 
 
5.2.2 Sexual function in females treated with auto-SCT for lymphoma (Paper II)    
In this paper, we found no difference in percentage of sexually active women in auto-SCT 
lymphoma survivors compared with age-matched controls. However, the survivors more 
frequently reported personal issues as a cause for sexual inactivity. Among the sexually 
active, the risk of sexual discomfort was higher among survivors than controls. 
In the general female population, having a partner was strongly related to sexual 
activity [191]. This resembles findings in the study cohort, as being in a paired relationship 




The auto-SCT survivors in our study more frequently reported personal issues (too 
tired, no interest in sex or had a physical problem) as reasons for sexual inactivity, compared 
with controls, which might represent indirect measures of the relationship between burden of 
late effects [40] and sexual inactivity [108]. In both the general population and among female 
NHL survivors, worse physical health has been related to reduced sexual function [104, 115, 
185]. 
There was a significant difference in sexual activity between postmenopausal 
survivors and survivors using HRT, with the latter being more sexually active.  Hormonal 
status and HRT was not available for the control group. However, these factors were reported 
in the cohort of the initial SAQ validation study [161] and indicates that the postmenopausal 
auto-SCT female survivors might be less sexually active, while survivors on HRT might not 
differ from the general population. Hence, the reference group chosen for the statistical 
models might be the one deviating from the norm, which needs to be considered when 
interpreting the result.  
Reduced sexual function has been related to older age in the general female 
population [115] and in samples of lymphoma survivors [92, 94]. Contrasting these results, 
younger age among auto-SCT survivors was related to lower sexual functioning with regard 
to sexual tiredness. Possible explanations could be that tiredness has a greater influence 
among those of younger age due to higher expectations of sexual functioning, or the 
reporting of sexual tiredness might be lower among older survivors due to lower expectations 
regarding sexual functioning, which might be considered an age-related response shift [171].  
Survivors more often reported sexual discomfort than controls. Among survivors, 
22% had dyspareunia always or often, while this was reported by 6.5% of controls. In the 
general population, the etiology of dyspareunia is complex and related to menopause, an 
increasing number of chronic health conditions, depression, other sexual problems and sexual 
aspects of relationships [117, 185, 202]. Ovarian insufficiency is frequent after auto-SCT 
[70] and theoretically, this might represent one of the main biological causes for sexual 
discomfort in the subgroup of women with POI or in elder women where auto-SCT might 
have caused a shortened time to menopause [117]. However, the cross-sectional design and 
small sample size might have prevented us from detecting these associations in this thesis. 




and the high prevalence has implications for follow-up. In a previous report, early initiation 
of HRT among women experiencing menopause shortly after SCT was related to better 
sexual function later [204]. Transition into menopause and sexual function, should be 
addressed at consultations with recommendations for HRT in women experiencing 
undesirable symptoms of menopause and especially among women with POI. Additionally, 
vaginal moisturizers and lubricants or referral to a specialist on sexual health should be 
considered.  
In the general female population various chronic somatic diseases and an increasing 
number of chronic conditions has been related to sexual dysfunction [185]. In this thesis, CF 
was associated with sexual tiredness and greater problems achieving orgasm. These 
relationships are possibly due to energy depletion and mental fatigue, which negatively 
influences the sexual experience in line with previous reports on the general population [185] 
and NHL survivors [104].  
Mental distress was also related to sexual tiredness in age-adjusted analyses. This 
result could be confounded by CF, which is known to be associated with both mental distress 
[47] and sexual tiredness within this study cohort. Nevertheless, sexual dysfunctions in 
women are often multifactorial and an evaluation of mental health in women with sexual 
dysfunction is advisable [185, 203].  
 
5.2.3 Concerns regarding sexual function in both gender  
Previous reports have described an increased prevalence of sexual dysfunction compared to 
the general population among survivors of HL with advanced disease treated with 
conventional chemotherapy [92], among male NLH survivors were the majority had received 
conventional chemotherapy [122] and recently sexual problems was reported among 62% of 
auto-SCT lymphoma survivors [190]. To the best of my knowledge, this thesis represents the 
largest detailed studies to date on sexual function in long-term lymphoma survivors after 
auto-SCT, showing significantly lower functioning among both males and females compared 
with age-matched controls. 
In the study cohort, no lymphoma or treatment related factors, except total body 
irradiation among women, were associated with sexual outcomes. Our results contrast 




disease was related to lower sexual functioning [92]. There are two plausible explanations for 
the lack of relationship between lymphoma related factors and outcomes in this thesis; either 
the heterogeneity within the study cohort was too large, hence the power to detect differences 
between defined subgroups were too small, or the intensity of the auto-SCT treatment 
overcame previous treatment burden.  
In age-adjusted models, total body irradiation was related to less drive and lower 
ejaculatory function among males and less sexual pleasure (importance of sex, enjoyment, 
drive, arousal, satisfaction) among female survivors. In previous reports in SCT treated 
survivors after hematological malignancies, total body irradiation was associated with sexual 
dysfunction in men [120] and mucosal damage and vaginal dryness in women [123]. 
Neuropathy, vascular damage and fibrosis interfering on sexual function including 
ejaculation, might result from radiotherapy [205]. There were a limited number of survivors 
treated with total body irradiation in our study, hence lack of an association to sexual 
discomfort among females might be a type II error. Theoretically and based on previous data 
such an association is likely. 
Infertility is a concern likely to influence sexual function among young cancer 
patients and survivors [206]. A recent paper examined knowledge of late effects within the 
current study cohort [49]. Simensen and colleagues observed that infertility was the late 
effect that most survivors recalled after auto-SCT. In the study cohort, fertility-related issues 
might have caused mental distress and secondarily lower sexual functioning, especially 
among the female survivors.  
 
5.2.4 Lifestyle behavior in lymphoma auto-SCT survivors (paper III) 
In this paper, the majority of auto-SCT survivors had a sedentary lifestyle and were 
overweight, while one of five were smoking and a minority had unhealthy alcohol 
consumption. Adherence to lifestyle recommendations for physical activity, BMI and non-
smoking was significantly more frequent among survivors compared with age-matched 
controls. In the study cohort, an unhealthier lifestyle was related to male gender, less 
chemotherapy regimens prior to auto-SCT a higher somatic burden and CF and I will focus 




The prevalence of physically inactive and overweight/obese persons is increasing 
worldwide. In 2015-16, in the Norwegian population (median age 39 years) 34% were 
physically inactive, 39% of females and 56% of males overweight while 19% were smoking 
[58, 207]. Previous studies on cancer survivors have reported an increased risk of a sedentary 
lifestyle and overweight/obesity compared with the general population [129, 140, 208, 209]. 
In a previous study on NHL survivors and SCT survivors of diverse malignancies survivors 
were less physically active than the general population [138, 154]. Contrasting these reports, 
survivors were more likely to practice healthy habits than controls (physical activity, diet and 
smoking) in a study on a large number of survivors after SCT for hematological malignancies 
[210]. Corroborating results in this thesis, where survivors were more likely to meet 
recommendations for physical activity, normal weight and smoking.  
There is consistent reports on a lower prevalence of smoking among cancer survivors 
in general [140, 208], survivors after SCT (20-30% lymphoma) [151] and among auto-SCT 
survivors in this thesis.  
Several possible explanations for the apparently healthier lifestyle among auto-SCT 
survivors exist: They might always have had a healthy lifestyle and good health, disregarding 
the lymphoma. Hence, they are positively selected during the cancer trajectory by staying 
alive (selection by survival). The majority were treated with auto-SCT due to progressive or 
relapsing disease which is an even more serious threat to life than the initial cancer diagnosis. 
Hence, the effect of a “teachable moment” might have been stronger in this study cohort than 
in other cohorts of survivors. Other possibilities were a stronger social desirability bias in 
reporting of lifestyle behavior with the same psychological mechanisms as for the teachable 
moment, and a liberal definition of physical activity causing an overestimation of healthy 
lifestyle. 
Regardless of a healthier lifestyle than the general population, there was still many 
survivors who presumably could benefit from lifestyle change. A population-based survey 
found that younger cancer survivors were more likely to be smoking compared with those of 
older age [211] and in a report on older NHL survivors only 6% were smoking [128]. In line 
with this finding, in the current study cohort, younger age was a risk factor for smoking and 
every fourth survivor under 40 years was smoking. This finding is supported by a previous 




younger survivors [151]. Smoking cessation is of special importance, due to the increased 
risk of smoke-related diseases like CVD and second cancers among lymphoma survivors [54, 
65] and in auto-SCT survivors as reported in this study cohort [2, 45, 56]. 
 Males had a 2-fold increased risk of being overweight and a 79% increased risk of an 
unhealthier lifestyle compared to female auto-SCT survivors. The difference between men 
and women might have been present before auto-SCT, as overweight and obesity is more 
common in males than females in the general population [207]. In addition, it might be a 
result of male cancer survivors being less likely to adopt health-promoting behaviors [128, 
152], also found among SCT-survivors [212].  
Survivors with more chemotherapy prior to auto-SCT had a 72% lower risk of an 
unhealthier lifestyle compared with survivors with auto-SCT as first line treatment. This 
lifestyle factor contributing most to this finding was probably BMI. Theoretically, higher 
cumulative doses of chemotherapy might cause physiological changes and a lower weight. 
This theory is in line with a lower percentage of overweight survivors in this study cohort 
compared with lymphoma survivors after conventional chemotherapy [128]. In the general 
population, BMI increases until the age of 65 years and decreases thereafter [207]. 
Theoretically BMI could be influenced by accelerated aging after chemotherapy among auto-
SCT survivors [196]. Of note, regarding BMI and health risk, it would probably have been 
more interesting to examine obesity [126], however adherence to recommendations were the 
aim of this thesis.  
A higher burden of somatic diseases was associated with an unhealthier lifestyle in 
the study cohort, which corroborates the well-known relationship between lifestyle and 
general health in the general population [124, 126] and among NHL lymphoma survivors 
[128], however in contrast to earlier findings among SCT-survivors [151].  
 
5.2.5 Chronic fatigue  
In this thesis, we examined several explanatory factors related to sexual and lifestyle 
outcomes. Of these, CF was repeatedly related to worse outcomes among auto-SCT 
survivors; sexual function and satisfaction among males, sexual tiredness in females and a 




Despite knowledge of the positive impact of physical activity on CF, auto-SCT 
survivors with CF were less physically active. These conditions possibly have mutual effect 
on each other, which probably increase the sustainability of both conditions and cause a 
vicious circle difficult to break out of [137]. A certain intensity of physical activity seems to 
be required for CF improvement to occur [213]. 
Prior studies have described the relationship between CF and more health disorders 
[1, 88]. This relationship was not directly examined in this thesis; however, the results are 
suggestive of a constellation of survivors with an unhealthier lifestyle, a higher somatic 
burden and CF. This information is valuable in the follow-up of auto-SCT survivors and 
helps to identify vulnerable survivors in need of support for lifestyle changes and early 
detection of risk factors for disease or prevalent health disorders including CF.  
Physical activity and cognitive behavioral therapy should be offered to survivors with 
CF, and probably at an early time point [80, 214]. Additionally, understanding, acceptance, 
adjustment of expectations and prioritizing in daily life are probably reasonable 
recommendations for survivors to improve coping with CF [215]. Considering the results 
within this thesis, an improvement of CF and fatigue level could perhaps secondarily 
improve sexual function among auto-SCT survivors. This needs to be investigated in future 
clinical trials.  
 
5.2.6 The burden of survival; the concept of accelerated aging 
In a cohort of auto/allo-SCT survivors of hematological malignancies, increased frailty was 
found compared with siblings, and frailty was related to subsequent mortality [216]. Among 
auto-SCT survivors in this thesis, one in five had ≥4 somatic diseases, one of three had CF, 
and sexual functioning were lower than among controls despite having a healthier lifestyle 
compared with controls, which intuitively should be related to better health outcomes. Could 
there be a universal factor influencing risk of late effects after chemotherapy? 
In 2006, a hypothesis on a possible cause for the increased frailty in cancer survivors 
was published, namely accelerated aging due to chemotherapy [197]. Maccormick described 
how chemotherapy possibly could influence four mechanisms related to aging; free radical 




A permanent shortening of myeloid stem-cells has been reported in auto-SCT lymphoma 
survivors [217]. However, a recent review found inconsistent results regarding telomere 
length after chemotherapy for solid and hematological malignancies, possibly owing to 
methodological diversity, and further research is warranted [218]. 
Sexual function is known to decrease with ageing, and perhaps accelerated aging 
among auto-SCT survivors could be a player in the complex interactions of sexual 




6    Chapter: CONCLUSIONS 
This thesis provides new knowledge about pattern of sexual function and lifestyle behavior in 
long-term lymphoma survivors treated with auto-SCT, the generalizability to similar groups 
of survivors is the main scientific value of this thesis and the findings should inform on 
information and follow-up of auto-SCT survivors. 
 
Aim 1: The proportion of sexually active female survivors did not differ from controls. 
However, personal issues were a more frequent reason for sexual inactivity among the female 
survivors than controls. Sexual functioning was reduced in male (overall sexual functioning 
and sexual satisfaction) and female (sexual discomfort, lower frequency of sexual activity 
compared with usual, sexual tiredness) auto-SCT survivors compared with controls (paper I 
and II). 
 
Aim 2:  Among male auto-SCT survivors, cardiovascular disease was related to erectile 
dysfunction while older age and a sedentary lifestyle were associated with lower overall 
sexual functioning. Older age and chronic fatigue were related to lower sexual satisfaction 
(paper I). 
Among female auto-SCT survivors, those of younger age and in a relationship were more 
likely to be sexually active compared with the opposites. Additionally, users of hormone 
substitution therapy were more sexually active compared with postmenopausal women. A 
distressed personality and treatment with total body irradiation were related to reduced sexual 
pleasure while younger age at survey, chronic fatigue, anxiety and depression were related to 
more sexual tiredness (paper II). 
 
Aim 3: The majority of auto-SCT survivors had a sedentary lifestyle (55%) and were 
overweight (55%), while 18% were smoking and 5% had an unhealthy alcohol consumption. 
The survivors had a lower risk of being sedentary, overweight and smoking compared with 
controls (paper III). 
 
Aim 4: Older age, chronic fatigue and a higher somatic burden was related to a sedentary 




overweight. Younger age, not in a paired relationship and chronic fatigue was related to 
smoking. Older age, more chemotherapy regimens prior to auto-SCT, chronic fatigue and a 




7    Chapter: IMPLICATIONS FOR THE FUTURE   
7.1 Sexual dysfunctions, profound yet neglected  
In the general population, persons above 50 years seldom discuss sexual problems with their 
doctors [219], and despite 43% of cancer survivors in general reported concerns about sexual 
dysfunctions, only 25% of them received care for their sexual concerns [220]. This is 
possibly due to health personnel’s barriers and cancer patients reluctance to address sexual 
problems [221]. Accordingly, sexuality has been a neglected issue during cancer survivorship 
care.  
Of note, transplanted NHL survivors reported a greater need for information on 
sexual function than NHL survivors after conventional chemotherapy 50% vs. 28%, 
respectively [222]. Among SCT-survivors, a discussion of possible adverse effects on sexual 
function post-treatment was related to a lower level of sexual problems at 3 years of follow-
up [223]. These observations along with the finding of reduced sexual functioning among 
auto-SCT survivors in this thesis encourage the integration of sexual function as a theme in 
the cancer care trajectory of auto-SCT survivors.  
Health care providers are encouraged to use models for communication about sexual 
problems [221] and to follow guidelines on interventions for sexual problems among cancer 
patients [203]. Sexuality is a complex phenomenon and a holistic approach is usually 
warranted [224]. Unfortunately, there is a lack of specialists within sexology in Norway. 
Referral to available expertise based on the probable cause of the survivor’s sexual 
dysfunction is nevertheless recommended [203].  
 
7.2 The importance of a healthy lifestyle  
Auto-SCT survivors have increased risk of life-threatening late effects like cardiovascular 
disease and secondary cancer as well as CF, and according to the results herein; sexual 
dysfunctions. However, the risk and occurrence of these conditions and other late effects may 
be modifiable by a healthy lifestyle, as indicated in relation to CVD [210] and ischemic heart 
disease post-SCT in particular [225]. The prevalence of unhealthy behavior reported in the 
study cohort inform on the need to include lifestyle behavior into cancer survivorship care of 




An evaluation of health-risk based on prior disease, lymphoma treatment and lifestyle 
behavior should be performed in auto-SCT survivors and lead to individualized 
recommendations and support for lifestyle change. However, weight reduction is difficult, 
and a focus on physical activity and a healthy diet may be more useful (E. Giovannucci, oral 
presentation, Onkologisk Forum 2019). Moreover, a respectful approach focusing on the 
individual’s preferences are mandatory.  
 
7.3 Cancer survivorship care  
Cancer survivorship care is an evolving area within oncology. The British National Cancer 
Survivorship Initiative has proposed a risk-based follow-up at different levels in the health 
care system (figure 15), and most auto-SCT survivors probably belong to the high-risk group. 
It is worth mentioning that specialized care delivery during follow-up has been related to an 
insufficient level of preventive health care [227]. Hence, a follow-up including both 
specialist health-care and the general practitioner could perhaps be the best alternative for 
both high- and moderate-risk survivors. 
 
Figure 25. Survivorship health care delivery according to risk of late effects. Adapted from Kiserud, Dahl, 
Fosså. Kreftoverlevere, 2019 [215]. 
 
The British group has also proposed a shift towards personalized advice and information 
from health personnel according to the individuals need and preferences instead of their 
diagnosis, aiming to increase self-management and empowerment of the survivors [228]. The 
personalized approach has also been acknowledged in follow-up of SCT survivors [40]. 




a behavioral change into a healthier lifestyle among cancer survivors [227], is in line with the 
British proposal.  
A consideration on how and when to reveal information on late effects is in place. 
There is agreement that attention on late effects prior to treatment and during follow-up is 
required. Most likely, receiving a treatment summary and survivorship care plan describing 
future risk and appropriate assessments at end of therapy are meaningful [229]. In a 
randomized clinical trial among SCT treated patients, receiving a survivorship care plan 
reduced mental distress [226] and written information was related to higher levels of 
knowledge on late effects among survivors within this thesis  [49]. The use of digital based 
information platforms is emerging and a smartphone application on survivorship among allo-
SCT treated patients was perceived informative, however more relevant >one year after 




7.4 Future research  
Cross-sectional studies have provided urgently needed information on prevalence of late-
effects and risk factors among cancer survivors. Most late effects are diseases common in the 
general population; hence an estimate of excess risk among cancer survivors is warranted. In 
Norway, there are two major surveys on the general population, the HUNT and the Tromsø 
study [232, 233]. In a future process of developing study questionnaires, it would be of 
importance to use instruments comparable to those used in these large, well-defined 
populations. In the last wave of the HUNT study, PROMs on sexual function is included. In 
recent years, a National Quality Registry for lymphoid malignancies have been established 
within the Cancer Registry [234]. An inclusion of relevant and validated PROMs for later use 
in longitudinal studies could be of interest.  
 
The dynamics, causality, and effect of interventions to improve on 1) sexuality and 2) 




longitudinal trials and interventional studies. Areas of great interest within the fields of this 
thesis: 
- Is reduced sexual activity and functioning related to POI, and is POI preventable by 
gonadotropin releasing hormone agonists?  
- Is it possible to mitigate sexual dysfunctions among auto-SCT survivors by 
informational and consultative interventions, and will this influence health-related 
QoL? 
- Which interventions are most efficient for durable lifestyle change to occur among 
auto-SCT survivors, and is lifestyle behavior important for health-related QoL in this 
group of cancer survivors?  
- Does accelerated aging occur after auto-SCT treatment, and is this related to risk of 
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Original text: Chronic fatigue and anxiety were related to lower sexual satisfaction. 
Correct text: Chronic fatigue were related to lower sexual satisfaction. 
 
Statistics 
Original text: The multivariable models were adjusted for age, relationship status, and level of 
education. 
Correct text: The multivariable models were adjusted for age, relationship status, level of 




Original text: Internal consistency (Cronbach’s alpha) in our study was: type D personality, 
0.90 for negative affectivity and 0.44 for social inhibition; CF, 0.92, 0.93 and 0.80 for total, 
physical and mental fatigue and HADS, 0.82 for depression and 0.86 for anxiety. 
Correct text: Internal consistency (Cronbach’s alpha) in our study was: type D personality, 
0.90 for negative affectivity and 0.84 for social inhibition; CF, 0.92, 0.93 and 0.80 for total, 
physical and mental fatigue and HADS, 0.82 for depression and 0.86 for anxiety. 
 
Original text: Assessment for PTSD was performed using IES, which combines seven 
questions on intrusion and eight questions on avoidance to produce a sum score (0–77). 
Correct text: Assessment for PTSD was performed using IES, which combines seven 
questions on intrusion and eight questions on avoidance to produce a sum score (0–75). 
 
 
APPENDIX A  
Study questionnaire, including male specific items 
 
T  T 
T  T 1
   HMAS2012 - menn 
        PAS:  
Dato for utfylling:  -201  
        dag     måned              år 
 
Hva er din høyde?        cm   Hva er din vekt?     kg 
 
Arbeid og sosiale forhold 
 
1. Hva er din nåværende sivilstatus? (Sett kryss x ved det svaret som passer) 
   
Aldri vært gift  
Gift/samboende  
Enkemann/enke  
Separert/skilt            
 
2. Hvilken utdanning er den høyeste du har fullført? 
 
Grunnskole (1-9 år)      
Videregående skole eller yrkesskole (10-12 år)  
Høyskole eller universitet (13-16 år)    
Høyere universitetsgrad (mer enn 16 år)   
 
3.a. Var du i arbeid da du fikk diagnostisert lymfekreft første gangen?        Ja       Nei   
 
b. Hvilket yrke hadde du, da du fikk diagnostisert lymfekreft? ……………………………... 
 
c. Var du i lønnet arbeid før høydosebehandlingen? Ja     Nei   
 
d. Oppgi ditt nåværende eller siste yrke: ………………… ……………………………….. 
 
4. Hvilket alternativ beskriver best din nåværende inntektskilde? 
 
Lønnsmottaker i heldagsjobb……………………………………………..     
Lønnsmottaker i deltidsjobb (gjelder også for deltidspensjoniter)………       
Selvstendig næringsdrivende /freelance………………………………….   
Arbeidsledighetstrygd……………………………………………………   
Uføretrygd/Førtidspensjonert …………………………………………….   
Alderstrygdet eller pensjonert på grunnlag av antall yrkesaktive år (AFP)..  
Hjemmeværende med ansvar for egen husholdning eller for familiemedlemmer  
Student…………………………………………………………………..   
Sykepenger……………………………………………………………….     
Arbeidsavklaringspenger…………………………………………………     
Yrkesrettet attføring……………………………………………………..   
 
Annet, spesifiser ___________________________ 
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5. Har du vært i lønnet arbeid (helt eller delvis) etter høydosebehandlingen?  
(Perioder med sykmelding regnes som å være ”i lønnet arbeid” fordi man bare kan sykmeldes 
om man er i lønnet arbeid.) 
 
Ja, hele tiden         
Ja, men bare deler av tiden       
Nei, ikke vært i arbeid siden   
høydosebehandlingen    
 
b. Hvis ”Ja, men bare deler av tiden”: Spesifiser omtrentlig antall år du har vært i lønnet  
 
arbeid etter høydosebehandlingen:    år 
 
6. Gikk du over på uførepensjon etter høydosebehandlingen? 
Nei      Ja  Hvis ja, når gikk du over på uførepensjon? Årstall:   
 
7. Gikk du over på alderspensjon etter høydosebehandlingen? 
 
Nei      Ja  Hvis ja, når gikk du over på alderspensjon? Årstall:  
 
 
8. Hvor mange timer lønnet arbeid per uke hadde du da du fikk lymfekreft første gangen? 
 
Da du fikk lymfekreft:   timer  
 
9. Hvor mange timer lønnet arbeid per uke har du nå eller siste gang du var i lønnet arbeid? 
 
                        timer 
 
De neste spørsmålene (spørsmål 10-17) besvares bare av dere som har vært i lønnet arbeid (helt 
eller delvis) da dere fikk lymfekreft: 
 
10. Har du skiftet arbeidsplass (arbeidsgiver) etter at du fikk lymfekreft? 
 
  Nei   Ja  - Besvar spørsmålet under: 
 
11. Var kreften noen gang årsak til at du skiftet arbeidsplas  ( rbeidsgiver)? 
 
  Nei      Ja, delvis     Ja, i hovedsak   
 
12. Har du skiftet yrke etter at du fikk lymfekreft? 
 
  Nei   Ja  - Besvar spørsmålet under: 
 
13. Var kreften noen gang årsak til at du skiftet yrke? 
 
  Nei      Ja, delvis     Ja, i hovedsak   
 
14. Har du vært arbeidsledig i perioder etter at du fikk lymfekreft? 
 
  Nei   Ja  - Besvar spørsmålet under: 
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15. Var kreften noen gang årsak til arbeidsledigheten? 
 
  Nei      Ja, delvis     Ja, i hovedsak   
 
16. Har du skiftet arbeidsoppgaver etter at du fikk lymfekreft? 
 
  Nei   Ja  - Besvar spørsmålet under: 
 
17. Var kreften noen gang årsak til endring i arbeidsoppgavene? 
 
  Nei      Ja, delvis     Ja, i hovedsak   
 
 
18. La oss gå ut i fra at arbeidsevnen din på sitt beste i ditt arbeidsliv ville fått 10 poeng. Hvor 
mange poeng vil du gi din nåværende arbeidsevne? (0 innebærer at du ikke er i stand til å arbeide 
i det hele tatt. Sett kun ett kryss ved det tallet som du mener best tilsvarer din nåværende 
arbeidsevne) 
  0  1  2  3  4  5  6  7  8  9 10 
Da du fikk lymfekreft første gangen             
  
I 2012                
 
19. Hvordan vurderer du at din arbeidsevne er med tanke på de fysiske krav ved ditt arbeid? 
 
Meget god   Ganske god   Rimelig god   Nokså dårlig   Svært dårlig
      
 
20. Mener du at din fysiske arbeidsevne er blitt nedsatt på grunn av kreftsykdommen? 
 
Ikke i det hele tatt Nokså lite I noen grad Ganske mye Svært mye 
        
 
21. Hvordan synes du at din arbeidsevne er med tanke på de psykiske krav ved jobben? 
 
Svært god   Ganske god   Rimelig god   Nokså dårlig   Svært dårlig 
      
 
22. Har den psykiske arbeidsevnen din, etter din mening blitt nedsatt på grunn av 
kreftsykdommen? 
 
Ikke i det hele tatt Nokså lite I noen grad Ganske mye Svært mye 
        
 
23. Hva er for tiden husstandens forventede årsinntekt før skatt (lønn og pensjon)? 
Ingen inntekt  
100.000 – 200.000  
201.000 – 400.000  
401.000 – 600.000  
601.000 – 800.000  
801.000 – 1.000.000  
Over 1.000.000  
 
T  T 
T  T 4
Helse og livskvalitet 
 
24. De neste spørsmålene er om hvordan du ser på din egen hels  og om du har andre 
sykdommer / helseproblemer. 
         Ja Nei 
a. Har du fått en annen kreftdiagnose etter høydosebehandlingen?   
 
 
b. Hvis ja, hvilken kreftdiagnose______________________________ 
 
 




Har du eller   Blir du fortsatt Hindrer 
   har du hatt   behandlet for  sykdommen/ 
   denne sykdommen/  sykdommen/  helseproblemet deg 
   dette helseproblemet?  helseproblemet? i aktiviteter i dag? 
 
25. Sykdom/problem 
  Ja Nei Ja Nei Ja Nei 
a. Slag…………………       
b. Høyt blodtrykk………       
c. Astma, kronisk bronkitt,  
    KOLS………………       
d. Sukkersyke / diabetes       
e. Magesår…………….       
f. Nyresykdom………..       
g. Leversykdom ………       
h. Anemi eller annen  
    blodsykdom………..       
i. Skjoldbrusk- 
   kjertelsykdom/ 
   lavt stoffskifte/ 
   høyt stoffskifte………       
j. Depresjon……………..       
k. Leddslitasje (artrose).        
l. Ryggsmerter…………       
m. Leddbetennelse        
n. Andre lidelser:  
angi nedenfor. 
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26. Stort sett, vil du si at din helse er 
Utmerket  
Meget god  
God   
Nokså god  
Dårlig   
 
27. Sammenlignet med for ett år siden, hvordan vil du si at helsen din stort sett er nå? 
 
Mye bedre nå enn for ett år siden   
Litt bedre nå enn for ett år siden   
Omtrent den samme som for ett år siden  
Litt dårligere nå enn for ett år siden   
Mye dårligere nå enn for ett år siden   
 
28. De neste spørsmålene handler om aktiviteter som du kanskje utfør r i løpet av en vanlig dag. 
Er din helse slik at den begrenser deg i utførelsen av disse aktivitetene nå? Hvis ja, hvor mye? 
 
Ja, begrenser Ja, begrenser Nei, begrenser 
meg mye meg litt meg ikke i det  
hele tatt 
a. Anstrengende aktiviteter som å løpe, løfte 
tunge gjenstander, delta i anstrengende idrett    
b. Moderate aktiviteter som å flytte et bord,  
støvsuge, gå en tur eller drive med  
hagearbeid………………………………..     
c. Løfte eller bære en handlekurv…………..    
d. Gå opp trappen flere etasjer………………    
e. Gå opp trappen en etasje………………….    
f. Bøye deg eller sitte på huk……………….    
g. Gå mer enn to kilometer………………….    
h. Gå noen hundre meter……………………    
i. Gå hundre meter…………………………    
j. Vaske eller kle på deg……………………    
 
29. I løpet av de siste 4 ukene har du hatt noen av de følgende probl mer i ditt arbeid eller i 
andre av dine daglige gjøremål på grunn av din fysiske hels? 
    Ja Nei 
a. Du har måttet redusere tiden du har brukt på arbeid eller på andre gjøremål…   
b. Du har utrettet mindre enn du hadde ønsket…………………………………..   
c. Du har vært hindret i å utføre visse typer arbeid eller gjøremål………………   
d. Du har hatt problemer med å gjennomføre arbeidet eller andre gjøremål……   
(for eksempel fordi det krevde ekstra anstrengelser) 
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30. I løpet av de siste 4 ukene har du hatt noen av de følgende probl mer i ditt arbeid eller i 
andre av dine daglige gjøremål på grunn av følelsesmessige probl mer? 
(som for eksempel å være deprimert eller engstelig) 
    Ja Nei 
a. Du har måttet redusere tiden du har brukt på arbeid eller på andre gjøremål…   
b. Du har utrettet mindre enn du hadde ønsket…………………………………..   
c. Du har utført arbeidet eller andre gjøremål mindre grundig enn vanlig………   
 
31. I løpet av de siste 4 ukene, i hvilken grad har din fysiske helse eller følelsesmessige 
problemer hatt innvirkning på din vanlige sosiale omgang med familie, venner, naboer eller 
foreninger? 
 
Ikke i det hele tatt  litt  en del  mye  svært mye 
      
 
32. Hvor sterke kroppslige smerter har du hatt i løpet av de siste 4 ukene? 
 
Ingen  meget svake  svake  moderate  sterke  meget sterke 
       
 
33. I løpet av de siste 4 ukene, hvor mye har smerter påvirket d tt vanlige arbeid (gjelder både 
arbeid utenfor hjemmet og husarbeid) 
Ikke i det hele tatt  litt  en del  mye  svært mye 
      
 
 
34. De neste spørsmålene handler om hvordan du har følt deg og hvordan du har hatt det de siste 
4 ukene. For hvert spørsmål, vennligst velg det svaralternativet som best beskriver hvordan du 
har hatt det. Hvor ofte i løpet av de siste 4 ukene har du: 
               Hele        Nesten  Mye av      En del av    Litt av      Ikke i det  
   tiden      hele tiden   tiden         tiden    tiden       hele tatt 
a. Følt deg full av tiltakslyst…       
b. Følt deg veldig nervøs………       
c. Vært så langt nede at ingenting  
har kunnet muntre deg opp….       
d. Følt deg rolig og harmonisk.       
e. Hatt mye overskudd……….       
f. Følt deg nedfor og trist……       
g. Følt deg sliten…………….       
h. Følt deg glad………………       
i. Følt deg trett……………….       
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35. I løpet av de siste 4 ukene, hvor mye av tiden har din fysiske helse eller følelsesmessige 
problemer påvirket din sosiale omgang (som det å besøke venner slektninger osv)? 
Hele tiden  nesten hele tiden  en del av tiden  litt av tiden  ikke i det hele tatt 
      
 
 
36. Hvor RIKTIG eller GAL er hver av de følgende påstander for deg? 
           Helt  Delvis  Vet  Delvis  Helt 
           riktig  riktig ikke   gal     gal 
a. Det virker som om jeg blir syk litt lettere enn andre.     
b. Jeg er like frisk som de fleste jeg kjenner…………      
c. Jeg tror at helsen min vil forverres………………..      
d. Jeg har utmerket helse……………………………      
 
 
37. Har du i løpet av de siste 12 måneder vært hos: 
Fastlege/allmennlege     
Annen legespesialist utenfor sykehus  
Konsultasjon uten innleggelse 
 - ved psykiatrisk poliklinikk   
 - ved annen poliklinikk i sykehus  
Kiropraktor      
Homøopat, akupunktør, soneterapeut,  
håndspålegger eller annen alternativ  
behandler      
 
38 a. Har du vært innlagt på sykehus i løpet av de siste 12 måneder?  Ja       Nei      
                             
 
 
b. Hvis Ja: grunn ……………………………………………………………………….. 
 
 
c. Hvilket sykehus………………………………………………………………………. 
 
39. Har du de siste 12 måneder vært hos tannlege/tannhelsetjenet ? Ja       Nei                                 
 
 
40. Hvordan vurderer du tannhelsen din? 
 
Meget dårlig    God     
Dårlig       Meget god   
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Hjertesykdommer  
 
I denne etterundersøkelsen er vi blant annet opptatt av problemer fra hjerte-karsystemet og 
nedenfor følger noen spørsmål om dette. 
 
41. Har du hatt hjerteinfarkt?  Ja      Nei    
42. Hvis ja, hvor mange ganger har du hatt dette?            ganger 
 
43. Årstall for hjerteinfarktet: infarkt 1 (årstall)    
infarkt 2 (årstall)   
 infarkt 3 (årstall)    
 
44. Har du kortere eller lengre perioder med uregelmessige hjert slag?  
 
Ja, kortere perioder       Ja, lengre perioder       Nei, aldri     
 
45. Har du, eller har du hatt angina pectoris (hjertekrampe)       Ja       Nei   
 
 
46. Hvis Ja, hvor mange ganger pr. uke har du merket hjertekrampe i løpet av den siste måneden? 
  
     1-2 ganger 3-4 ganger   5-8 ganger   Flere 
a. Ved anstrengelse                 
b. Når du er i ro om dagen                 
c. Om natta                 
 
47. Har du opplevd anfall av plutselig besvimelse?  Ja      Nei                                   
 
48. I tilfelle ja på spørsmål 42, hvor mange ganger det siste åre ?     ganger 
 
49. a. Har du noen gang fått annen behandling for angina pectoris enn tabletter? 
 
Ja       Nei                                  
 
Hvis ja:   b. Har du blitt hjerteoperert (bypass)?       
c. Har du blitt blokket/fått innsatt stent?    
d. Har du fått pacemaker?      
e. Har lege sagt at du har hjerteflimmer (atrieflimmer)?  
 
50. Har lege sagt at du har hjertesvikt (svakt hjerte, vann i lungene, hovne ben)? 
 
Ja       Nei       
                            
51.a. Har du annen hjertesykdom?     Ja     Nei     
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52. Hvis du har hjertesykdom, virker dette på ditt daglige funksjo snivå? 
 
 Ingen begrensninger. Vanlig fysisk aktivitet gir ingen uvanlig tretthet,  
 tungpust eller brystsmerter. 
 
  Lett begrensning av fysisk aktivitet, men ubesværet i hvile. Vanlig fysisk  
 aktivitet gir tretthet, tungpust eller brystsmerter. 
 
  Betydelige begrensning av fysisk aktivitet, men ubesværet i hvile. Selv  
 små fysiske anstrengelser gir tretthet, tungpust eller brystsmerter. 
 
  Umulig å utføre noen som helst fysisk anstrengelse, periodevis også  
 tungpust eller brystsmerter i hvile.  
 
 
53. a. Har du foreldre, søsken eller barn som har, eller har hatt hjerteinfarkt før de fylte 60 år?  
 
Ja       Nei                                  
 
 
b. Hvis Ja, beskriv: …………………………………………………………………………. 
 
54. Hvor mange ganger har du vært til blodtrykkskontroll hos lege/sykepleier siste 12 måneder 
 
      ganger 
 
55. Har du hatt døgnregistrering av ditt blodtrykk med automatisk måler? Ja       Nei                                 
 
56. Har du målt blodtrykket ditt selv hjemme (egenmåling)? Ja     Nei                                 
 
57. Har du noen gang blitt undersøkt på sykehus pga høyt blodtrykk?   Ja       Nei                                 
 
58. Har du brukt blodtrykksmedisin?                         Ja       Nei    
 
59. Bruker du fortsatt blodtrykksmedisin?                      Ja       Nei                            
 
60. Hvis Ja: Omtrent hvor gammel var du første gang du begynte med blodtrykksmedisin?  
 
Ca.   år 
 
61. Har du noen gang hatt hjerneslag (blodpropp eller blødning i hjernen)?   Ja       Nei      
                             
 
62. Hvis Ja: Hvor mange ganger har du hatt hjerneslag?       ganger 
 
63. Årstall for hjerneslag:       hjerneslag 1 (årstall)    
hjerneslag 2 (årstall)   
 hjerneslag 3 (årstall)    
 
64. Var du innlagt på sykehus i forbindelse med ditt siste hjerneslag? Ja       Nei       
              
 
65. Har du kommet deg etter siste hjerneslag?   Ja, helt    Ja, delvis      Nei   
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66. Har du sukkersyke/diabetes?  Ja        Nei     
                              
 
67. Hvis Ja: I hvilket år ble diagnosen stilt?   År   
 
 
68. Hvis du har sukkersyke/diabetes, bruker du: 
 





69. Prøv å fyll ut medikamentlisten så fullstendig som mulig. 
Vær vennlig og skriv med blokkbokstaver. 
 
 








Antall doser pr dag 
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Hukommelse og konsentrasjon 
I løpet av den siste uka:  Ikke i det       litt   ganske  veldig 
   hele tatt                   mye      mye 
70. Har du hatt problemer med å konsentrere deg, for eksempel  
med å lese en avis eller å se på TV?...............………………     
71. Har du hatt problemer med å huske ting…………………     
 
   Nei ja, noe ja, mye 
72. Har hukommelsen endret seg siden du var yngre?    
 
    av og  
73. Har du problemer med å huske:  Aldri til ofte 
a. Hendelser for få minutter siden…………………………    
b. Navn på andre mennesker………………………………    
c. Datoer……………………………………………………     
d. Å gjøre det du har planlagt………………………………    
e. Hendelser som skjedde for noen dager siden……………    
f.  Hendelser som skjedde for år siden………………………    
g. Å holde tråden i samtaler…………………………………    
 
Hvordan er du i det daglige? 
74. Nedenfor følger en rekke utsagn som folk ofte bruker for å beskrive seg selv. Kryss av for 
det svaret som passer best for deg. Det finnes ingen riktige eller gale svar. Det er din egen 
oppfatning som gjelder. 
           Passer        Passer                     Passer for    Passer 
           slett ikke    sjelden     Nøytral   det meste     helt 
a. Jeg kommer lett i kontakt med folk jeg møter                        
b. Jeg lager ofte problemer av små ting………..                                     
c. Jeg snakker ofte til fremmede……………….                                                 
d. Jeg føler meg ofte ulykkelig…………………                                                   
e. Jeg er ofte irritert…………………………….                                                                                                        
f. Jeg føler meg ofte hemmet sammen med andre.      
g. Jeg ser negativt på ting………………………       
h. Jeg synes det er vanskelig å innlede en samtale                     
i. Jeg er ofte i dårlig humør……………………..                                                         
j. Jeg er en ”lukket” person…………………….                                                           
k. Jeg foretrekker å holde andre folk på avstand.                          
l. Jeg tar meg ofte i at jeg bekymrer meg for noe                     
m. Jeg føler meg ofte ”nede i kjelleren”………                                     
n. Når jeg er sammen med andre,  
    vet jeg ikke hva jeg skal snakke om ……….           
 
75.  
            Ja Nei 
a. Er du ofte bekymret?.................................................................................   
b. Blir dine følelser lett såret?.....................................................................   
c. Hender det ofte at du går trett?....................................................................   
d. Plages du ofte av “nerver”?...................................................................   
e. Har du ofte følt deg trøtt og likeglad uten grunn?................................   
f. Bekymrer du deg for at fryktelige ting skal skje?.........................................   
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Tretthet/utmattelse  
 
Vi vil gjerne vite om du har følt deg sliten, svak eller i mangel av overskudd de siste fire ukene. 
Vennligst besvar ALLE spørsmålene ved å krysse av for det svaret du synes passer best for deg. 
Vi ønsker at du skal besvare alle spørsmålene selv om du ikke har hatt slike problemer. Vi spør 
om hvordan du har følt deg i det siste og ikke om hvordan du følte deg for lenge siden. Hvis du 
har følt deg sliten lenge, ber vi om at du sammenlikner deg med hvordan du følte deg sist du var 
bra.  
 
            Mindre     Ikke mer      Mer enn     Mye m r  
76.                                       enn vanlig   enn vanlig     vanlig     enn vanlig 
a. Har du problemer med at du føler deg sliten?     
b. Trenger du mer hvile?     
c. Føler du deg søvnig eller døsig?     
d. Har du problemer med å komme i gang med ting?     
 
            Ikke i        Ikke mer      Mer enn     Mye m r  
                              det hele tatt    enn valig     vanlig      enn vanlig 
e. Mangler du overskudd?     
f. Har du redusert styrke i musklene dine?     
 
            Mindre        Som        Mer enn     Mye m r  
                                     enn vanlig      vanlig        vanlig     enn vanlig 
g. Føler du deg svak?     
h. Har du vansker med å konsentrere deg?     
 
            Mindre     Ikke mer      Mer enn     Mye m r  
                                      enn vanlig   enn vanlig     vanlig     enn vanlig 
i. Forsnakker du deg i samtaler?     
j. Er det vanskeligere å finne det rette ordet?     
 
            Bedre      Ikke verre      Verre         Mye verre  
                          enn vanlig   enn vanlig    enn va lig  enn vanlig 
k. Hvordan er hukommelsen din?     
 
 
77. Hvis du føler deg sliten for tiden, omtrent hvor lenge har det vart? 
Mindre enn en uke   
Mindre enn tre måneder  
Mellom tre og seks måneder  
Seks måneder eller mer  
 
78. Hvis du føler deg sliten for tiden, omtrent hvor mye av tiden kjenner du det? 
25% av tiden    
50% av tiden    
75% av tiden    
Hele tiden    
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Hvordan du føler deg. 
Her kommer noen utsagn om hvordan du føler deg. For hvert spørsmål setter du kryss for ett av de 
fire svarene som best beskriver dine følelser den siste uken. Ikke tenk for lenge på svaret – de 
spontane svarene er best. 
79. 
a. Jeg føler meg nervøs og urolig 
  Nei  
  Litt  
  En god del  
  Svært mye  
 
b. Jeg gleder meg fortsatt over  
ting slik jeg pleide før 
  Avgjort like mye  
  Ikke fullt så mye  
  Bare lite grann  
  Ikke i det hele tatt  
         
c. Jeg har en urofølelse som om  
noe forferdelig vil skje   
  Ja, og noe svært ille  
  Ja, ikke så veldig ille  
  Litt, bekymrer meg lite  
  Ikke i det hele tatt  
 
d. Jeg kan le og se det morsomme i 
situasjoner 
  Like mye nå som før  
  Ikke like mye nå som før   
  Avgjort ikke som før  
  Ikke i det hele tatt   
 
e. Jeg har hodet fullt av bekymringer         
  Veldig ofte  
  Ganske ofte  
  Av og til  
  En gang i blant   
 
f. Jeg er i godt humør 
  Aldri   
  Noen ganger   
  Ganske ofte 
  For det meste          
 
g. Jeg kan sitte i fred og ro og kjenne meg 
avslappet 
  Ja, helt klart   
  Vanligvis 
  Ikke så ofte 
  Ikke i det hele tatt 
 
h. Jeg føler meg som om alt går 
langsommere  
  Nesten hele tiden  
  Svært ofte  
  Fra tid til annen  
  Ikke i det hele tatt   
 
i. Jeg føler meg urolig som om 
jeg har sommerfugler i magen            
  Ikke i det hele tatt   
  Fra tid til annen   
  Ganske ofte   
  Svært ofte  
            
j. Jeg bryr meg ikke lenger om hvordan jeg 
ser ut 
  Ja, har sluttet å bry meg  
  Ikke som jeg burde 
  Kan hende ikke nok 
  Bryr meg som før 
  
k. Jeg er rastløs som om jeg stadig må være aktiv 
  Uten tvil svært mye   
  Ganske mye   
  Ikke så veldig mye   
  Ikke i det hele tatt   
 
l. Jeg ser med glede fram til hendelser og ting 
  Like mye som før  
  Heller mindre enn før   
  Avgjort mindre enn før   
  Nesten ikke i det hele tatt  
 
m. Jeg kan plutselig få en følelse av panikk 
  Uten tvil svært ofte   
  Ganske ofte   
  Ikke så veldig ofte 
  Ikke i det hele tatt 
 
n. Jeg kan glede meg over gode bøker, radio/TV
  Ofte   
  Fra tid til annen 
  Ikke så ofte 
  Svært sjelden
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Vekst og utvikling etter kreftsykdom  
 
Instruksjon: Det hender at folk rapporterer positive endringer etter store påkjenninger. Vi ønsker å 
undersøke i hvilken grad kreftsykdommen har bidratt til positive endringer i livet ditt. Bruk skalaen og 
sett et kryss i det svaralternativet som passer best.  
 
0 = Jeg opplevde ikke denne forandringen som følge av kreftsykdommen 
1 = Jeg opplevde denne forandringen i svært liten grad som følge av kr ftsykdommen 
2 = Jeg opplevde denne forandringen i liten grad som følge av kreftsykdommen 
3 = Jeg opplevde denne forandringen i middels grad som følge av krftsy dommen 
4 = Jeg opplevde denne forandringen i stor grad som følge av kreftsy dommen 
5 = Jeg opplevde denne forandringen i svært stor grad som følge av kr ftsykdommen 
80.          0      1     2     3     4     5 
a. Jeg har endret mine prioriteringer når det gjelder hva som er viktig i livet        
b. Jeg setter mer pris på livet mitt …………………………………………       
c. Jeg har fått nye interesser ……………………………………………….       
d. Jeg har mer tro på meg selv ……………………………………………..        
e. Jeg har fått en ny forståelse av åndelige spørsmål ……………………...        
f. Jeg har oppdaget at jeg kan stole på andre i vanskelige p rioder………..        
g. Jeg har lagt om kursen i livet mitt ……………………………………        
h. Jeg føler mer nærhet til andre mennesker ……………………………        
i. Jeg er mer villig til å uttrykke følelsene mine ………………………….        
j. Jeg er sikrere på at jeg kan håndtere vanskeligheter………………… …       
k. Jeg får mer ut av livet mitt …………………………………………….        
l. Jeg har lettere for å godta ting som de har blitt ……………………… ..       
m. Jeg setter mer pris på hver eneste dag ……………………………….        
n. Jeg har fått nye muligheter jeg ellers ikke ville ha fått ……………… .       
o. Jeg har fått mer medfølelse for andre …………………………………        
p. Jeg gjør mer for å ta vare på dem jeg bryr meg om …………………..       
q. Jeg er mer tilbøyelig til å forandre på ting som trenger å endres……. .       
r. Jeg har en sterkere religiøs tro …………………………………… ..       
s. Jeg har oppdaget at jeg er sterkere enn jeg trodde ………………….       
t. Jeg har lært mye om hvor flotte mennesker kan være ………………         
u. Jeg har lettere for å akseptere at jeg trenger andre…………………… .       
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Følelser i forhold til høydosebehandlingen 
Vennligst beskriv hvordan du har hatt det de siste syv dagene ved å sette kryss i det svaret som best 
beskriver din tilstand. 
81.  I høy  Ganske   
a. Jeg har hatt perioder med sterke følelser            grad     mye    Middels  Noe     Litt     Aldri 
      omkring høydosebehandlingen……………….       
b. Ting jeg har sett og hørt minnet meg plutselig 
      om høydosebehandlingen …………………….       
c. Tanker om høydosebehandlingen har trengt  
      seg på også når jeg ikke har villet……………       
d. Bilder fra høydosebehandlingen har plutselig  
      dukket opp i tankene mine……………………       
e. Enhver påminnelse har gjenopplivet følelser  
      knyttet til høydosebehandlingen ……………...       
f. Jeg har hatt vanskelig for å sove på grunn av  
      tanker og bilder om høydosebehandlingen …...       
g. Jeg har hatt vonde drømmer om  
      høydosebehandlingen …………………………       
h. Jeg vet mange uforløste følelser er der,  
      men jeg har skjøvet dem bort…………………       
i. Jeg har ikke tillat meg å bli følelsesmessig  
      berørt når jeg tenker på høydosebehandlingen 
      eller blir minnet om den………………………       
j. Jeg har ønsket å bli kvitt minner om  
      høydosebehandlingen ………………………..       
k. Jeg har forsøkt å la være å snakke om  
      høydosebehandlingen ….…………………….       
l. Jeg har opplevd det uvirkelig, som om  
      høydosebehandlingen ikke var hendt eller ikke  
      var virkelig……………………………………       
m. Jeg har holdt meg unna ting eller situasjoner  
      som kan minne meg om høydosebehandlingen        
n. Mine følelser rundt høydosebehandlingen  
      er nærmest lammet………………………….       
o. Jeg har ikke tillat meg selv å ha tanker om  
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Kosthold og matvaner 
82. Hvor ofte spiser du vanligvis disse matvarene? (sett ett kryss pr. linje) 
 
        0-3       1-3           4-6 1 gang     2ggr  
      ganger     ganger     ganger        pr.     el mer 
      pr. mnd    pr. uke     pr. uke      dag        pr. dag 
a. Frukt/bær……………………………….      
b. Grønnsaker……………………………..      
c. Sjokolade/smågodt……………………..      
d. Kokte poteter…………………………..      
e. Pasta/ris…………………………………      
f. Pølser/hamburgere……………………..      
g. Fet fisk (laks, ørret, sild, makrell  
uer som pålegg eller middag)…………..      
 
83. Bruker du følgende kosttilskudd? (sett ett kryss for hvert kosttilskudd) 
     Ja     av  
         daglig       og til     nei 
a. Tran……………………………………………………………….    
b. Omega 3-kapsler……………………………………………….    
c. Vitamin- og/eller mineraltilskudd………………………………...    
 
84. Hvor mange glass drikker du vanligvis av følgende? ½ liter = 3 glass, sett ett kryss pr. linje 
 
    Sjelden      1-6       1gl.     2-3         4gl. 
    eller          gl. pr      pr      gl. pr    eller mer 
    aldri       uke       dag     dag       pr dag 
a. Vann, farris o.l…………..      
b. Helmelk (søt/sur)………..      
c. Annen melk (søt sur)……      
d. Brus/saft med sukker……      
e. Brus/saft uten sukker……      




85. Hvor mange kopper kaffe/te drikker du pr. døgn?  
(sett 0 dersom du ikke drikker kaffe/te daglig? 
 
  a. Kokekaffe b. annen kaffe        c. te  
Antall kopper     
 
 
86. Hvor mange kopper kaffe drikker du om kvelden? (etter kl 18)    
 
Antall kopper  
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87. Røyker du selv? 
Nei, jeg har aldri røykt…………………………..  
Hvis du aldri har røykt, hopp til spørsmål 90  
 
Nei, jeg har sluttet å røyke……………………….  
Ja, sigaretter av og til (fest/ferie, ikke daglig)……  
Ja, sigarer/sigarillos/pipe av og til……………….  
Ja, sigaretter daglig……………………………….  
Ja, sigarer/sigarillos/pipe daglig………………….  
 
88. Svar på dette hvis du nå røyker daglig eller tidligere har røykt daglig: 
a. Hvor mange sigaretter røyker eller røykte du vanligvis daglig?   Sigaretter pr. dag 
b. Hvor gammel var du da du begynte å røyke daglig?    år gammel 
c. Hvis du tidligere har røykt daglig, hvor gammel var du da du sluttet  år gammel 
 
 
89. Svar på dette hvis du røyker eller har røykt av og til, men ikke daglig: 
a. Hvor mange sigaretter røyker eller røykte du vanligvis i måneden?  Sigaretter pr.mnd 
b. Hvor gammel var du da du begynte å røyke av og til?    år gammel 
c. Hvis du tidligere har røykt av og til, hvor gammel var du da du sluttet  år gammel 
 
 
90. Omtrent hvor ofte har du i løpet av de siste 12 måneder drukket alkohol?  
(regn ikke med lettøl) 
 
4-7 ganger pr. uke   Ca 1 gang pr. måned  
2-3 ganger pr. uke   Noen få ganger pr. år  
Ca 1 gang pr. uke   Ingen ganger siste år  
2-3 ganger pr. måned   Aldri drukket alkohol  
 
         Ja  Nei 
91. Har du drukket alkohol i løpet av de siste 4 uker?   
 
92. Hvis ja på spørsmål 100, har du drukket så mye at du har kjent deg sterkt beruset (full)?  
 
Nei    
Ja, 1-2 ganger   
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93. Hvor mange glass øl, vin eller brennevin drikker du vanligvis i løpet av 2 uker? 
(regn ikke med lettøl) sett 0 hvis du ikke drikker alkohol. 
 
       a. Øl     b. Vin          c. Brennevin 
Antall glass    
 
94. Hvor ofte drikker du 5 glass eller mer av øl, vin eller br nnevin ved samme anledning? 
    Aldri månedlig ukentlig daglig  
         
 
Mosjon / fysisk aktivitet 
 
Med mosjon mener vi at du f.eks går tur, går på ski, svømmer eller driver trening/idrett. 
95. Hvor ofte driver du mosjon? (ta et gjennomsnitt)  
Aldri     
Sjeldnere enn en gang i uka  
En gang i uka    
2-3 ganger i uka   
Omtrent hver dag   
 
Dersom du driver slik mosjon, så ofte som en eller flere ganger i uka;  
96. Hvor hardt mosjonerer du? (ta et gjennomsnitt) 
Tar det rolig uten å bli andpusten eller svett   
Tar det så hardt at jeg blir andpusten og svett  
Tar meg nesten helt ut     
 
97. 
  Mindre enn 15 min        15-29 min        30 min-1 time      Mer enn 1 time   
 
Etnisitet 
98. Etnisitet: Hvilken etnisk bakgrunn har dine biologiske foreldre? (Sett x ved svaret som passer) 
 
                                    Mor     Far                             
 
Norsk      
Nordisk(utenom norsk)      
Samisk      
Europeisk      
Asiatisk      
Afrikansk   
Nordamerikansk   
Latinamerikansk   
Australsk   
Blandet   
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99. Etnisitet: Hvilken etnisk bakgrunn har du? (Sett x ved svaret som passer) 
 
Norsk  
Nordisk(utenom norsk)       











100. Før kreftbehandlingen (første gang du fikk lymfekreft):      
 
     Ja Nei 
a. Hadde du prøvd å få barn?    
b. Hadde du fått barn     
 
 
101. Fødselsår for barn født før kreftbehandlingen:  barn 1     
  barn 2   
  barn 3   
  barn 4   
 
102. Etter høydosebehandlingen: 
     Ja Nei 
a. Har du prøvd å få barn?    
b. Har du fått barn     
 
 
103. Fødselsår for barn etter høydosebehandlingen: barn 1     
  barn 2   
  barn 3   
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104. Har dere brukt metoder for assistert befruktning for å oppnå graviditet etter  
høydosebehandlingen? Ja  Nei  
 
 
105. Hvis ja, hvilken type assistert befruktning: 
IVF/prøverørsbefruktning     
ICSI/mikroinjeksjonsmetoden   
Inseminasjon av sæd    
  
                             Ja   Nei 
106. Fikk du tilbud om nedfrysning av sæd før kreftbehandlingen / høydosebehandlingen?        
 
 Ja   Nei 
107. Hvis ja, fikk du frosset ned sæd før kreftbehandlingen / høydosebehandlingen?      
 
108. Hvis ja, har du benyttet den nedfrosne sæden i forsøk på å o pnå graviditet etter             Ja   Nei    
kreftbehandlingen / høydosebehnadlingen?..............................................................         
 
       Ja   Nei 
109. Hvis ja, har du fått barn etter høydosebehandlingen ved bruk av den nedfrosne sæden?   
 
110. Hvis ja oppgi fødselsår for barnet / barna.        barn 1      
  barn 2   
  barn 3   
  barn 4   
 Ja   Nei 
111. Har dere benyttet donorsæd til å få barn etter høydosebehandlingen?        
   
112. Hvis ja oppgi årstall for barnet / barna født ved hjelp av donorsæd.   barn 1  
                barn 2  
                         barn 3  
                         barn 4   
113. Adopsjon  
     Ja Nei 
Har du adoptert barn?     
 
 
114. Årstall for adopsjon   barn 1      
  barn 2   
  barn 3   
  barn 4   
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Mannlig seksualitet  
 
Seksualdrift 
La oss definere seksualdrift som en følelse som kan omfatte ønske om seksuell aktivitet (onani eller 
samleie), tanken på å ha sex eller frustrasjon som følge av mangel på sex.  
Kryss av for det svaret som passer på alle spørsmålene, m  sett bare ett kryss for hvert spørsmål. 
 
115. Hvor mange dager har du følt seksualdrift de siste  30 dagene? 
 Ingen dager 
 Bare noen få dager 
 Noen dager 
 De fleste dagene 
 Nesten hver dag 
 
116. Hvordan vurderer du nivået på seksualdriften din de siste 30 dagene? 
  Ingen drift 
  Lav drift 
  Middels drift 
  Ganske sterk drift 
  Sterk drift 
 
Reisning 
117. Hvis du er blitt seksuelt stimulert på noen måte de siste 30 dagene; hvor ofte har du fått delvis 
eller full reisning? 
 Aldri  
 Noen få ganger 
 Ganske ofte 
 Vanligvis 
 Alltid  
 
118. Hvis du har hatt reisning de siste 30 dagene; hvor ofte var penis stiv nok til at du kunne ha 
samleie? 
 Aldri  
 Noen få ganger 




119. Hvor store vansker har du hatt med å få reisning de siste 30 dagene? 
 Har ikke fått reisning 
 Store vansker 
 Noen vansker 
 Få vansker 
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Sæduttømming 
120. Hvor store vansker har du hatt med å få sæduttømming når du er blitt seksuelt stimulert de siste 
30 dagene? 
 Har ikke hatt noen seksuell stimulering 
 Store vansker 
 Noen vansker 
 Få vansker 
 Ingen vansker 
 
121. I hvilken grad har du over de siste 30 dagene sett på mengden sæ  ved uttømming som et problem 
for deg? 
 Har ikke hatt sæduttømning 
 Stort problem 
 Middels problem 
 Lite problem 
 Ikke noe problem 
 
Problemvurdering 
122. I hvilken grad har du over de siste 30 dagene sett på manglende s ksualdrift som et problem? 
 Stort problem 
 Middels problem 
 Lite problem 
 Ganske lite problem 
 Ikke noe problem 
 
123. I hvilken grad har du over de siste 30 dagene vurdert din evne til å få og beholde reisning som et 
problem? 
 Stort problem 
 Middels problem 
 Lite problem 
 Ganske lite problem 
 Ikke noe problem 
 
124. I hvilken grad har du over de siste 30 dagene sett på din sæduttømming som et problem? 
 Stort problem 
 Middels problem 
 Lite problem 
 Ganske lite problem 
 Ikke noe problem 
 
Samlet tilfredshet 
125. Hvor tilfreds har du samlet sett vært med ditt seksualliv de siste 30 dagene?  
 Veldig utilfreds 
 For det meste utilfreds 
 Omtrent like tilfreds som utilfreds 
 For det meste tilfreds 
 Svært tilfreds 
 
Takk for at du tok deg tid å besvare spørreskjemaet! 
APPENDIX B  
Female specific study questionnaire items 
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99. Etnisitet: Hvilken etnisk bakgrunn har du? (Sett x ved svaret som passer) 
 
Norsk  
Nordisk(utenom norsk)       









Menstruasjonsforhold og fruktbarhet 
 
100. Hvor gammel var du da du fikk første menstruasjon?  år 
Ja        Nei 
101. Har du fremdeles regelmessig menstruasjon       
 
102. Hvis du ikke lenger har regelmessig menstruasjon, hvor gammel var du da den sluttet               
                                                                                                                                             år
                                                                                                                            Ja Nei   
103. Har du brukt eller bruker du østrogentilskudd (kvinnelig kjønnshormon)?      
 
 
104. Hvis ja, oppgi hvilken tidsperiode (i årstall) du har brukt dette: _________________________ 
 
105. Før kreftbehandlingen (første gang du fikk lymfekreft):      
 
     Ja Nei 
a. Hadde du prøvd å få barn?    
b. Hadde du fått barn     
106. Fødselsår for barn født før kreftbehandlingen:  barn 1      
  barn 2   
  barn 3   
  barn 4   
107. Etter høydosebehandlingen: 
     Ja Nei 
a. Har du prøvd å få barn?    




T  T 
T  T 20
108. Fødselsår for barn etter høydosebehandlingen: barn 1      
  barn 2   
  barn 3   
  barn 4   
 
109. Har dere brukt metoder for assistert befruktning for å oppnå graviditet etter  
høydosebehandlingen? Ja  Nei  
 
110. Hvis ja, hvilken form for assistert befruktning: 
IVF/prøverørsbefruktning     
ICSI/mikroinjeksjon   
Inseminasjon av sæd    
                             Ja   Nei 
111. Har du fått barn etter høydosebehandlingen ved bruk av assistert befruktning?     
 
112. Hvis ja, oppgi årstall for fødsel av barnet / barna.     
 barn 1     
 barn 2   
    barn 3   
    barn 4   
 Ja   Nei 
113. Har dere benyttet donoregg til å få barn etter høydosebehandlingen?        
 
114. Hvis ja, fikk du barn ved hjelp av donoregg?       
 
 
115. Hvis ja oppgi årstall for fødsel av barnet / barna født ve hj lp av donoregg.    
 barn 1                  
 barn 2  
 barn 3  
 barn 4  
 
116. Adopsjon 
     Ja Nei 
Har du adoptert barn?     
 
117. Årstall for adopsjon   barn 1      
  barn 2   
  barn 3   
  barn 4   
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Samliv og seksualitet        Ja Nei 
118. Er du gift eller har et intimt forhold for tiden? ……………………………                       
119. Har du fått en ny seksualpartner i løpet av de siste seks månedene?……..                                                        
120. Er du engasjert i noe seksuelt forhold med noen for tiden?……………….   
                                           
Hvis du har svart Ja på spørsmål 120, det vil si at du er seksuelt aktiv for tiden, gå videre til spørsmål 
122-133.  
Hvis du har svart Nei på spørsmål 120, det vil si at du ikke er seksuelt aktiv for tiden, svar på spørsmål 
121, men ikke 122-133. 
 
 
Jeg er ikke seksuelt aktiv for tiden av følgende grunner: 
(sett kryss i alle de boksene som passer for deg) 
121. 
a) Jeg har ingen partner for tiden      ………………………….  
b) Jeg er for trett………………………………………………..  
c) Min partner er for trett……………………………………….  
d) Jeg er ikke interessert i sex……………………………………  
e) Min partner er ikke interessert i sex…………………………  
f) Jeg har et fysisk problem som gjør seksuelle  
   forhold vanskelige eller ubehagelige…………………………    
g) Min partner har et fysisk problem som gjør seksuelle  
    forhold vanskelige eller ubehagelige……………………….   
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I løpet av den siste måneden: (sett kryss i den boksen som passer best med dine seksuell  følelser og 
erfaringer i løpet av siste måned) 
                            Veldig mye    En del      Litt    Slett ikke 
122. Var det å ”ha sex” en viktig del av livet ditt  
    siste måned?……………………………………………                       
 
123. Hadde du glede av seksuell aktivitet siste måned?…….               
 
124. Generelt, var du for trett til å ha sex?………………….                     
 
125. Ønsket du å ha sex med din partner siste måned?………            
 
126. Når du hadde sex, hvor mye merket du tørrhet i  
    skjeden siste måned?…………………………………….                    
 
127. Følte du smerte eller ubehag ved inntrengning i  
    skjeden siste måned?…………………………………...                     
 
128. Generelt, følte du deg tilfreds etter seksuell  
    aktivitet siste måned?......................................................                     
 
 
                                                                                                    5 ganger   3-4 ganger   1-2 ganger   Ingen  
                                                                                                    eller mer                                         ganger    
                    
129. Hvor ofte har du hatt seksuell aktivitet siste måned?                                       
  
                                                                                    Mye mer     Litt mer      Omtrent   Mindre enn 
                                                                                                                           samme        vanlig 
130. Hvordan var frekvensen av den seksuelle aktiviteten  
        sammenlignet med det som er vanlig for deg?……           
  
                                                                                         Veldig      Ganske          Litt            Ikke 
131. Var du fornøyd med frekvensen av den seksuelle  
        aktiviteten siste måned?..................................                                           
 
                            Veldig mye  En del    Litt    Slett ikke 
132. Hvor opphisset ble du ved seksuell aktivitet  
        siste måned?……………………………………..              
 
                                                                                                             Alltid        Ofte     I blant    Aldri 
133. Hvor ofte fikk du orgasme ved seksuell aktivitet  
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Abstract
Reduced sexual function may have negative implications on health related quality of life among lymphoma survivors. A
national cross-sectional study among long-term lymphoma survivors after high-dose therapy with autologous stem-cell
transplantation auto-SCT treated during 1987–2008 was conducted in 2012–2014. The current study explored sexual
functioning among these survivors. Sixty-six percent (n= 159) of eligible men with complete questionnaire data were
included, median age was 55 years. The Brief Sexual Function Inventory (BSFI) was used to assess sexual function and
sexual satisfaction, compared with age-matched controls. In addition, sexual problems were defined based on predetermined
cutoff values for BSFI domain scores. Sexual drive and erections firm enough to have sexual intercourse were reported to be
present only a few days or less last month among 30% and 41% of survivors, respectively. Sexual satisfaction was reported
by 39% of survivors. The survivors had significantly lower scores on all BSFI domains and an increased risk of problems
with sexual drive and erection compared with controls. In multivariable models, cardiovascular disease was significantly
associated with worse erectile function, while age > 55 years, chronic fatigue, and physical inactivity were significantly
associated with lower sexual functioning overall. Chronic fatigue and anxiety were related to lower sexual satisfaction.
Introduction
Lymphoma therapy, in particular high-dose therapy with
autologous stem-cell transplantation (auto-SCT), is asso-
ciated with multiple long-term adverse effects, including
sexual problems [1], which is important for quality of life
(QoL) in lymphoma survivors [2, 3]. After conventional
chemotherapy, 22–50% of non-Hodgkin lymphoma (NHL)
and Hodgkin lymphoma (HL) survivors report reduced
sexual function [2, 4, 5]. Among 246 male lymphoma
survivors, reduced sexual function was associated with
increasing age, low testosterone levels, poor physical
health, and increased mental distress (mean 14.8 years post
treatment) [6]. Reduced sexual function in HL survivors
(n= 3208) with up to 27 months follow-up, was associated
with advanced stage disease, older age, pretreatment sexual
function, and reduced health related QoL [2].
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In male stem-cell transplanted (SCT) cancer survivors,
reduced sexual function is frequent, with lack of sexual
drive, erectile dysfunction (ED) and sexual dissatisfaction
being the most common problems median 3 years post-SCT
[7, 8]. However, sexual problems related to graft-versus-
host disease dominate the reports [9–12].
Thus, there is a need for studies on sexual function in
large samples of auto-SCT male lymphoma survivors, with
long follow-up time [1, 12–15]. In addition, lymphoma
patients have increased risk of cardiovascular disease
(CVD), of which ED is an independent predictor in the
general population [16]. However, the association between
sexual function and CVD has not previously been studied in
male lymphoma survivors.
Our primary aim was to evaluate sexual functioning and
sexual satisfaction among male long-term lymphoma sur-
vivors after auto-SCT, and to compare the findings with
those of normative controls. Our secondary aim was to
investigate the associations between survivors’ character-
istics, especially psychological and somatic status including
CVD, and sexual outcomes.
Subjects and methods
Study sample
During 2012–2014, a cross-sectional study was conducted
at all four centers responsible for auto-SCT of lymphoma
patients in Norway. Eligible subjects were lymphoma sur-
vivors (≥18 years) treated with auto-SCT during
1987–2008, alive per 31.12.2012 [17, 18]. Preestablished
exclusion criteria were active cancer treatment and
unknown address. Overall, 242 eligible male survivors
received postal invitation, of whom 77% (n= 187) com-
pleted a questionnaire (Fig. 1). Those also treated with
allogeneic-SCT (n= 16), total brain irradiation (n= 1), or
who delivered an incomplete Brief Sexual Function
Inventory (BSFI) (n= 9) were excluded. In addition, two
males with active cancer treatment were identified during
data preparation for the current study. The remaining 159
male participants represented the sample included in the
analyses. Overall 148 (93%) of these men also participated
in a clinical examination with height, weight, and blood
pressure measurement in addition to blood sampling.
Information on lymphoma diagnosis and treatment was
collected retrospectively from medical records [19].
Controls
Normative data on sexual function using the BSFI from a
sample of Norwegian males aged 20–59 years were avail-
able (n= 3494). The questionnaire was mailed and the
respondents returned it anonymously. Total respondent rate
was 34%, and among men without cancer a valid BSFI
questionnaire was obtained from 27% (n= 929) [20].
Response rate varied according to age and was lowest
among 20–29 years old (19%) increasing to 50–59 years
Excluded:
- Active cancer treatment: n=2*
- Total brain irradiation: n=1
- Allogenic SCT: n=16
- Not valid BSFI questionnaire: n=9
728 adult lymphoma patients treated
with auto-SCT in Norway,1987–2008
415 alive per 31.12.2012
399 invited to survey
312 completed questionnaire
Non-responders: n=87
Gender: males n=55, females n=32
Male non-responders:
Age at auto-SCT: median 41 (range 18-63)
Age per 31.12.2012: median 49 (range 25-72)
Lymphoma entities: agg NHL n=31, indolent NHL n=8,
HL n=15, other n=1
Treatment regimes prior to auto-SCT: 1 n=13, 2 n=33, ≥3 n=8,
unknown n=1
Myeloablative regime: BEAM n=51, TBI n=4
Radiotherapy: yes n=35, no n=20
n=16Excluded:
- No address: n=3
- Emigrated: n=1













lymphoma, TBI total body
irradiation, BSFI Brief Sexual
Function Inventory. Asterisk
indicates that two non-eligible
survivors were identified during
data assessment for the present
study, hence they were excluded
from analyses
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(37%) and decreased among those >70 years (29%). Fre-
quency matching was performed with 10-year intervals,
with three times as many controls as survivors randomly
drawn within each interval.
Measurements
Fasting blood samples were collected before 10.00 a.m.
Testosterone, sex hormone-binding globulin (SHBG) and
luteinizing hormone (LH) were measured at one laboratory,
using Roche E-platform. Free androgen index (FAI) was
calculated: testosterone × 10/SHBG. We categorized
gonadal hormonal status according to age-specific refer-
ence values [21] of FAI and LH: (1) normal FAI+ normal
LH, (2) normal FAI+ elevated LH, (3) low FAI+ any
level of LH, and (4) ongoing testosterone replacement
therapy.
The participants completed a multi-instrument ques-
tionnaire (125-items), including information on educational
level, relationship status, current medication, the BSFI [20],
Type-D14 for type-D personality [22], Fatigue Ques-
tionnaire (FQ) [23], Hospital Anxiety and Depression Score
(HADS) [24], and items on physical activity [25] and
smoking. Details on study questionnaire, instruments
(Type-D14, FQ), physical activity and operationalization
related to the instruments in addition to data on prevalence
of chronic fatigue and associated factors in auto-SCT
lymphoma survivors of both gender have been presented
previously [18, 26].
The BSFI is an 11-item questionnaire on sexual experi-
ences the last 30 days. The instrument constitutes three
functional domains (drive two items, erection three items, and
ejaculation two items), one problem assessment domain (one
item on drive, erection, and ejaculation, respectively), and one
item on overall sexual satisfaction [27]. Participants rated their
responses from 0 to 4, with 0 presenting the poorest function,
biggest problem or least satisfaction, and 4 the opposites. We
calculated domain scores by adding values for corresponding
items divided by number of items (range 0–4), and a total
BSFI score (adding all values except sexual satisfaction, range
0–40) as a measure of overall sexual functioning. Due to
some difference in answer alternatives on item 7 (Fig. 1)
between survivors and controls, score 2 and 3 were merged
for controls. Caseness was not part of the original BSFI, but
has been described as a method to compare sexual problems
between cases and controls [28]. Total sum score for each
domain was calculated, and cutoff values for caseness (pro-
blem) were defined as; drive ≤ 3, erection ≤ 7, ejaculation ≤ 5,
and satisfaction ≤ 1. In addition, a combined sum score for
drive, erection, and ejaculation (DEE) was created and pro-
blem defined as DEE ≤ 10. A problem with overall sexuality
was defined as the presence of either a satisfactory problem
and/or a DEE problem.
The HADS assess anxiety (seven items) and depression
(seven items), item agreement scored 0–3 with a possible
range 0–21. Cutoff for anxiety or depression caseness was
≥8 for both conditions.
Cronbach’s coefficient alpha was calculated to assess
internal consistency: BSFI 0.94, Type-D personality;
negative affectivity 0.90 and social inhibition 0.88, FQ total
score 0.93 and HADS anxiety 0.83, depression 0.81.
Cardiovascular comorbidity
Information about CVD and risk factors were based on
physicians’ report (transient ischemic attack, stroke, angina
pectoris, and myocardial infarction), examinations (height
and weight for calculation of BMI), blood samples or med-
ication (hypertension, diabetes type 1 or 2, and hypercho-
lesterolemia) when available (n= 149), and self-reported data
for the remaining participants (n= 12). Obesity was defined
as body mass index ≥30 kg/m2. Hypertension, hypercholes-
terolemia, or diabetes were defined as systolic blood pressure
≥140mmHg or diastolic blood pressure ≥90mmHg (three
consecutive measurements, mean value of last two), low-
density lipoprotein ≥4.1 mmol/L (160mg/dL) and hemoglo-
bin A1c ≥ 6.5% or fasting glucose ≥7.0 mmol/L, respectively
as previously described [17].
In order to elaborate on cardiovascular risk and sexual
function, we constructed a categorical variable with four
groups: (1) neither cardiovascular risk factors (smoking,
obesity, hypertension, or hypercholesterolemia), diabetes
type 1 or 2, nor CVD (angina pectoris, myocardial infarc-
tion, transient ischemic attack, or stroke); (2) ≥1 cardio-
vascular risk factor, but no diabetes or CVD; (3) prevalent
diabetes type 1 or 2; (4) prevalent CVD.
Medication interfering with sexual function
The following medications were considered to have possi-
ble adverse effects on sexual functioning: antidepressants,
benzodiazepines, antipsychotics, morphine, beta-blockers,
thiazide diuretics, and spironolactone [29, 30], while pro-
erectile medication was sildenafil and tadalafil. A catego-
rical variable with four groups was constructed; (1) no
medication interfering with sexual function (none); (2)
medication with possible adverse effects on sexual function;
(3) testosterone replacement therapy; and (4) pro-erectile
medication. Men who used testosterone replacement ther-
apy were categorized as such, regardless of other medica-
tion interfering on sexual function.
Statistics
Descriptive characteristics were presented as numbers
(percent) for binary variables, median (range) for age and
Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell. . .
time variables, and mean (standard deviation) for the BSFI
scores. Independent sample t-test with equal variances not
assumed was used to compare means between normally
distributed data. We performed age-stratified binary logistic
regression, age-adjusted, and multivariable analyses using
linear regression models to assess associations between
independent and outcome variables, presented with odds
ratio (OR) [95% confidence intervals] or unstandardized
regression coefficient beta. We added a quadratic term of
age and time to assess nonlinearity. The multivariable
models were adjusted for age, relationship status, and level
of education. Variables with a p value ≤ 0.25 in age-adjusted
models were included as independent variables in a multi-
variable model. A backward selection process was
performed.
Effect sizes were used as a measure to evaluate clinical
significance and were reported as standardized mean dif-
ference with standard deviations of the controls as
denominator due to heteroskedasticity, equation:
SMD ¼ meansurvivors meancontrolsSDcontrols [31, 32]. Effect size was con-
sidered to have none (0–0.20), small (0.21–0.49), and
moderate (ES ≥ 0.50) clinical significance [33].
A two-sided p value ≤ 0.05 was considered statistically
significant. SPSS version 25 was used as statistical software
(IBM Corporation, Armonk, NY, USA).
Ethics
Approval from Regional Ethics Committee South East (no
#2011/1353) and a written informed consent prior to
inclusion from all study participants were obtained.
Results
Attrition analysis
Respondents were significantly older compared with non-
respondents at diagnosis, at auto-SCT and at survey,
(median age was 42 vs 38 years, 45 vs 41 years, and 55 vs
49 years, respectively). No significant differences in lym-
phoma entities, number of treatment regimes prior to auto-
SCT, myeloablative regimen, or radiotherapy were found.
Study sample characteristics
Median age at survey for included survivors was 55 years
and median time from auto-SCT to survey was 8.1 years
(Table 1). Two participants were <18 years at diagnosis (10
and 13 years) and transplanted 29 and 19 years old,
respectively. Low FAI was present in 15% of the survivors
and 5% received testosterone replacement treatment.
Anxiety, depression, and chronic fatigue caseness were
present in 14%, 14%, and 27%, respectively, 52% had ≥1
cardiovascular risk factor and 13% had CVD. Fifty-five
percent of survivors were sedentary with a level of physical
activity below recommendations [19]. In total, 18% of
survivors were smoking daily or occasionally.
Among survivors, 75% were in a relationship (married or
cohabitant) and 47% had completed more than 12 years of
education (primary and secondary school), the corre-
sponding numbers were 86 and 72% for controls.
Sexual outcomes
Thirty percent of survivors reported sexual drive only a few
days or less last month, and 41% reported erections firm
enough to have sexual intercourse only a few times or less
last month. Sexual satisfaction was reported by 39% of the
survivors (Fig. 2). Survivors had lower score on all BSFI
items and sexual domains compared with controls (all p
values < 0.001) (Fig. 3 and Table 2) and the differences in
domain scores were clinically significant. Effect size for
overall sexual functioning declined with increasing age,
while the opposite was the case for sexual satisfaction. The
two participants <18 years at diagnosis reported higher
BSFI scores than mean of the 20–40-year-old survivors
(data not shown).
Among the survivors, 43% had sexual drive problems,
54% had erectile problems, and 40% overall sexual pro-
blems (Table 3). The corresponding proportions among
controls were 24, 31, and 19%. The probability of a sexual
problem among survivors was 3–5-fold increased for all
domains in comparison with controls (Fig. 4 and Table 3).
Age-stratified comparisons with controls showed greatest
increased risk for sexual drive problems among men 41–65
years old, and greatest increased risk of erectile and satis-
factory problems among men >65 years (Table 3).
Medication interfering with sexual function
In total, 127 men (80%) reported no current medication or
no medication likely to interfere with sexual function, 21
men (13%) used medication with a possible adverse effect
on sexual function and three men (2%) used pro-erectile
medication. Eight men (5%) used testosterone replacement
therapy.
Factors associated with sexual outcomes
In age-adjusted analyses, longer time since auto-SCT, TBI
or subdiaphragmal irradiation, chronic fatigue, anxiety
symptoms, diabetes type I or II, CVD, medication with
possible adverse effect on sexual function, testosterone
replacement therapy, low FAI, and being sedentary were
significantly associated with a lower sexual functioning
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Age at diagnosis, years, median (range) 42.0 (10–65)
Age at auto-SCT, years, median (range) 45.0 (18–67)
Age at survey, years, median (range) 55.0 (26–77) 55.0 (20–79)
Time auto-SCT—survey, years, median (range) 8.2 (3.2–23)
In a relationshipa 119 (75) 412 (86)
Education > 12 years 74 (47) 343 (72)
Lymphoma and treatment
Lymphoma entity
Aggressive Non-Hodgkin lymphomab 108 (68)
Indolent Non-Hodgkin lymphomac 15 (9.4)
















Total body irradiation 27 (17)
Curable diseaseh 102 (64)
Relapse after auto-SCT 27 (17)
Hormonal status and therapy*
Gonadal statusi
Normal FAI and LH 79 (50)
Normal FAI and elevated LH 32 (20)
Low FAI and any level of LH 24 (15)
Testosterone replacement therapy 8 (5.0)
Comorbidity
Type-D personalityj 33 (21)
Chronic fatigue 43 (27)
Anxiety caseness 22 (14)
Depression caseness 22 (14)
Cardiovascular risk or diseasek
None 44 (28)
≥1 Cardiovascular risk factorl 82 (52)
Diabetes type 1 or 2 13 (8.2)
Cardiovascular diseasem 20 (13)
Medication interfering with sexual function
None 127 (80)
Possible adverse effect on sexual functionn 21 (13)
Testosterone replacement therapyo 8 (5.0)




Missing values among cases: in a relationship, n= 1; income, n= 3;
gonadal hormonal status, n= 16; Type D personality, n= 12; chronic
fatigue, n= 1; hypercholesterolemia, n= 11; myocardial infarction,
n= 1; sedentary, n= 3; missing values among controls: in a relation-
ship, n= 3; education, n= 6
Data are presented as numbers (%) unless otherwise specified
Auto-SCT high-dose chemotherapy with autologous stem-cell trans-
plantation, BEAM high-dose chemotherapy regime (carmustine,
etoposide, cytarabine, and melphalan), FAI free androgen index, LH
luteinizing hormone
Asterisk indicates n= 143 because 16 participants did not have blood
samples available
aSurvivors: married or cohabitant. Controls: married or in an intimate
relationship
bIncludes: lymphoblastic lymphoma, n= 13; Burkitt lymphoma, n=
8; diffuse large B-cell lymphoma, n= 27; mantle cell lymphoma, n=
30; T-cell lymphomas, n= 16; transformed lymphoma, n= 12, other
(not specified), n= 2
cIncludes follicular or other indolent lymphomas
dIrradiated field unknown
eIrradiated fields supradiaphragmal: ear/nose/throat/thyroideal, n= 3;
collum, n= 9; supra/infraclavicular, n= 12; axillar, n= 9; columna,
n= 3, mediastinal, n= 20; mantle field, n= 4; other, n= 8
fTwo of the TBI-treated participants also received subdiaphragmal
irradiation and was categorized in that group, hence they do not appear
in this group. Additional irradiated fields: collum, n= 1; supra/
infraclavicular, n= 1; other, n= 1
gIrradiated fields subdiaphragmal: abdominal, n= 20; paraaortal, n=
1; reversed Y, n= 2; pelvic, n= 4; groin, n= 5; spleen; n= 1; lower
extremities, n= 2. Additional irradiated fields supradiaphragmal: ear/
nose/throat, n= 1; collum, n= 5; supra/infraclavicular, n= 6;
columna, n= 3; mediastinal, n= 5, mantle field, n= 4; other, n= 6.
Total body irradiation, n= 2
hCurable: lymphoblastic lymphoma, Burkitt lymphoma, diffuse large
B-cell lymphoma, T-cell lymphoma; palliative: follicular or other
indolent lymphoma, mantle cell lymphoma, transformed lymphoma
iSurvivors on testosterone replacement therapy excluded. According to
age-specific reference values: FAI: 20–29, 4.8–13.6; 30–39 years,
3.8–11.0; 40–49 years, 3.1–9.1; 50–59 years, 2.7–7.7; 60–69 years,
2.3–6.5; 70–79 years, 2.1–5.5. LH IU/L: 20–29, 1.95–9.4; 30–39
years, 1.93–9.7; 40–49 years, 1.95–10.0; 50–59 years, 2.01–10.4;
60–69 years, 2.10–10.8; 70–79 years, 2.22–11.2
jType-D personality; negative affectivity and social inhibition
kSurvivors with risk factors or diabetes type 1 or 2 in addition to
disease were categorized as disease
lRisk factors: obesity (body mass index >30) (n= 18), smoking daily
or occasionally (n= 26, of note three smokers were categorized as
cardiovascular disease hence do not appear here), hypertension (n=
36), hypercholesterolemia (n= 43, 5 missing)
mDisease: stroke or transitory ischemic attack (n= 10), angina pectoris
(n= 8), or myocardial infarction (n= 7, 1 missing). Four males had >1
disease, hence appear in more than one group
nAntidepressant (n= 3), benzodiazepines (n= 5), antipsychotics (n=
1), morphine (n= 1), beta-blocker (n= 11), thiazide diuretics (n= 6),
spironolactone (n= 1). Four males used more than one of these
medications, hence appear in more than one group
oFour of these men used additional medication interfering with sexual
function: case 1, thiazide diuretics and beta-blocker; case 2, beta-
blocker, antidepressant, and morphine; case 3, antidepressiva; case 4,
tadalafil
pSildenafil (n= 2), tadalafil (n= 2), one male used both medications
qPhysical activity less than 150 min/week of moderate activity, or less
than 75 min of strenuous activity
rDaily or occassionally
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1. On how many days have you  felt sexual drive?
0 % 20 % 40 % 60 % 80 % 100 %
2. How would you rate your level of sexual drive?
5. How much difficulty did you have getting an erection?
8. To what extent have you cosidered a lack of sex drive to be a 
problem?
9. To what extent have you cosidered your ability to get and
keep erections to be a problem?
10. To what extent have you cosidered your ejaculation to be a
problem?
11. Overall, how satisfied have you been with your sex life?
1:no days; 2: none at all; 3-4: not at all; 5: did not get erections at all; 6: no sexual stimulation; 7-10: big problem; 11: very dissatisfied.
1: few days; 2: low; 3-4: a few times; 5-6: a lot of difficulty; 7-10: medium problem; 11: mostly dissatisfied.
1: most days; 2: medium high; 3-4: usually; 5-6: little difficulty; 7-10: very small problem; 11: mostly satisfied.
1: every day; 2: high; 3-4: always; 5-6: no difficulty; 7-10: no problem; 11: very satisfied.
1: some days; 2: medium; 3-4: fairly often; 5-6: some difficulty; 7-10: small problem; 11: neutral or mixed.
6. How much difficulty have you had ejaculating when you have
been sexually stimulated?
7. How much did you cosider the amount of semen you
ejaculated to be a problem for you?
4. When you have erections how often were they firm enough to
have sexual intercourse?
3. How often have you had partial or full erections when you
were sexually stimulated in any way?
Fig. 2 Male lymphoma survivors treated with high-dose chemotherapy with autologous stem-cell transplantation response to the Brief Sexual
Function Inventory items
Respons score;
Mean item score ±1 SD


















0 - 4 (never or poore function-always or good function)
0 - 4 (big problem - no problem)
Respons score;
0 - 4 (very unsatisfied - very satisfied)
5: How much difficulty did you have getting an erection during
the past 30 days?
6: In the past 30 days, how much difficulty have you had
ejaculating when you have been sexually stimulated?
7: In the past 30 days, how much did you consider the amount
of semen you ejaculate to be a problem for you?
8: In the past 30 days, to what extent have you considered a lack
of sexual drive to be a problem ?
9: In the past 30 days, to what extent have you considered your
ability to get and keep erection to be a problem ?
10: In the past 30 days, to what extent have you considered your
ejaculation to be a problem ?
11: Overall, during the past 30 days, how satisfied have you been
with you sex life?
1: During the past 30 days, on how many days have you
felt sexual drive?
2: During the past 30 days, how would you rate your level
of sexual drive?
3: Over the past 30 days, how often have you had partial or full
sexual erections when you were sexually stimulated in any way?
4: Over the past 30 days, when you had erections, how often
were they firm enough to have sexual intercourse?
Fig. 3 Brief Sexual Function
Inventory (BSFI) mean item
score in male lymphoma
survivors treated with high-dose
chemotherapy with autologous
stem-cell transplantation (n=
159) and controls (n= 477)
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overall, in addition to age >55 years. Longer time since auto-
SCT, subdiaphragmal irradiation, type-D personality,
chronic fatigue, anxiety, CVD, and low FAI were sig-
nificantly associated with lower sexual satisfaction (Table 4).
In multivariable models age >55 years, chronic fatigue
and presence of CVD was negatively associated with lower
erectile function, while age >55 years, chronic fatigue,
medication with possible adverse effect on sexual function,
testosterone replacement therapy, and a sedentary lifestyle
were significantly associated with a lower sexual function-
ing overall. Chronic fatigue was significantly associated
with a lower overall sexual satisfaction (Table 4).
Discussion
In this considerable sample of male auto-SCT lymphoma
survivors, 40% had overall sexual problems, and both
Table 2 BSFI outcomes (sexual function domains, total BSFI score, and sexual satisfaction) among male auto-SCT lymphoma survivors and














1.81 (0.95) 2.22 (1.36) 2.72 (1.41) 2.56 (1.27) 23.4 (10.8) 1.97 (1.22)
Controls (n= 477) 2.24 (0.83) 2.94 (1.11) 3.46 (0.82) 3.21 (1.04) 29.9 (8.53) 2.61 (1.05)
p valuea <0.001 <0.001 <0.001 <0.001 <0.001 <0.001




2.47 (1.04) 3.17 (1.08) 3.53 (0.79) 2.93 (1.23) 30.3 (9.14) 2.11 (1.28)
Controls (n= 55) 2.65 (0.80) 3.60 (0.57) 3.85 (0.34) 3.65 (0.68) 34.8 (4.60) 2.60 (1.05)
p valuea 0.50 0.12 0.11 0.03 0.06 0.15




2.12 (0.77) 2.78 (1.13) 3.28 (0.95) 2.77 (1.25) 27.5 (9.39) 2.23 (1.14)
Controls (n= 191) 2.52 (0.71) 3.40 (0.80) 3.77 (0.45) 3.57 (0.70) 33.5 (5.81) 2.78 (0.98)
p valuea <0.001 <0.001 <0.001 <0.001 <0.001 0.001




1.50 (0.95) 1.80 (1.34) 2.16 (1.61) 2.35 (1.33) 19.8 (10.9) 1.86 (1.29)
Controls (n= 128) 2.07 (0.74) 2.67 (1.04) 3.35 (0.86) 3.03 (1.13) 28.0 (8.43) 2.55 (1.10)
p valuea <0.001 <0.001 <0.001 0.002 <0.001 0.001




1.19 (0.75) 0.99 (0.84) 1.85 (1.46) 2.16 (1.10) 15.5 (7.67) 1.44 (1.12)
Controls (n= 103) 1.70 (0.82) 2.05 (1.22) 2.84 (1.04) 2.54 (1.22) 22.8 (9.21) 2.39 (1.10)
p valuea 0.003 <0.001 0.002 0.13 <0.001 <0.001
SMDb −0.62 −0.87 −0.95 −0.31 −0.79 −0.86
Range score possible: sexual drive 0–4, erectile function 0–4, ejaculatory function 0–4, problem assessment 0–4, total BSFI score 0–40, sexual
satisfaction 0–4
Bold type indicating statistical significance (p value < 0.05) or moderate clinical significance (effect size ≥ 0.50)
Data are presented as mean (SD) unless otherwise specified
BSFI Brief Sexual Function Inventory, Auto-SCT high-dose chemotherapy with autologous stem-cell transplantation, SMD standardized mean
difference
aIndependent sample t-test, equal variances not assumed
bEquation: SMD ¼ meansurvivors meancontrolsSDcontrols
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functioning and satisfaction were reduced compared with
age-matched controls.
There is a lack of studies comparing sexual function
among auto-SCT lymphoma survivors with controls.
However, supporting our findings are studies reporting on a
sexual functioning inferior to controls in both lymphoma
survivors who did not have auto-SCT and survivors of
hematological malignancies after SCT [6, 10]. Compared
with lymphoma survivors not treated with auto-SCT, sexual
functioning might be even worse in our study group, as
indicated by a comparison of effect sizes [6].
Stratified by age, we observed an increasing difference in
erectile function and sexual satisfaction between survivors
and controls with increasing age groups, despite the
opposite trend for assessment of sexual problems. Expec-
tations of normal sexual functioning are likely to differ
between age groups, leading to a response shift where the
older survivors report less problems related to a certain
reduction in sexual function, than younger survivors. In
addition, the younger survivors might have been more
resilient to functional reductions before satisfaction was
affected.
The associations found in age-adjusted models reflect the
multifactorial (social, psychological, and physiological)
interactions on sexual function also described in the general
population [29, 34].
In multivariable models, survivors aged 41–55 years did
not differ in sexual outcomes compared with the reference
Table 3 Age-stratified odds ratios for BSFI caseness (problem) comparing auto-SCT lymphoma survivors with normative controls using logistic
regression models
Domain problem






Total sample, n= 159 cases/477 controls
Auto-SCT survivors 69 (43) 86 (54) 59 (37) 41 (26) 55 (35) 63 (40)
Controls 114 (24) 148 (31) 80 (17) 42 (8.8) 74 (16) 90 (19)
Odds ratio [95% CI],
reference= controlsa
2.96 [1.96, 4.47] 3.66 [2.39, 5.61] 3.96 [2.51, 6.26] 5.62 [3.20, 9.87] 2.97 [1.96, 4.50] 3.08 [2.05, 4.62]
Young sample (20–40 years)
n= 18 cases/55 controls
Auto-SCT survivors 3 (17) 5 (28) 4 (22) 1 (5.6) 5 (28) 5 (28)
Controls 8 (15) 4 (7.3) 1 (1.8) 0 8 (15) 8 (15)
Odds ratio [95% CI],
reference= controls
NA NA NA NA NA NA
Middle-aged sample (>40–55 years)
n= 65 survivors/191 controls
Auto-SCT survivors 18 (28) 23 (35) 13 (20) 6 (9.2) 16 (25) 17 (26)
Controls 19 (9.9) 23 (12) 9 (4.7) 1 (0.5) 23 (12) 23 (12)
Odds ratio [95% CI],
reference= controls
3.47 [1.69–7.13] 4.00 [2.05–7.81] 5.06 [2.05–12.5] NA 2.39 [1.17–4.87] 2.59 [1.28, 5.23]
Old sample (>55–65 years)
n= 49 survivors/128 controls
Auto-SCT survivors 28 (57) 34 (69) 24 (49) 19 (39) 20 (41) 24 (49)
Controls 36 (28) 55 (43) 27 (21) 12 (9.4) 23 (18) 25 (20)
Odds ratio [95% CI],
reference= controls
3.41 [1.72, 6.76] 3.01 [1.49, 6.07] 3.59 [1.78, 7.25] 6.12 [2.68, 14.0] 3.15 [1.52, 6.51] 3.96 [1.94, 8.05]
Oldest sample (>65 years)
n= 27 survivors/103 controls
Auto-SCT survivors 20 (74) 24 (89) 18 (67) 15 (56) 14 (52) 17 (63)
Controls 51 (50) 66 (64) 43 (42) 29 (28) 20 (19) 34 (33)
Odds ratio [95% CI],
reference= controls
2.91 [1.13–7.48] 4.49 [1.27–15.9] 2.79 [1.15–6.80] 3.19 [1.33–7.63] 4.47 [1.82–11.0] 3.45 [1.43–8.34]
Bold type indicating statistical significance (p value < 0.05). Data are presented as numbers (%) unless otherwise specified
BSFI Brief Sexual Function Inventory, auto-SCT high-dose chemotherapy with autologous stem-cell transplantation, DEE drive, erection, and
ejaculation, NA not applicable
aAge-adjusted
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group (survivors age 26–40 years), however a significant
worsening was found for patients above the age of 55 years.
A relationship between increasing age and reduced sexual
functioning is well known in the general population [34]
and from previous reports on lymphoma survivors [2, 6].
Reduced physical health, adverse effects of multipharmacy
in the elderly, decrease in testosterone, and lack of partner
may contribute to this finding [35].
In this study, chronic fatigue was significantly associated
with lower sexual functioning and satisfaction, in line with
earlier findings [36], and this illustrates the detrimental
effect chronic fatigue has on many aspects of life.
Thirteen percent of survivors had CVD with a significant
negative association with erectile function. Atherosclerosis
as well as endothelial dysfunction are common causes of
both CVD and ED [37]. Hence, these conditions share
many risk factors. ED precedes CVD by 2–5 years [16], and
we believe this is of special importance as auto-SCT lym-
phoma survivors are at increased risk of fatal CVD [1, 38].
The majority of survivors were sedentary with reduced
overall sexual functioning compared with the physically
active survivors. Contrasting earlier reports, physical inac-
tivity was not related to ED in particular [39]. Sedentary
survivors had a reduced sexual function that they con-
sidered more problematic compared with the physically
active. However, the sedentary survivors did not report
lower sexual satisfaction than the physically active
survivors.
In age-adjusted analyses, low FAI was related to lower
sexual functioning overall and less sexual satisfaction.
These significant associations were lost in multivariable
models indicating that factors described above were more
important than FAI for sexual outcomes. Our findings are
diverging from previous reports describing associations
between sexual function and testosterone levels [6, 40]. We
present two plausible explanations: (1) Low FAI seems to
be associated with CVD [41], a factor included in our
multivariable analyses, and (2) a small proportion of sur-
vivors had gonadal dysfunction in our study, reducing the
power to detect a significant association.
All auto-SCT lymphoma survivors treated in Norway
until 2008 were accounted for and invited to participate in
the survey. A high participation rate assures good repre-
sentativeness, and external validity of our results. With long
follow-up time, reversible aspects of sexual functions
should be restored after treatment. In addition, long follow-
up time enables us to examine the association between CVD
and ED.
The BSFI is a validated instrument with good psycho-
metric properties, and using a control group reporting on the
same instrument is a considerable strength, especially in an
area where a diversity of instruments have been used. The
response rate in the control group was low, which is a
problem with questionnaire studies of sexuality in the
general population. In addition, the representativeness was
unknown [20]. However, the normative data resemble
findings in a similar American study using the BSFI with
better response rate [42]. Hence, we believe the control
group was adequate, but we advise for careful interpreta-
tions. In addition, differences in education and relationship
status between survivors and controls might represent
selection bias.
Further limitations include the cross-sectional design that
prevents us from addressing causality. Adding medication
in the multivariable models in order to adjust for possible
effects on sexual function might have diminished the
associations between both CVD and mental distress with
the sexual outcomes as colinearity between these variables
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Fig. 4 Odds ratio and 95%
confidence interval [95%] for
Brief Sexual Function Inventory







(caseness) if total score on
current domain: sexual drive ≤ 3;
erectile function ≤ 7; ejaculatory
function ≤ 5; DEE (drive,
erection, ejaculation)
problems ≤ 10; sexual
satisfaction ≤ 1; overall sexual
problem= either DEE problem
or overall satisfaction problem
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are likely to be present. Our outcomes of interest were
based on patient reported outcome measures, which are
associated with recall difficulties [43]. The sample size of
young survivors was small hence, statistical analyses on
effect size are uncertain.
Clinical implications
Erectile dysfunction might be a symptom of silent CVD and
addressing sexual function at consultations may reveal auto-
SCT survivors in need of support for lifestyle changes or
medical intervention in order to ameliorate cardiovascular
risk factors and possibly avoid or delay CVD events
[30, 44, 45]. In particular, physical activity might have
positive implications for CVD, chronic fatigue, and anxiety
that are more prevalent in SCT survivors [15], and perhaps
erectile function can be improved [39]. Treatment for sexual
problems should be offered according to previously pub-
lished guidelines [46]. First, assessment of gonadal function
and testosterone replacement therapy should be considered.
Second, in case of erectile dysfunction use of pro-erectile
medication (assuming no contraindications) or use of a
vacuum erectile device is recommended and finally survi-
vors with relational or psychosocial problem should be
referred to individual or couple counseling.
Conclusion
Our study identifies sexual dysfunction as a problem for
many male auto-SCT survivors, however sexuality is a
neglected issue during follow-up [47]. Hence, physicians
should address sexual function before, during, and after
treatment in order to identify sexual problems and their
cause in auto-SCT survivors. By acknowledging the
importance of sexual function after cancer, we believe that
more auto-SCT male survivors will have sexual problems
diagnosed, treated, and hopefully improved.
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Abstract 40 
BACKGROUND: Sexual function in female lymphoma survivors after high-dose therapy 41 
with autologous stem-cell transplantation (auto-SCT) is largely unstudied.  42 
METHODS: Female lymphoma survivors treated with auto-SCT in Norway 1987-2008 were 43 
eligible participants (n=157). A multi-item questionnaire including a complete Sexual 44 
Activity Questionnaire was returned by 70% (n=110) of the women. A comparison to age-45 
matched normative controls was performed.   46 
RESULTS: Sexual inactivity was equal among survivors and controls. The survivors reported 47 
personal issues more frequent as reason for inactivity compared with controls (44% vs. 28%, 48 
p=0.04). The sexually active survivors reported more sexual discomfort, greater reduction in 49 
frequency of sexual activity, and more sex-related tiredness compared with controls (p-value 50 
and effect size [95% confidence interval]; p=<0.001, 0.70 [0.44, 0.97], p=0.03, -0.29 [-0.55, -51 
0.03] and p= <0.001, 0.64 [0.37, 0.90] respectively).  52 
Sexual activity was related to older age (odds ratio (OR) 0.58 [0.43, 0.82] per 10 years), being 53 
in a relationship (OR 28.6 [6.9, 118.9]) and hormonal replacement therapy (OR 6.0 [1.49, 54 
24.2]). Tiredness in relation to sexual activity was associated with younger age, chronic 55 
fatigue and mental distress. 56 
CONCLUSIONS: Sexual inactivity due to personal issues and sexual discomfort were more 57 
frequent among auto-SCT survivors than controls and should be addressed at follow-up. 58 
  59 
3  
Introduction  60 
High-dose chemotherapy with autologous stem-cell transplantation (auto-SCT) is standard 61 
treatment for eligible patients with relapsed/refractory Hodgkin (HL) or non-Hodgkin 62 
lymphoma (NHL), as well as first line treatment for some subgroups of NHL. Lymphoma 63 
survivors have an increased risk of late effects including second cancer, cardiopulmonary 64 
disease, chronic fatigue and mental distress [1, 2], in addition to premature ovarian 65 
insufficiency (POI) in premenopausal women [3]. These conditions may negatively affect 66 
sexual function.  67 
In general, female sexual dysfunction is often multifactorial and problems are related 68 
to sexual drive, arousal, dyspareunia, lack of orgasm, satisfaction and among younger women, 69 
infertility [4-6]. The incidence of sexual dysfunction varies according to the problem being 70 
assessed [4]. Of note, vaginal dryness and dyspareunia are more frequent in women >50 years 71 
than those <50 years, most likely related to menopausal changes (vulvovaginal atrophy and 72 
reduced sexual responsiveness (arousal, sexual pleasure and orgasm) and physical and mental 73 
health [4, 7, 8].   74 
Previous studies examining sexual function among HL survivors after conventional 75 
chemotherapy (both gender) have reported persisting lower sexual function among patients 76 
with advanced disease [9]. The malignancy had a negative impact on sexual life among 24-77 
36% of lymphoma survivors [10], and only 38% were satisfied with their sexual life [11]. 78 
After auto-SCT for hematological malignancies, sexual activity was reported by 55% of 79 
females (n=64) with three years follow-up [12]. Additionally, two small studies on pooled 80 
auto/allogeneic-SCT cohorts reported that  sexual functioning decreased from one to three 81 
years post-treatment [13], and half of these women reported problems with arousal, 82 
lubrication, pain and orgasm [13, 14]. Generalization of these findings to female auto-SCT 83 
lymphoma survivors is difficult due to both small sample sizes and graft-versus-host disease 84 
4  
as a major and specific cause of sexual problems for allogeneic-SCT survivors. However, in a 85 
recent comprehensive study on late effects after auto-SCT for lymphoma, sexual problems 86 
occurred in 62% of survivors. Accordingly, larger samples providing detailed data on sexual 87 
functioning in these survivors are warranted.  88 
The main objectives of the present study were to evaluate sexual activity and sexual 89 
function among female auto-SCT survivors compared with controls, and associations between 90 
survivors’ characteristics and sexual outcomes. 91 
 92 
Patients and methods 93 
Study population 94 
During 2012-2014 we performed a cross-sectional study of all auto-SCT lymphoma survivors 95 
in Norway, aged ≥18 years at auto-SCT and treated 1987-2008 [15, 16]. Exclusion criteria 96 
were ongoing cancer treatment or unknown residence. Invitation was mailed to 157 eligible 97 
females, of which 80% (n=125) complied. Five survivors also treated with allogeneic-SCT 98 
and 10 survivors with incomplete Sexual Activity Questionnaire (SAQ) were excluded. 99 
Hence, 110 female participants were included in this study (Figure 1). Information regarding 100 
lymphoma history and treatment were extracted retrospectively from medical records [17]. A 101 
consultation providing information on medical history, clinical examination and blood 102 
samples was performed on 90 participants (82%). 103 
 104 
Controls 105 
Controls were drawn from a sample of 1 176 Norwegian females aged 20-69 years, reporting 106 
on the SAQ [18]. The total response rate was 42% and response rates according to age were: 107 
20-34 years; 32%, 35-44 years, 47%; 45-55 years 50% and 56-69 years, 41%. Frequency 108 
matching was performed with five controls randomly drawn within each 10-year interval.  109 
5  
The SAQ 110 
The SAQ was constructed in order to measure the impact of medical treatments on sexual 111 
functioning and to differentiate on menopausal status [19]. The psychometric properties have 112 
been tested in women with and without cancer and compliance, reliability and validity has 113 
been good [19-21].  114 
The SAQ consists of three parts; 1) information on marriage or intimate relation, 115 
current sexual relationship or not; 2) reasons for sexual inactivity, and 3) sexual functioning 116 
last month, addressing four domains: pleasure (desire, enjoyment and satisfaction), discomfort 117 
(vaginal dryness and dyspareunia), habit (frequency of sexual activity compared to normal) 118 
and tiredness (too tired for sex) [18, 19, 21]. In our study, two items (one on orgasm and one 119 
on arousal), were included and added to the pleasure domain according to a previous report 120 
[21].  121 
Reasons for sexual inactivity were categorized into no partner, partner issues and 122 
personal issues.  123 
Responses in sexual functioning last month were rated 0-3, with zero representing the lowest 124 
degree of pleasure or discomfort, lower frequency of sexual behavior than usual for the 125 
respondent and less sexual tiredness and three representing the opposites. The sexual function 126 
domain scores were made by summing up scores from the respective items; pleasure (range 0-127 
18 (24); discomfort (range 0-6), habit and tiredness (both range 0-3). 128 
Participants who were sexually inactive last month omitted part 3, while the sexually 129 
active omitted part 2 of the SAQ. Cronbach’s alpha for sexual functioning indicated high 130 
internal consistency reliability: 0.83, survivors and 0.85 controls. 131 
Instruments for patient reported outcome measures 132 
The responding women completed a questionnaire (133-items), including information on 133 
educational level, the SAQ [19], distressed type personality [22], Fatigue Questionnaire [23], 134 
6  
and mental distress (Hospital Anxiety and Depression Scale (HADS) [24]. Previous reports on 135 
the study cohort have presented the questionnaires and their operationalization [16, 25, 26]. 136 
Cronbach’s alpha; distressed type personality, social competence 0.84, nervousness 0.90; 137 
chronic fatigue caseness 0.92; anxiety caseness 0.89; and depression caseness 0.85. 138 
 139 
Menstrual status and HRT 140 
Fasting morning blood samples were analyzed for estradiol, luteinizing hormone (LH) and 141 
follicle stimulating hormone (FSH) and performed at a single laboratory at Oslo University 142 
Hospital (Roche E-platform). Women reported on regularity of menstrual bleedings, age at 143 
last bleeding in case of amenorrhea, on previous or present estrogen supplemental therapy and 144 
duration of such.  145 
Menstrual status was defined according to hormonal levels and bleeding status 146 
(supplementary data) and the survivors were categorized according to menstrual status and 147 
ongoing HRT. Premature ovarian insufficiency (POI) was defined by postmenopausal status 148 
or initiation of HRT before the age of 40 years. 149 
 150 
Statistical analysis 151 
Binary variables were presented as number (percent), age and time as median (range) and the 152 
SAQ scores as mean (standard deviation (SD)). We used Pearson Chi-square test to assess 153 
proportion of sexually inactive survivors compared with controls, and differences in reasons 154 
for sexual inactivity between these two groups. We used independent sample t-test to compare 155 
SAQ item and functional domain mean values among sexually active survivors and controls 156 
(the latter additionally analyzed according to three age groups (20-44 years, 45-54 years, ≥55 157 
years of age). Standardized mean difference (SMD) with 95% confidence intervals [95%CI] 158 
was calculated as effect size to measure the difference between two groups and imply clinical 159 
7  
relevance; small (SMD 0.21-0.49), moderate (SMD 0.50-0.80) and large (SMD ≥0.80).  [27-160 
29]. We used age-adjusted logistic regression models to estimate odds ratios (ORs) with 161 
[95%CI] of being sexually active according to selected characteristics of the survivors. 162 
Finally, we used age-adjusted linear regression models to assess regression coefficients for the 163 
association between selected independent variables and SAQ functional domains as 164 
dependent variables in sexually active survivors. A second-degree polynomial for age and 165 
time were added to assess non-linearity. The dependent variables in the linear regression 166 
models may take up a limited number of values (minimum 4, maximum 19), but are assumed 167 
to be approximations of an underlying continuous scale and residual analyses confirmed 168 
model assumptions. Sensitivity analyses with non-parametric methods were performed and 169 
detected no qualitative differences in results (data available upon request). 170 
Statistical significance was considered when a two-sided p-value ≤0.05 was found. 171 
SPSS version 25 was used as statistical software (IBM Corporation, Armonk, New York, 172 
USA).  173 
 174 
Results 175 
Attrition analysis 176 
There were no differences between responding and non-responding survivors with regard to 177 
age characteristics, lymphoma entity, myeloablative regimen or radiotherapy use. 178 
 179 
Characteristics of study sample 180 
Median age at auto-SCT was 45 years (range 19-65 years) and at survey 53 years (range 24-181 
75 years) (Table 1). Median follow-up time from transplantation was 9 years (range 3.6-25 182 
years). The majority (63%) had a primary diagnosis of aggressive NHL, and 13% were treated 183 
8  
with total body irradiation (TBI) as conditioning regimen for auto-SCT. Overall 74% of the 184 
survivors were in a paired relationship. 185 
 186 
Survivors and controls 187 
Sexual activity or inactivity  188 
Median age at survey for sexually active and inactive survivors were 48 and 65 years, 189 
respectively (controls: 49 and 61 years). The prevalence of sexual inactivity did not differ 190 
between survivors and controls (37% vs. 41%, p= 0.42). The most common reason for sexual 191 
inactivity in both samples was lack of partner (Table 2). Personal issues as reasons for sexual 192 
inactivity were reported significantly more often among survivors than controls (44% vs. 193 
28%, p=0.04).  194 
Sexual functioning   195 
Item responses among sexually active survivors and controls are displayed in Figure 2a and b. 196 
Reduced sexual frequency was reported by 26% of survivors (controls: 17%), and both 197 
frequency and frequency satisfaction were statistically lower among survivors compared with 198 
controls (p-value 0.03 and 0.04, respectively) (Figure 2a).  199 
Vaginal dryness was present among 30% of survivors and 14% of controls, while pain 200 
or discomfort during sexual penetration were reported by 22% and 7%, respectively (Figure 201 
2b). Sexually related tiredness was reported by 35% of survivors and 15% of controls. These 202 
item responses were statistically significantly different between survivors and controls (p-203 
values <0.001).  204 
Examining responses by the functional domains, survivors experienced more sexual 205 
discomfort than controls (p-value <0.001, effect size 0.70 [0.44, 0.97]) (Table 2) sexual habit 206 
and tiredness differed between survivors and controls with, clinical significance of small and 207 
moderate strength (effect size -0.29 [-0.55, -0.03] and effect size 0.64 [0.37, 0.90], 208 
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respectively). Analyzed according to three age groups, sexual discomfort and sexual tiredness 209 
were significantly lower among young (20-44 years) and middle-aged (45-54 years) survivors 210 
compared with their peers. Sexual habit was lower among women ≥55 years compared with 211 
controls of the same age (data not shown).  212 
 213 
Survivors 214 
Factors associated with sexual activity or inactivity 215 
Older survivors were less likely to be sexually active (OR 0.58 [0.43, 0.82] per 10 years) than 216 
younger ones, while married or cohabiting survivors were more likely to be sexually active 217 
(OR 28.0 [6.9, 118.0]) than those not in a paired relationship (Supplementary Table 1). No 218 
lymphoma, treatment or comorbidity related factors were associated with sexual activity. 219 
Factors associated with sexual functioning  220 
In age-adjusted models, TBI and presence of a distressed personality were negatively 221 
associated with sexual pleasure. Younger age, a distressed personality, chronic fatigue, 222 
anxiety and depression were related to more sexual tiredness (Table 3). Additionally, chronic 223 
fatigue and symptoms of anxiety were negatively associated with an ability to reach orgasm 224 
(analyzed as single items, data not shown). Lymphoma entity or number of regimens prior to 225 
auto-SCT were not associated with sexual functioning (data not shown).  226 
Menstrual status, HRT and associations to sexual outcomes  227 
At survey, 67 women (61%) were postmenopausal without HRT, 26 women (24%) were 228 
HRT-users and presumably postmenopausal and 17 women (16%) were premenopausal, 229 
median age was 63, 43 and 35 years, respectively. Sexual activity was reported by 48% of 230 
postmenopausal women, 88% on HRT and by 82% of premenopausal women. Women on 231 
HRT had a higher probability of being sexually active compared with postmenopausal women 232 
OR 6.00 [1.49, 24.2] (Supplementary table 1). No statistically significant associations were 233 
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identified between sexual functioning and menstrual status and hormone therapy among the 234 
sexually active survivors (data not shown).  235 
POI and HRT: Forty-two women were at risk of POI at time of auto-SCT, of which 22 236 
women developed POI and 14 women were still at risk of developing POI at time of survey. 237 
Thirty-five women reported HRT use after auto-SCT, of which 30 women initiated HRT 238 
within the first two years after auto-SCT (six with temporary ovarian insufficiency, 19 POI 239 
and five women ≥40 years). Two of the 22 women with POI after auto-SCT did not receive 240 
HRT.  241 
 242 
Discussion  243 
In the present national study on female sexual function after auto-SCT for lymphoma, 244 
personal issues as cause of sexual inactivity and sexual discomfort were more often reported 245 
by long-term survivors compared with controls. Those of younger age, with a partner, and 246 
HRT-user were more likely to be sexually active, while a distressed personality, TBI, mental 247 
distress and chronic fatigue were related to reduced sexual functioning.  248 
Although the proportion of sexually active survivors did not differ from controls, the 249 
proportion of sexually active postmenopausal women in our sample was lower than in a 250 
previous report among healthy women (48% vs 77%, respectively) [19]. The prevalence of 251 
sexually active auto-SCT survivors overall was in line with a previous report on SCT 252 
survivors [30] however, slightly higher than in the study by Wong et al. (63% vs 55%) [12]. 253 
This difference was possibly due to a greater proportion of women in our sample having a 254 
partner (74% vs 58%), compared with the sample in the study by Wong et al. Additionally, 255 
the two samples differed with regard to follow-up time and cancer diagnosis, hence a direct 256 
comparison between the two was difficult.  257 
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Lack of partner was consistently related to sexual inactivity in the general population 258 
[6] among NHL [11] and SCT survivors [12, 13] and in this cohort. The more frequent 259 
reporting of personal issues as cause of sexual inactivity, and lower sexual functioning among 260 
survivors compared with controls may be related to auto-SCT survivors’ increased risk of 261 
several adverse late-effects of  physiological, psychological, and sociocultural nature [31], 262 
with a possible negative impact on sexuality [32]. A recent comprehensive report, found 263 
sexual problems to be the most frequently reported late effect among auto-SCT lymphoma 264 
survivors, reported by 62% (both genders) [33]. In that study, median age was higher than in 265 
our cohort, a factor related to more sexual problems. Additionally, we were unable to estimate 266 
prevalence of women defining their sexual functioning as problematic. Hence, it was difficult 267 
to compare prevalence between the two cohorts. 268 
Nonetheless, survivors of current cohort experienced more sexual discomfort than 269 
controls, which could be related to postmenopausal status, increased number of chronic 270 
diseases or depression as reported in the general population [8]. Nevertheless, the survivors 271 
were not less sexually satisfied than their peers. Similar resilience in female sexuality has 272 
been reported in long-term cohorts of gynecological cancer survivors [34]. Being sexually 273 
active may provide rewards in other important areas like emotional and relational comfort and 274 
satisfaction [32], which might overcome the sexual discomfort. 275 
TBI has previously been associated with sexual discomfort in SCT treated female 276 
leukemia patients [35]. No such association was found in our sample, possibly due to small 277 
sample size. However, an association with reduced sexual pleasure was identified.  278 
Survivors with chronic fatigue, increased anxiety or depression were more frequently 279 
too tired to have sex, and the former two reported more difficulties achieving orgasm than 280 
survivors without such problems. These sexual problems might be related to a negative 281 
impact on the sexual experience caused by energy depletion, mental fatigue or mental distress 282 
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[11], as previously reported in the general population [36] and NHL survivors [11]. 283 
Corroborating our finding, a relationship between chronic fatigue and sexual dysfunction has 284 
previously been reported among young survivors of hematological malignancies and HL 285 
survivors [9, 37].   286 
POI has been reported among 70-100% of women after SCT [38]. Herein, a smaller 287 
proportion developed POI after auto-SCT, though the prevalence might increase with longer 288 
follow-up. Associations between POI and sexual outcomes are likely to exist [14, 39], 289 
however, the study design and lack of statistical power might have prevented us from 290 
detecting these associations. Ovarian protection by GnRH agonist prior to auto-SCT for 291 
lymphoma patients is promising, however remains to be confirmed in randomized clinical 292 
trials [40, 41].  293 
 Time to menopause may be shortened in women ≥40 years and cause undesirable 294 
symptoms [7, 42]. We believe the proportion of non-POI women in our study who initiated 295 
HRT within the first two years post auto-SCT illustrates this. HRT use was associated with 296 
being sexually active possibly due to; younger age; increased likelihood of addressing 297 
menopausal symptoms among sexually active women; and alleviation of genitourinary 298 
symptoms and promoted maintenance of sexual activity. This is supported by a previous 299 
finding that among women experiencing menopause in the first years post-SCT, early HRT 300 
was important for later sexual functioning, especially satisfaction [13].  301 
It was a considerable strength that the sampling frame was well-known and response 302 
rate high in this national survey. The SAQ instrument is well validated and with good 303 
psychometric properties [18, 19]. Additionally, the attrition analyses did not show any 304 
significant differences, allowing us to emphasize the external validity of our findings. The 305 
inclusion of a control group is another strength. Even though, the response rate in the 306 
normative study was lower than appreciable. 307 
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The cross-sectional design is a limitation, and causality could not be addressed. 308 
Further limitations include that 10 women (8.3%) were excluded from analysis due to 309 
incomplete reporting on the SAQ, patient-reported outcomes are associated with recall 310 
difficulties and sexual function is an especially sensitive issue to report on [43]. The SAQ 311 
instrument does not assess single women’s or same-sex sexuality nor aspects of infertility, 312 
sexual intimacy or body image, and unadjusted confounders are likely to exist due to the 313 
complexity of female sexuality. We had reduced power to identify statistically significant 314 
associations due to a small sample size. A minority of participants (n=10) used medication 315 
(except from HRT) that possibly could interfere on sexual functioning. We did not adjust for 316 
medication in the analyses. 317 
Conclusion and future implications 318 
Reports show an incongruence in health personnel’s attention towards sexual health, and 319 
cancer patients’ need [44, 45]. Hence, investigations of sexuality in cohorts of female cancer 320 
survivors are warranted to raise the awareness and attention on this sensitive issue.  321 
 In light of a recently published guideline for management of sexual problems after 322 
cancer [46] and our data we recommend the following for female auto-SCT patients: 1) 323 
Ovarian preserving interventions could be considered [47, 48]. 2) At discharge from hospital, 324 
women should be informed on use of vaginal moisturizers and lubricants [46]. 3) Awareness 325 
of enhanced transition into menopause post-SCT and early initiation of systemic or local 326 
hormone therapy when indicated [46]. 4) Awareness of chronic fatigue and mental distress in 327 
relation to reduced sexual functioning. 5) Women with more complex or concerning sexual 328 
problems are in need of counselling or sexual therapy and health authorities should provide 329 
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Figure Legends  479 
Figure 1. Flowchart of female lymphoma survivors after high dose chemotherapy with 480 
autologous stem-cell transplantation, detailing non-eligible and eligible survivors and among 481 
eligible participants, detailing women providing data for specific parts of the Sexual Activity 482 
Questionnaire. 483 
 484 
Figure 2. Sexual Activity Questionnaire item response regarding sexual pleasure, habit 485 
(Figure 2a), sexual discomfort and tiredness (Figure 2b), in sexually active survivors and 486 
controls. 487 
15 females excluded due to: total brain 
irradiation, n=2*; allogenic SCT, n=5; not 
valid SAQ questionnaire among the 
sexually active, n= 10  
728 adult lymphoma patients treated 
with auto-SCT in Norway, 1987 – 2008 
415 alive per 31.12.2012 
399 invited to survey  
32 female non-responders 
16 excluded due to: no address, n=3; 
emigrated, n=1; active cancer treatment, 
n=4; deceased, n=8   
313 deceased 
110 women provided data for the 
present study 
*These 2 had incomplete 
SAQ questionnaire and 
appear in both groups 
242 male subjects   
69 women sexually active reported on 
the SAQ part 1 and 3 
41 women not sexually active, reported 
on the SAQ part 1 and 2 
157 females invited to survey  
0% 20% 40% 60% 80% 100%
1. Last month,was having sex an important part of your life?
Controls
2. Last month, did you enjoy sexual activity?
Controls
4. Last month,did you desire to have sex with your partner?
Controls
7. Last month, in general did you feel satisfied after sexual activity?
Controls
8. Last month, how often did you engage in sexual activity?
Controls
9. How did this frequency of sexual behavior compare with what is usual for you?
Controls
10. Last month, were you satisfied with the frequency of sexual activity?
Controls
11. During sexual relations last month, how aroused were you?
12. During sexual relations last month, how often did you have orgasm?
Figure 2a 
1-8,10,11: not at all. 9: not as much; 12: never.
1-7,10,11: a little; 8: 1-2 times; 9: about the same; 12: some times.
1-7,10, 11: somewhat. 8: 3-4 times. 9: somewhat more; 12: often.
1-7,10, 11: very much; 8: ≥5 times; 9: much more; 12: always.
Mean (SD)       p-value
 
1.57 (0.90)       0.50 
            
1.65 (0.91) 
  






























0% 20% 40% 60% 80% 100%
5. During sexual relations last month, how frequently did you notice dryness of your vagina?
Controls
6. Last month, did you feel pain or discomfort during penetration?
Controls
3. Too tired to have sex
Controls
Figure 2b 
1-8,10,11: not at all. 9: not as much; 12: never.
1-7,10,11: a little; 8: 1-2 times; 9: about the same; 12: some times.
1-7,10, 11: somewhat. 8: 3-4 times. 9: somewhat more; 12: often.
1-7,10, 11: very much; 8: ≥5 times; 9: much more; 12: always.
Mean (SD)      p-value
 








1.25 (0.90)      <0.001 
 
0.73 (0.80) 
Table 1. Characteristics of study population at diagnosis and survey, and normative 
controls 







Age at diagnosis, years, median (range) 40 (17-65)  
Age at auto-SCT,  years, median (range) 45 (19-65)  
Age at survey, years, median (range)  53 (24-75)a 56 (20-69)
Time auto-SCT – survey, years, median (range) 9.0 (3.6-25)  
In a relationshipb 81 (74) 428 (78) 
Education >12 years 51 (46) 207 (31) 
LYMPHOMA AND TREATMENT  
Lymphoma entity  
     Aggressive Non-Hodgkin lymphomac 69 (63)  
     Indolent Non-Hodgkin lymphomad 11 (10)  
     Hodgkin lymphoma 30 (27)  
Stage at diagnosis  
     I-II 33 (30)  
     III-IV 76 (69)  
N0 chemotherapy regimes prior to auto-SCT  
     1   27 (25)  
     2 73 (66)  
     ≥3 10 (9.1)  
Received radiotherapy  
     None 35 (32)  
     Othere 12 (11)  
     Supradiaphragmal 24 (22)  
     Total body irradiation 14 (13)  
     Subdiaphragmal 25 (23)  
Myeloablative regimen  
     BEAM 96 (87)  
     Total body irradiation 14 (13)  
MENSTRUAL STATUS and HORMONE THERAPYf  
Hormonal groups  
  Postmenopausal without current HRT 67 (61)  
  HRTg 26 (24)  
  Premenopausal 17 (16)  
Premature ovarian insufficiency 32 (29)h  
COMORBIDITY  
Distressed personalityi 21 (19)  
Chronic fatigue caseness 40 (36)  
Emotional distress, HADS  
   Anxiety caseness 31 (28)  
   Depression caseness 14 (13)  
                                                            
a Two women <30 years. 
b Survivors: Married or cohabitant. Controls: Married or in an intimate relationship. 
c Includes: Lymphoblastic lymphoma, n=8; Burkitt lymphoma, n=3; diffuse large B-cell lymphoma, n=30; mantle cell 
lymphoma, n=6; T-cell lymphomas, n=10; transformed lymphoma, n=12. 
d Includes follicular or other indolent lymphomas. 
e Irradiated field unknown. 
f Based on self-report of regular bleeding, age at last menstrual bleeding, assessment of serum estradiol, FSH and LH levels. 
g Estrogen therapy, n=25; oral contraceptive pill, n=1. 
h Pre-lymphoma diagnosis, n=5; post-diagnosis and pre-auto-SCT, n=5; post-auto-SCT, n=22. 
i Type D personality; negative affectivity and social inhibition. 
 
Abbreviations: Auto-SCT, high-dose chemotherapy with autologous stem-cell transplantation; BEAM, high-dose 
chemotherapy regime (carmustine, etoposide, cytarabine and melphalan); HRT, hormone replacement 
therapy; HADS, Hospital Anxiety and Depression Scale. 
Missing values among cases: stage, n=1; education, n=2; income, n=3; premature ovarian insufficiency, n=2; 
distressed personality, n=10; chronic fatigue, n=3; sedentary, n=1; smoking, n=1. 
Missing values among controls: education, n=2.  
Data presented as numbers (%) unless otherwise specified. 
 
Table 2 Comparison of (A) reasons for sexual inactivity and (B) SAQ functional domains among 
female auto-SCT lymphoma survivors and normative controls  
 Survivors Controls p-value Effect size [95%CI]#
A) SEXUALLY INACTIVE WOMEN n=41 n=228  
Reasons for sexual inactivitya  
   No partner at the moment 21 (51) 105 (46) 0.54  
   Partner issues 6 (15) 53 (23) 0.22  
        My partner is too tired 3 21  
        My partner is not interested in sex 2 21  
        Partner physical problem 1 27  
   Personal issues 18 (44) 64 (28) 0.04  
        I am too tired 6 32                
        I am not interested in sex 12 41  
        I have physical problem 5 18  
   Other reasons 12 (29) 50 (22) 0.30  
B) SEXUALLY ACTIVE WOMEN n=69 n=322  
SAQ functional domainsb  
Sexual pleasure, mean (SD) 11.0 (3.87) 11.6 (4.17) 0.27 -0.15 [-0.41, 0.12]
Discomfort, mean (SD) 1.90 (1.90) 0.88 (1.34) <0.001 0.70 [0.44, 0.97]
Habit, mean (SD) 0.75 (0.47) 0.90 (0.53) 0.03 -0.29 [-0.55, -0.03]
Too tired to have sex, mean (SD) 1.25 (0.90) 0.73 (0.80) <0.001 0.64 [0.37, 0.90]
Abbreviations: auto-SCT, high-dose chemotherapy with autologous stem-cell transplantation; SAQ, Sexual 
Activity Questionnaire; CI, confidence interval. 
Bold type indicates moderate effect size (≥0.50). 
Data are presented as numbers (%) unless otherwise specified. 
#Effect size calculated as standardized mean difference (SMD) equation gHedges: = 	 	( ) ( )	 	    
 (A correction factor for small sample size was added to the equation.) 
                                                            
a A proportion of survivors (9.8%) and controls (9.6%) reported more than one cause, thus appear in more than 
one group. 
b Possible range of scores: sexual pleasure 0-18; discomfort 0-6; habit 0-3; too tired to have sex 0-3. 
Table 3. Regression coefficients for the association between SAQ functional domains and 
selected characteristics of sexually active female auto-SCT survivors (n=69), age-adjusted 
linear regression models 
 Pleasureab
 
β [95% CI] 
Discomfortb
 
β [95% CI] 
Habitb
 
β [95% CI] 
Too tired to have 
sexb 
β [95% CI] 
SOCIO-DEMOGRAPHICS 
Age at survey, per 10 
years 
-0.91 [-1.87, 0.05] -0.04 [-0.40, 0.32] -0.02 [-0.11, 0.07] -0.21 [-0.37, 0.00]*
In a relationshipc, n=62 -1.43 [-5.51, 2.65] -0.09 [-1.64, 1.46] -0.11 [-0.49, 0.28] 0.57 [-0.12, 1.27]
Education > 12 years, 
n=36 




-4.67 [-8.55, -0.80]* 0.59 [-0.93, 2.12,] 0.12 [-0.26, 0.49] 0.22 [-0.48, 0.92]
Radiotherapy 
   None, n= 18 Ref. Ref. Ref. Ref.
   Supradiaphragmal, n=18 -2.96 [-6.23, 0.32] 0.11 [-1.22, 1.43] 0.05 [-0.29, 0.38] 0.23 [-0.39, 0.85]
   Subdiaphragmal, n=20 -2.36 [-5.51, 0.78] -0.63 [-1.90, 0.63] -0.03 [-0.34, 0.29] 0.18 [-0.41, 0.77]
   TBI, n= 7 -6.18 [-10.4, -1.91]** 0.34 [-1.38, 2.07] 0.13 [-0.30, 0.56] 0.35 [-0.46, 1.15]




-3.86 [-6.99, -0.73]* 0.38 [-0.81, 1.57] -0.15 [-0.42, 0.12] 0.63 [0.11, 1.14]*
Chronic fatigue caseness, 
n=25 
-1.84 [-4.42, 0.74] 0.53 [-0.44, 1.50] -0.23 [-0.47, 0.01] 0.57 [0.14, 1.01]*
Anxiety caseness, n=21 -1.55 [-4.22, 1.12] -0.21 [-1.21, 0.80] -0.20 [-0.44, 0.04] 0.72 [0.29, 1.16]**
Depression caseness, n=6 -4.53 [-9.12, 0.05] 1.21 [-0.41, 2.82] -0.28 [-0.68, 0.12] 0.82 [0.10, 1.54]* 
Abbreviations: SAQ, Sexual Activity Questionnaire; β, unstandardized coefficient beta; CI, Confidence Interval; 
auto-SCT, high-dose chemotherapy with autologous stem-cell transplantation; TBI, total body irradiation.  
Missing values: Type D personality, n=5; chronic fatigue caseness, n=1. 
*p-value<0.05; **p-value<0.01; ***p-value<0.001.  
Data are presented as unstandardized coefficient beta [95% Confidence interval] unless otherwise specified. 
                                                            
a Including items on arousal and orgasm. 
b Possible range of scores: sexual pleasure 0-24; discomfort 0-6; habit 0-3; too tired to have sex 0-3. 
c Married or cohabitant. 
d Myeloablative regimen containing TBI or not. 
e Type-D personality; negative affectivity and social inhibition. 
Supplementary data 
Definition of explanatory variable “hormonal groups” according to premenopausal, hormone 
replacement therapy (HRT) and postmenopausal without HRT: Premenopausal status was defined 
as regular bleedings and cyclic ovarian function (any level of estradiol, FSH<20 IU/l and LH<15 
IU/l)1. Perimenopausal status was defined by irregular bleeding or amenorrhea in addition to estradiol 
>0.10 - <0.30 nmol/l, FSH>20 IU/l and LH>15 IU/l; however, these women (n=3) were included in 
the postmenopausal category. Postmenopausal status was defined by persistent amenorrhea, estradiol 
<0.10 nmol/l, FSH >20 IU/l and LH >15 IU/l). In case of inconsistency among reported menstrual 
bleeding and blood samples, an individual consideration was performed (n=5). Women on HRT 
(estrogen supplemental therapy n=25, oral contraceptives n=1) were presumed postmenopausal, 
however categorized as HRT.  
 
1. Haakensen VD, Bjoro T, Luders T, Riis M, Bukholm IK, Kristensen VN et al. Serum estradiol levels 
associated with specific gene expression patterns in normal breast tissue and in breast carcinomas. 
BMC Cancer. 2011; 11: 332 doi:10.1186/1471-2407-11-332. 
 
Supplementary table 1. Odds Ratios of being sexual active among female auto-SCT 









OR [95% CI] 
SOCIO-DEMOGRAPHICS    
Age at survey, median (range) 65 (26-75) 48 (24-72) 0.58 [0.43, 0.82]a** 
Time auto-SCT to survey, median (range) 8.6 (3.8, 25) 9.0 (3.6, 25) 1.00 [0.68, 1.46]b 
In a relationshipc 19 (46) 62 (90) 28.6 [6.9, 118.9]*** 
Education > 12 years 15 (37) 36 (52) 1.22 [0.51, 2.89] 
LYMPHOMA AND TREATMENT    
Lymphoma entity    
   Aggressive NHLd 26 (63) 43 (62) Ref. 
   Indolent NHL 8 (20) 3 (4.3) 0.24 [0.06, 1.01] 
   Hodgkin lymphoma 7 (17) 23 (33) 0.79 [0.23, 2.72] 
No regimes prior to auto-SCT    
   1 9 (22) 18 (26) Ref. 
   2 27 (66) 46 (67) 0.63 [0.23, 1.69] 
   ≥3 5 (12) 5 (7.2) 0.44 [0.09, 2.09] 
TBI myeloablative regimee 7 (17) 7 (10) 0.55 [0.17, 1.76] 
Received radiotherapy    
   None 17 (42) 18 (26) Ref. 
   Supradiaphragmal 6 (15) 18 (26) 1.72 [0.50, 5.89] 
   Subdiaphragmal 5 (12) 20 (29) 3.30 [0.96, 11.3] 
   Total body irradiation 7 (17) 7 (10) 0.77 [0.21, 2.78] 
   Other 6 (15) 6 (8.7) 0.56 [0.13, 2.43] 
COMORBIDITY    
Distressed personalityf 8 (20) 13 (19) 0.73 [0.26, 2.11] 
Chronic fatigue caseness 15 (37) 25 (36) 0.75 [0.31, 1.81] 
Anxiety caseness 10 (24) 21 (30) 1.14 [0.45, 2.89] 
Depression caseness 8 (20) 6 (8.7) 0.37 [0.11, 1.23] 
MENSTRUAL STATUS and HORMONE 
THERAPYg 
   
Hormonal groups    
   Postmenopausal without HRT 35 (85) 32 (46) Ref. 
   HRT 3 (7.3) 23 (33) 6.00 [1.49, 24.2]* 
   Premenopausal 3 (7.3) 14 (20) 2.59 [0.44, 15.2]  
Premature ovarian insufficiency 11 (27) 21 (30) 0.68 [0.25, 1.83] 
Abbreviations: SAQ, sexual activity questionnaire; OR, odds ratio; CI, Confidence Interval; auto-SCT, high-dose 
chemotherapy with autologous stem-cell transplantation; TBI, total body irradiation; HRT, Hormone 
replacement therapy. 
*p-value<0.05; **p-value<0.01; ***p-value<0.001.  
Data are presented as numbers (%) unless otherwise specified. 
                                                          
a Per 10 years. 
b Per 5 years. 
c Married or cohabitant. 
d Lymphoblastic lymphoma, n=8; Burkitt lymphoma, n=3; diffuse large B-cell lymphoma, n=30; mantle cell 
lymphoma, n=6; T-cell lymphomas, n=10; transformed lymphoma, n=12. 
e Myeloablative regime containing TBI or not. 
f Type-D personality; negative affectivity and social inhibition. 
g Based on self-report of regular bleeding, age at last menstrual bleeding, assessment of serum estradiol, FSH 
and LH levels. 
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